Heteroaromatic compounds, their preparation and use
Aromatic heterocyclic compounds are developed to address the lack of effective ENPP1 inhibitors, enhancing antitumor immunity and tumor suppression by targeting the STING pathway, with potential synergies in cancer treatment.
Patent Information
- Application Number
- JP2024535749
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-24
- Filing Date
- 2022-12-15
- Publication Date
- 2024-12-05
AI Technical Summary
Current small molecule drugs for ENPP1 inhibitors are lacking in efficacy and pharmacokinetic results, necessitating the development of new compounds with improved therapeutic potential.
Development of aromatic heterocyclic compounds represented by a specific formula, which act as ENPP1 inhibitors, targeting the STING pathway to enhance antitumor immunity and suppress tumor immunosuppression.
The novel aromatic heterocyclic compounds effectively inhibit ENPP1, enhancing antitumor immunity and reducing tumor immunosuppression, with potential synergistic effects when combined with radiotherapy and immune checkpoint inhibitors.
Smart Images

Figure 2024545235000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of pharmaceutical technology, specifically to aromatic heterocyclic compounds as ENPP1 inhibitors, and methods for preparing and using the compounds. [Background technology]
[0002] Cancer cells have chromosomal instability, and as cancer cells divide, DNA fragments or entire chromosomes may be duplicated, mutated, or completely deleted. The more unstable the chromosomes, the more likely DNA fragments will appear in places where they should not, such as floating in the cytoplasm outside the cell nucleus. Cells recognize these free DNA fragments as evidence of viral invasion, triggering an internal alarm, causing inflammation, and mobilizing immune cells to the tumor site to launch an immune attack.
[0003] STING, or Stimulator of interferon genes, is widely expressed in the endoplasmic reticulum of various immune cells, where it primarily recognizes cyclic dinucleotides (CDNs), thereby detecting DNA leakage in the cytoplasm and eliciting immune responses.
[0004] DNA is normally found in the nucleus and mitochondria, and its appearance in the cytoplasm is an abnormal phenomenon. cGAS senses DNA in the cytoplasm and synthesizes cyclic 2',3'-cGAMP (2',3'-cGAMP) from ATP or GTP, which can activate STING. However, ENPP1 is the only enzyme capable of hydrolyzing 2',3'-cGAMP. ENPP1 hydrolyzes 2',3'-cGAMP, preventing signals from reaching immune cells. In the process, it releases adenosine, an immunosuppressant molecule that also has an anti-inflammatory effect. In addition, ENPP1 expression is associated with increased metastasis and drug resistance to immunotherapy.
[0005] ENPP1 is a type II transmembrane glycoprotein with nucleotriptyline and phosphodiesterase activity, belonging to the extracellular nucleotriptyline / phosphodiesterase (ENPP) family, which consists of seven functionally distinct proteins (1-7). ENPP1 structure contains two N-terminal SMB domains (SMB1 and SMB2), two linker regions (L1 and L2), one catalytic domain, and one nuclease-like domain. ENPP1 is differentially expressed in immune cells, with low levels in NK cells, DCs, and macrophages and high levels in neutrophils. ENPP1 is also expressed in some B cells, where it may be involved in regulating T cell activity. ENPP1 expression is elevated in M2 subtype macrophages, while M2 subtype macrophages play a role in tumor promotion. ENPP1 expression is elevated in astrocytic tumors, breast cancer, and head and neck tumors. ENPP1 expression varies significantly among different tumor tissues. ENPP1 is specifically overexpressed in a subset of tumors and may be a driver of tumor immune escape and metastasis.
[0006] ENPP1 plays an important role in stimulating many immune responses through the STING pathway, selectively activating the STING signaling pathway in tumor cells and other cells in the tumor microenvironment, achieving high selectivity. ENPP1 can also catalyze the hydrolysis of ATP to PPi and AMP, promoting the production of adenosine, which has strong immunosuppressive properties. Inhibition of ENPP1 inhibits ATP hydrolysis, thereby reducing adenosine production and relieving tumor immunosuppression.
[0007] While STING agonists indiscriminately activate STING in both cancer and host cells, ENPP1 plays a role in restricting the scope of STING activation to tumor tissue and the tumor microenvironment, enhancing antitumor immunity. ENPP1 is selectively upregulated in metastatic and chromosomally unstable tumor cells. ENPP1 inhibitors can systemically suppress the ability of invasive tumor cells to evade immune surveillance, avoiding the technical difficulties of intratumoral administration of STING agonists.
[0008] The combination of ENPP1 inhibitors with radiation therapy has shown enhanced efficacy in animal models, and also has a certain synergistic effect when combined with immune checkpoint inhibitors such as PD-1 and PARP inhibitors. While the development of ENPP1 inhibitors is currently in the preclinical development stage, many pharmaceutical companies have filed patent applications related to ENPP1 inhibitors, such as WO2021061803A1, WO2021158829A1, WO2020190912A1, WO2019177971A1, and WO2019046778A1.
[0009] Using a mouse ischemic heart injury model, it was demonstrated that various cell populations are recruited to the heart after cardiac injury, and that cardiomyocytes play a crucial role in cardiac repair by regulating nucleotide metabolism and non-cardiomyocyte cell death (Shen Li et al., 2022). Cardiac injury induces the expression of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which hydrolyzes extracellular ATP to form AMP. In response to AMP, cardiomyocytes release adenine and specific ribonucleosides, disrupting pyrimidine biosynthesis in the octenis monophosphate (OMP) synthesis step, inducing genotoxic stress and increased p53-mediated non-cardiomyocyte cell death. Because non-cardiac cells are important for cardiac repair, rescuing pyrimidine biosynthesis via uridine administration or genetic targeting of the ENPP1 / AMP pathway can improve repair after cardiac injury.
[0010] Although some small molecules of ENPP1 inhibitors are known in the prior art, currently, no small molecule drugs have been clinically marketed, and therefore, there is a strong demand for the development of novel compounds with better efficacy and pharmacokinetic results and market potential. The present inventors have invented a compound having a novel structure represented by the general formula, and found that the compound having this structure exhibits excellent effects and actions, and is of great significance for the development of ENPP1 inhibitors. Summary of the Invention [Problem to be solved by the invention]
[0011] The present invention aims to provide compounds having an aromatic heterocyclic structure as ENPP1 inhibitors, methods for preparing the compounds, and uses thereof in the treatment of diseases mediated by ENPP1.
[0012] A first aspect of the present invention provides a compound represented by the following formula (I), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0013] In the formula, X1, X2, X3, X4, and Y are each independently CH or N; and if X1, X2, X3, and X4 are all CH, then Y is not CH;
[0014] R A is a substituent of the ring in which X1 is present, and R B is a substituent on the ring in which Y occurs, and each R A and R Bare independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-OR1, -Z-SR1, -Z-NR2R3, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, -ZC(O)R4, -ZC(O)OR1, -ZC(O)(CR5R6) n C(O)R4, -ZC(O)(CR5R6) n C(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3- to 20-membered heterocyclyl, 5- to 16-membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0015] n1 is 1, 2, 3 or 4; n2 is 1 or 2; Ring A is a 6-10 membered heterocyclyl or a 6-12 membered heteroaryl;
[0016] Rc is a substituent of ring A, and each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-OR1, -Z-SR1, -Z-NR2R3, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, -ZC(O)R4, -ZC(O)OR1, -ZC(O)(CR5R6) n C(O)R4, -ZC(O)(CR5R6) nC(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-20 membered heterocyclyl, C 6-12 aryl, 5-16 membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0017] n3 is 1, 2, 3, 4, 5 or 6; Z is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein said alkylene, alkyleneoxy, alkylenethio may be substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH; Ring B is C3- 10 Cycloalkyl, 3-20 membered heterocyclyl, C6- 14 aryl, or 5-16 membered heteroaryl;
[0018] [ka]
[0019] Each R Eare independently hydrogen, deuterium, halogen, oxo, oxime, carboxy, -CN, -OH, -SH, -NO2, -NH2, -W-OR1, -W-SR1, -WC(O)R4, -WC(O)OR1, -W-OC(O)R1, -W-OC(O)OR1, -WC(O)NR2R3, -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2R3, -W-NR2 C(O)R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W-NR2S(O)2R4, -W-OS(O)2R 4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3- to 20-membered heterocyclyl, and 5- to 16-membered heteroaryl; and the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0020] n is 1, 2 or 3; n4 is 1, 2, 3, 4, 5 or 6; W is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein said alkylene, alkyleneoxy, alkylenethio may be substituted with one or more substituents selected from deuterium, halogen, oxo, —CN, —CN, —OH, —NH;
[0021] L is a bond, -O-, -S-, or C 1-6 Alkylene, C 1-6 Alkyleneoxy, C 3-6 Cycloalkylene, C 1-6 Archillencio, C 2-6 Alkenylene, C 2-6 alkynylene, wherein said alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene and alkynylene are selected from the group consisting of deuterium, halogen, C 1-3 Alkyl, C 1-6 optionally substituted with one or more substituents selected from alkoxy, oxo, -CN, -OH, -NH;
[0022] R1, when present, is independently hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3- to 20-membered heterocyclyl, wherein alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are substituted with halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, phenyl, C 1-3 Haloalkyl, C 1-4 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0023] R2 and R3, when present, are each independently hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, where alkyl and alkoxy are halogen, deuterium, cyano, hydroxy, amino, carboxy, C 1-3 Alkyl, C 1-4 Alkoxy, C 1-4 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0024] R4, when present, is independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3- to 20-membered heterocyclyl, wherein alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are substituted with halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, phenyl, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0025] R5 and R6 are independently hydrogen, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, C 3-6 cycloalkenyl, 3- to 20-membered heterocyclyl, and 5- to 16-membered heteroaryl, and the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 It may be optionally substituted with one or more substituents selected from haloalkyl.
[0026] Multiple R A , R B , R C or R E When R exists simultaneously, A , R B , R C or R E may be the same or different.
[0027] In a preferred embodiment of the first aspect of the present invention, X1 is N, and X2, X3 and X4 are all CH.
[0028] In a preferred embodiment of the first aspect of the present invention, X3 is N and X1, X2 and X4 are all CH.
[0029] In a preferred embodiment of the first aspect of the present invention, X1 and X3 are both N and X2 and X4 are both CH.
[0030] In a preferred embodiment of the first aspect of the present invention, X1, X2, X3 and X4 are all CH.
[0031] In a preferred embodiment of the invention relating to the first aspect, in any of the above-mentioned embodiments of the first aspect, Y is CH; or Y is N.
[0032] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, 3- to 6-membered heterocyclyl, -ZC(O)R4, -ZC(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0033] Or, each R Aare independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, 3- to 6-membered heterocyclyl, -ZC(O)R4, -ZC(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0034] Or, each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, 3- to 6-membered heterocyclyl, -ZC(O)R4, -ZC(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy;
[0035] Or, each R A are independently hydrogen, deuterium, F, Cl, Br, oxime, -CN, -OH, -SH, -NO2, -NH2, -NR2C(O)R4, -NR2C(O)OR1, 3-6 membered heterocyclyl, -C(O)R4, -C(O)OR1, -C(O)NR2R3, -S(O)2R4, -S(O)2NR2R3, methyl, ethyl, propyl, isopropyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl, vinyl, ethynyl, propenyl, propynyl;
[0036] Or, each R A are independently hydrogen, F, Cl, Br, oxime, -CN, -OH, -NH2, -NHC(O)C 1-3 Alkyl, -NHC(O)OC 1-3 Alkyl, 3-4 membered heterocyclyl, -C(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl, -C(O)NHC 1-3 Alkyl, -S(O)2C 1-3 Alkyl, -S(O)2NH2, -S(O)2NHC 1-3 alkyl, methyl, ethyl, methoxy, ethoxy, methylthio, vinyl, propenyl, ethynyl, cyclopropyl, tert-butyl;
[0037] [ka]
[0038] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, n1 is 1, 2 or 3; or n1 is 1 or 2.
[0039] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, each R B are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, where alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl are substituted with deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0040] Or, each R B are independently hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO2, -NH2, methyl, ethyl, propyl, isopropyl, vinyl, propenyl, ethynyl, propynyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl;
[0041] Or, each R B are independently hydrogen, F, Cl, Br, -OH, -NH2, methyl, ethyl, methoxy, ethoxy, vinyl, ethynyl; Alternatively, R B is selected from hydrogen, —NH 2 , methyl, methoxy, and ethynyl.
[0042] In a preferred embodiment of the invention relating to the first aspect, n2 is 1 in any of the preceding embodiments of the first aspect.
[0043] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, ring A is a 6-9 membered heterocyclyl or a 6-12 membered heteroaryl; Alternatively, ring A is a 6-8 membered heterocyclyl or a 6-8 membered heteroaryl; Alternatively, ring A is a 6-membered heterocyclyl or a 6-membered heteroaryl;
[0044] Alternatively, ring A is piperidinyl, hexahydropyrimidinyl, piperazinyl, 1,3-oxazinyl, morpholinyl, thiomorpholinyl, 1,3-thiazinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyrazinyl, 1,4,5,6-tetrahydropyrimidinyl, homopiperidinyl, homopiperazinyl, homomorpholinyl, pyridinyl, pyridazinyl, pyrimidinyl, 1,4-diazepane, 1,5-diazocane, 1,4-oxazepane, 1,3-oxazepane, 1,4-oxazacyclooctane, 2,3,6,7-tetrahydro-1,4-diazepine;
[0045] [ka]
[0046] [ka]
[0047] [ka]
[0048] [ka]
[0049] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -ZC(O)OR1, -ZNR2C(O)R4, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C3-6 cycloalkyl, 3-8 membered heterocyclyl, 5-8 membered heteroaryl, C6- 12 and aryl; wherein said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0050] Or, each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -ZC(O)OR1, -ZNR2C(O)R4, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-3 Alkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C3-6 cycloalkyl, 3-6 membered heterocyclyl, 5-8 membered heteroaryl, C6- 12 and aryl; wherein said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C1-6 optionally substituted with one or more substituents selected from haloalkoxy;
[0051] Or, each R C are independently hydrogen, halogen, oxo, oxime, -CN, -OH, -SH, -NH2, -C(O)OC 1-6 Alkyl, carboxyl group, -NHC(O)C 1-6 Alkyl, -S(O)2C 1-6 Alkyl, -S(O)2NH2, -CH2S(O)2C 1-6 Alkyl, C 1-3 Alkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C3-6 cycloalkyl, 3-6 membered heterocyclyl, 5-8 membered heteroaryl, C6- 12 and aryl; wherein said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is selected from the group consisting of halogen, oxo, oxime, -CN, -OH, -NO, -NH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0052] Or, each R C are independently hydrogen, F, Cl, Br, oxo, oxime, -CN, -OH, -SH, -NH2, -C(O)OC 1-4 Alkyl, carboxy, -NHC(O)C 1-4 Alkyl, -S(O)2C 1-4 Alkyl, -S(O)2NH2, -CH2S(O)2C 1-4Alkyl, tetrahydrofuranyl, pyrrolyl, phenyl, methyl, ethyl, normal propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, vinyl, propenyl, ethynyl, propynyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, and methoxymethyl.
[0053] [ka]
[0054] In a preferred embodiment of the invention relating to the first aspect, n3 is 1, 2 or 3 in any of the preceding embodiments of the first aspect.
[0055] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, [ka]
[0056] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, ring B is C5- 10 Cycloalkyl, 3-20 membered heterocyclyl, C6- 14 aryl or 5-16 membered heteroaryl;
[0057] Alternatively, Ring B is C5-7 cycloalkyl, 5-7 membered monocyclic heterocyclyl, 5-14 membered spiroheterocyclyl, 5-14 membered fused heterocyclyl, C6- 10 aryl, 5-6 membered monocyclic heteroaryl or 5-14 membered fused heteroaryl;
[0058] Alternatively, Ring B is C6 cycloalkyl, C7 cycloalkyl, 6-membered monocyclic heterocyclyl, 7-membered monocyclic heterocyclyl, 4-membered / 4-membered spiro heterocyclyl, 4-membered / 5-membered spiro heterocyclyl, 5-membered / 4-membered spiro heterocyclyl, 5-membered / 5-membered spiro heterocyclyl, 4-membered / 6-membered spiro heterocyclyl, 6-membered / 4-membered spiro heterocyclyl, 5-membered / 6-membered spiro heterocyclyl, 6-membered / 5-membered spiro heterocyclyl, 6-membered / 6-membered spiro heterocyclyl, 4-membered / 4-membered fused heterocyclyl, 4-membered / 5-membered fused heterocyclyl, 5-membered / 4-membered fused heterocyclyl, 5-membered / 5-membered fused heterocyclyl, 5-membered / 6-membered fused heterocyclyl. fused heterocyclyl, 6-membered / 5-membered fused heterocyclyl, 4-membered / 6-membered fused heterocyclyl, 6-membered / 4-membered fused heterocyclyl, 6-membered / 6-membered fused heterocyclyl, phenyl, naphthyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 5-membered / 5-membered fused heteroaryl, 5-membered / 6-membered fused heteroaryl, 6-membered / 5-membered fused heteroaryl, 6-membered / 6-membered fused heteroaryl, wherein the heteroatoms in said heterocyclyl, heteroaryl, fused heterocyclyl, fused heteroaryl, spirocyclic heterocyclyl are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;
[0059] [ka]
[0060] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, R D are -WC(O)NR2R3, -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2C(O)R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W-NR2S(O)2R4, -W-OS(O)2R4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2, [ka]
[0061] or R D -WC(O)NR2R3, -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2C(O)R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W- selected from NR2S(O)2R4, -W-OS(O)2R4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2;
[0062] Alternatively, R D -C 0-3 Alkylene-C(O)NHOH, -C 0-3 Alkylene-OC(O)NH2, -C 0-3 Alkylene-SO2NH2, -C 0-3 Alkylene-NHS(O)H, -C 0-3 Alkylene -OS(O)H, -C 0-3 Alkylene-NHS(O)2NH2, - C 0-3 Alkylene -OS(O)2NH2, -C 0-3 Alkylene-P(O)(OH)2, -C 0-3 Alkylene-P(S)(OH)2, -C 0-3 Alkylene-OP(S)(OH)2, -C 0-3 Alkylene-B(OH)2, -C 0-3 Alkylene -S(O)2OH, -C 0-3 Alkylene C(O)NH2, -C 0-3 Alkylene S(O)2C 1-3 Alkyl, -C 0-3 Alkylene-OS(O)2-C 1-3 Alkyl, -C 0-3 Alkylene-S(O)2-C 1-3 Alkylene -C(O)OH, -C 0-3 Alkylene-S(O)C 1-3 Alkylene-NH2, -C 0-3 Alkylene -S(O)NHCHC(O)OH, -C 0-3AlkyleneNHS(O)2CH3, -C 0-3 AlkyleneS(O)ND, -C 0-3 AlkyleneS(O)2NHNH2, -C 0-3 AlkyleneS(O)2NHSC 1-3 Alkyl, -C 0-3 Alkylene-NHS(O)2C 1-3 Alkyl, -C 0-3 Alkylene-NH-C(O)C 1-3 Alkyl, -C 0-3 Alkylene-NH-CONH2, -C 0-3 Alkylene-NH-COO C 1-3 Alkyl or -C 0-3 alkylene-S(O)NHOH, or [ka]
[0063] or R D -C 0-3 Alkylene-C(O)NHOH, -C 0-3 Alkylene-OC(O)NH2, -C 0-3 Alkylene-SO2NH2, -C 0-3 Alkylene-NHS(O)H, -C 0-3 Alkylene -OS(O)H, -C 0-3 Alkylene-NHS(O)2NH2, - C 0-3 Alkylene -OS(O)2NH2, -C 0-3 Alkylene-P(O)(OH)2, -C 0-3 Alkylene-P(S)(OH)2, -C 0-3 Alkylene-OP(S)(OH)2, -C 0-3 Alkylene-B(OH)2, -C 0-3 Alkylene -S(O)2OH, -C 0-3 Alkylene C(O)NH2, -C 0-3 Alkylene S(O)2C 1-3 Alkyl, -C 0-3 Alkylene-OS(O)2-C 1-3 Alkyl, -C 0-3 Alkylene-S(O)2-C 1-3 Alkylene -C(O)OH, -C0-3 Alkylene-S(O)C 1-3 Alkylene-NH2, -C 0-3 Alkylene -S(O)NHCHC(O)OH, -C 0-3 AlkyleneNHS(O)2CH3, -C 0-3 AlkyleneS(O)ND, -C 0-3 AlkyleneS(O)2NHNH2, -C 0-3 AlkyleneS(O)2NHSC 1-3 Alkyl, -C 0-3 Alkylene-NHS(O)2C 1-3 Alkyl, -C 0-3 Alkylene-NH-C(O)C 1-3 Alkyl, -C 0-3 Alkylene-NH-CONH2, -C 0-3 Alkylene-NH-COO C 1-3 Alkyl or -C 0-3 alkylene-S(O)2NHOH;
[0064] Alternatively, R D are -methylene-C(O)NHOH, -methylene-OC(O)NH2, -methylene-SO2NH2, -methylene-NHS(O)2H, -methylene-OS(O)2H, -methylene-NHS(O)2NH2, -methylene-OS(O)2NH2, -methylene-P(O)(OH)2, -methylene-P(S)(OH)2, -methylene-OP(S)(OH )2, -methylene-B(OH)2, -C(O)NHOH, -OC(O)NH2, -SO2NH2, -NHS(O)2H, -OS(O)2H, -NHS(O)2NH2, - OS(O)2NH2, -P(O)(OH)2, -P(S)(OH)2, -OP(S)(OH)2, -B(OH)2;-S(O)2OH, -C(O)NH2, -S(O)2C 1-3 Alkyl, -OS(O)2C 1-3 Alkyl, -S(O)2C 1-3 Alkylene C(O)OH, -S(O)C 1-3 Alkylene-NH2, -S(O)2NHCH2C(O)OH, -NHS(O)2CH3, -S(O)2ND2, -S(O)2NHNH2, -methylene-NHS(O)2C 1-3Alkyl, -methylene-NH-C(O)C 1-3 Alkyl, -methylene-NH-CONH2, -NH-COOC 1-3 alkyl, or -S(O)2NHOH, or [ka]
[0065] Alternatively, R D are -methylene-C(O)NHOH, -methylene-OC(O)NH2, -methylene-SO2NH2, -methylene-NHS(O)2H, -methylene-OS(O)2H, -methylene-NHS(O)2NH2, -methylene-OS(O)2NH2, -methylene-P(O)(OH)2, -methylene-P(S)(OH)2, -methylene-OP(S)(OH )2, -methylene-B(OH)2, -C(O)NHOH, -OC(O)NH2, -SO2NH2, -NHS(O)2H, -OS(O)2H, -NHS(O)2NH2, - OS(O)2NH2, -P(O)(OH)2, -P(S)(OH)2, -OP(S)(OH)2, -B(OH)2;-S(O)2OH, -C(O)NH2, -S(O)2C 1-3 Alkyl, -OS(O)2C 1-3 Alkyl, -S(O)2C 1-3 Alkylene C(O)OH, -S(O)C 1-3 Alkylene-NH2, -S(O)2NHCH2C(O)OH, -NHS(O)2CH3, -S(O)2ND2, -S(O)2NHNH2, -methylene-NHS(O)2C 1-3 Alkyl, -methylene-NH-C(O)C 1-3 Alkyl, -methylene-NH-CONH2, -NH-COOC 1-3 alkyl, or —S(O)2NHOH;
[0066] Alternatively, R Dis -C(O)NHOH, -SO2NH2, -methylene-NHS(O)2NH2, -NHS(O)2NH2, -B(OH)2, -P(O)(OH)2, -OP(S)(OH)2, -OS(O)2NH2, -S(O)2OH, -C(O)NH2, -S(O)2CH3, -OS(O)2CH3, -S(O)2CH2CH2C(O)OH, -S(O)2CH2NH2, -S(O)2NHCH2C(O)OH, -NHS(O)2CH3, -S(O)2ND2, -S(O)2NHNH2, -methylene-NHS(O)2CH3, -methylene-NH-C(O)CH3, -methylene-NH-CONH2, -NH-COOCH3, or -S(O)2NHOH, or [ka]
[0067] Selected from;R D is selected from —C(O)NHOH, —SONH, -methylene-NHS(O)NH, —NHS(O)NH, —B(OH), —P(O)(OH), —OP(S)(OH), —OS(O)NH, —S(O)OH, —C(O)NH, —S(O)CH, —OS(O)CH, —S(O)CHCHC(O)OH, —S(O)CHNH, —S(O)NHCHC(O)OH, —NHS(O)CH, —S(O)ND, —S(O)NHNH, —methylene-NHS(O)CH, -methylene-NH—C(O)CH, -methylene-NH—CONH, —NH—COOCH, or —S(O)NHOH.
[0068] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 Alkoxy, C 3-8and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0069] Or, each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C3-6 cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0070] Or, each R E are independently hydrogen, halogen, -OH, -SH, C 1-3 Alkyl, C 1-3 Alkoxy, C3-6 cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0071] Or, each R Eare independently hydrogen, F, Cl, Br, -OH, -SH, -methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl;
[0072] [ka]
[0073] In a preferred embodiment of the invention relating to the first aspect, in any of the above embodiments of the first aspect, n4 is 1, 2, 3 or 4; or n4 is 1, 2 or 3.
[0074] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, L is a bond, —O—, —S—, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C3-6 cycloalkylene, C 1-3 alkylenethio, C2-6 alkenylene, and C2-6 alkynylene, and the alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are each independently selected from the group consisting of deuterium, halogen, and C 1-3 Alkyl, C 1-3 optionally substituted with one or more substituents selected from alkoxy, oxo, -CN, -OH, -NH;
[0075] Alternatively, L is a bond, -O-, -S-, methylene, ethylene, propylene, cyclopropylene, cyclobutylene, C 1-3 Alkyleneoxy, C 1-3alkylenethio, vinylene, ethynylene, wherein said methylene, ethylene, propylene, cyclopropylene, cyclobutylene, alkyleneoxy, alkylenethio, vinylene, ethynylene may be substituted with one or more substituents selected from deuterium, halogen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, oxo, -CN, -OH, and -NH;
[0076] Alternatively, L is a bond, -O-, -S-, cyclopropylene, methylenemethoxy, methylenemethyl, methylene-OH, methylene-NH2, ethylene, propylene;
[0077] [ka]
[0078] A second aspect of the present invention provides a compound represented by the following formula (I), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0079] In the formula, X1, X2, X3, X4, and Y are each independently CH or N; and if X1, X2, X3, and X4 are all CH, then Y is not CH;
[0080] R A is a substituent of the ring in which X1 is present, and R B is a substituent on the ring in which Y occurs, and each R A and R Bare independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-OR1, -Z-SR1, -Z-NR2R3, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, -ZC(O)R4, -ZC(O)OR1, -ZC(O)(CR5R6) n C(O)R4, -ZC(O)(CR5R6) n C(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3- to 20-membered heterocyclyl, 5- to 16-membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0081] n1 is 1, 2, 3 or 4; n2 is 1 or 2; Ring A is a 6-10 membered heterocyclyl or a 6-12 membered heteroaryl;
[0082] Rc is a substituent of ring A, and each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-OR1, -Z-SR1, -Z-NR2R3, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, -ZC(O)R4, -ZC(O)OR1, -ZC(O)(CR5R6) n C(O)R4, -ZC(O)(CR5R6) nC(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3- to 20-membered heterocyclyl, and 5- to 16-membered heteroaryl; and the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0083] n3 is 1, 2, 3, 4, 5 or 6; Z is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein said alkylene, alkyleneoxy, alkylenethio may be substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH; Ring B is C3- 10 Cycloalkyl, 3-20 membered heterocyclyl, C6- 14 aryl or 5-16 membered heteroaryl;
[0084] R Dis selected from -W-OC(O)OR1, -WC(O)NR2R3, -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2C(O)R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W-NR2S(O)2R4, -W-OS(O)2R4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2;
[0085] Each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR1, -W-SR1, -WC(O)R4, -WC(O)OR1, -W-OC(O)R1, -W-OC(O)OR1, -WC(O)NR2R3, -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2R3, -W-NR2C(O) R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W-NR2S(O)2R4, -W-OS(O)2R4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2, C 1-6 Alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3-20 heterocyclyl, 5-16 membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0086] n4 is 1, 2, 3, 4, 5 or 6; W is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein said alkylene, alkyleneoxy, alkylenethio may be substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH;
[0087] L is a bond, -O-, -S-, C 1-6 Alkylene, C 1-6 Alkyleneoxy, C3-6 cycloalkylene, C 1-6 alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are selected from the group consisting of alkylenethio, C2-6 alkenylene, and C2-6 alkynylene, and wherein the alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are selected from the group consisting of deuterium, halogen, and C 1-3 Alkyl, C 1-6 optionally substituted with one or more substituents selected from alkoxy, oxo, -CN, -OH, -NH;
[0088] R1, if present, is independently hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3- to 20-membered heterocyclyl, where alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are optionally substituted with halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, Phenyl, C 1-3 Haloalkyl, C 1-4 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0089] R2 and R3, when present, are each independently hydrogen, C1-6 alkyl, or C1-6 alkoxy, where alkyl or alkoxy is selected from halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, phenyl, C 1-3Haloalkyl, C 1-3 haloalkoxy, halophenyl);
[0090] R4, when present, is independently hydrogen, deuterium, or C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3- to 20-membered heterocyclyl, where alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are optionally substituted with halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, Phenyl, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0091] R5 and R6, when present, are each independently hydrogen, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, C 3-6 cycloalkenyl, 3- to 20-membered heterocyclyl, and 5- to 16-membered heteroaryl, and the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 It may be optionally substituted with one or more substituents selected from haloalkyl.
[0092] In a preferred embodiment of the second aspect of the present invention, X1 is N and X2, X3 and X4 are all CH.
[0093] In a preferred embodiment of the second aspect of the present invention, X3 is N and X1, X2 and X4 are all CH.
[0094] In a preferred embodiment of the second aspect of the present invention, X1 and X3 are both N and X2 and X4 are both CH.
[0095] In a preferred embodiment of the second aspect of the present invention, X1, X2, X3 and X4 are all CH.
[0096] In a preferred embodiment of the invention relating to the first aspect, in any of the above-mentioned embodiments of the first aspect, Y is CH; or Y is N.
[0097] In a preferred embodiment of the invention relating to the first aspect, in any of the foregoing embodiments of the first aspect, each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0098] Or, each R A are independently hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0099] Or, each R A are independently hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C2-4 alkenyl, C2-4 alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy;
[0100] Or, each R A are independently hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO2, -NH2, methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl;
[0101] Or, each R Aare independently hydrogen, F, Cl, Br, —OH, methyl, ethyl, methoxy, ethoxy; Alternatively, R A is selected from hydrogen, F, Cl, methoxy.
[0102] In a preferred embodiment of the second aspect of the present invention, n1 is 1, 2 or 3; more preferably, n1 is 1 or 2.
[0103] In one preferred embodiment of the second aspect of the present invention, each R B are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0104] More preferably, each R B are independently hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO2, -NH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl; More preferably, each R Bare independently hydrogen, F, Cl, Br, —OH, methyl, ethyl, methoxy, ethoxy; most preferably, R B is selected from hydrogen.
[0105] In a preferred embodiment of the second aspect of the present invention, n2 is 1.
[0106] In one preferred embodiment of the second aspect of the present invention, ring A is a 6-9 membered heterocyclyl or a 6-12 membered heteroaryl; Preferably, ring A is a 6-membered heterocyclyl or a 6-membered heteroaryl; Preferably, Ring A is piperidinyl, hexahydropyrimidinyl, piperazinyl, 1,3-oxazinyl, morpholinyl, thiomorpholinyl, 1,3-thiazinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyrazinyl, 1,4,5,6-tetrahydropyrimidinyl, homopiperidinyl, homopiperazinyl, homomorpholinyl, pyridinyl, pyridazinyl, pyrimidinyl;
[0107] [ka]
[0108] [ka]
[0109] [ka]
[0110] [ka]
[0111] In a preferred embodiment of the invention relating to the second aspect, in any of the foregoing embodiments of the second aspect, each R Care independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0112] Or, each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl; said alkyl, alkoxy, alkylthio, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy;
[0113] Or, each R C are independently hydrogen, halogen, oxo, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 and cycloalkyl; said alkyl, alkoxy, alkylthio, and cycloalkyl are halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-3 Alkyl, C 1-3Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0114] Or, each R C are independently hydrogen, F, Cl, Br, oxo, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl;
[0115] Alternatively, each Rc is independently hydrogen, -CH2CF3, oxo, -CH2CH2CH2OH, -CH2CH2CH2OCH3.
[0116] In a preferred embodiment of the invention relating to the second aspect, in any of the above-mentioned embodiments of the second aspect, n3 is 1, 2, or 3.
[0117] In a preferred embodiment of the invention relating to the second aspect, in any of the preceding embodiments of the second aspect: [ka]
[0118] In a preferred embodiment of the invention relating to the second aspect, in any of the foregoing embodiments of the second aspect, ring B is C5- 10 Cycloalkyl, 3-20 membered heterocyclyl, C6- 14 aryl or 5-16 membered heteroaryl;
[0119] Alternatively, Ring B is C5-7 cycloalkyl, 5-7 membered monocyclic heterocyclyl, 5-14 membered spiroheterocyclyl, 5-14 membered fused heterocyclyl, C6- 10aryl, 5-6 membered monocyclic heteroaryl or 5-14 membered fused heteroaryl;
[0120] Or, ring B is C6 cycloalkyl, C7 cycloalkyl, 6-membered monocyclic heterocyclyl, 7-membered monocyclic heterocyclyl, 4-membered / 4-membered spiro heterocyclyl, 4-membered / 5-membered spiro heterocyclyl, 5-membered / 4-membered spiro heterocyclyl, 5-membered / 5-membered spiro heterocyclyl, 4-membered / 6-membered spiro heterocyclyl, 6-membered / 4-membered spiro heterocyclyl, 5-membered / 6-membered spiro heterocyclyl, 6-membered / 5-membered spiro heterocyclyl, 6-membered / 6-membered spiro heterocyclyl, 4-membered / 4-membered fused heterocyclyl, 4-membered / 5-membered fused heterocyclyl, 5-membered / 4-membered fused heterocyclyl, 5-membered / 5-membered fused heterocyclyl, 5-membered / 6-membered fused heterocyclyl, 6-membered / 5-membered fused heterocyclyl, 4-membered / 6-membered fused heterocyclyl, 6-membered / 4-membered fused heterocyclyl, 6-membered / 6-membered fused heterocyclyl, phenyl, naphthyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 5-membered / 5-membered fused heteroaryl, 5-membered / 6-membered fused heteroaryl, 6-membered / 5-membered fused heteroaryl, 6-membered / 6-membered fused heteroaryl, wherein the heteroatoms in said heterocyclyl, heteroaryl, fused heterocyclyl, fused heteroaryl, spiroheterocyclyl are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;
[0121] [ka]
[0122] In a preferred embodiment of the invention relating to the second aspect, in any of the foregoing embodiments of the second aspect, R Dis selected from -WC(O)NR2OR1, -W-OC(O)NR2R3, -W-NR2C(O)R4, -W-NR2C(O)OR1, -W-NR2C(O)NR2R3, -WS(O)2R4, -W-SO2NR2R3, -W-NR2S(O)2R4, -W-OS(O)2R4, -W-NR2S(O)2NR2R3, -W-OS(O)2NR2R3, -WP(O)(OR1)2, -WP(S)(OR1)2, -WOP(S)(OR1)2, -WB(OH)2;
[0123] Alternatively, R D is selected from -methylene-C(O)NHOH, -methylene-OC(O)NH2, -methylene-SON2NH2, -methylene-NHS(O)2H, -methylene-OS(O)2H, -methylene-NHS(O)2NH2, -methylene-OS(O)2NH2, -methylene-P(O)(OH)2, -methylene-P(S)(OH)2, -methylene-OP(S)(OH)2, -methylene-B(OH)2, -C(O)NHOH, -OC(O)NH2, -SON2NH2, -NHS(O)2H, -OS(O)2H, -NHS(O)2NH2, -OS(O)2NH2, -P(O)(OH)2, -P(S)(OH)2, -OP(S)(OH)2, -B(OH)2;
[0124] Alternatively, R D is selected from -methylene-C(O)NHOH, -methylene-SON2NH2, -methylene-NHS(O)2H, -methylene-NHS(O)2NH2, -methylene-P(O)(OH)2, -methylene-P(S)(OH)2, -methylene-OP(S)(OH)2, -methylene-B(OH)2, -C(O)NHOH, -SON2NH2, -NHS(O)2NH2, -OS(O)2NH2, -P(O)(OH)2, -P(S)(OH)2, -OP(S)(OH)2, -B(OH)2;
[0125] Alternatively, R D is selected from -C(O)NHOH, -SO2NH2, -methylene-NHS(O)2NH2, -NHS(O)2NH2, -B(OH)2, -P(O)(OH)2, -OP(S)(OH)2, -OS(O)2NH2.
[0126] In a preferred embodiment of the invention relating to the second aspect, in any of the preceding embodiments of the second aspect, each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-8 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0127] Or, each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 and cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0128] Or, each R E are independently hydrogen, halogen, -OH, -SH, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 and cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-3 Alkyl, C1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy;
[0129] Or, each R E are independently hydrogen, F, Cl, Br, -OH, -SH, -methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl; Or, each R E are independently hydrogen or F.
[0130] In a preferred embodiment of the invention relating to the second aspect, in any of the above embodiments of the second aspect, n4 is 1, 2, 3 or 4; or n4 is 1, 2 or 3.
[0131] In a preferred embodiment of the invention relating to the second aspect, in any of the foregoing embodiments of the second aspect, L is a bond, —O—, —S—, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 3-6 Cycloalkylene, C 1-3 Archillencio, C 2-6 Alkenylene, C 2-6 Alkynylene, wherein the alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are substituted with deuterium, halogen, C 1-3 Alkyl, C 1-3 optionally substituted with one or more substituents selected from alkoxy, oxo, -CN, -OH, -NH;
[0132] Alternatively, L is a bond, -O-, -S-, methylene, ethylene, propylene, cyclopropylene, cyclobutylene, C 1-3 Alkyleneoxy, C 1-3alkylenethio, vinylene, ethynylene, wherein said methylene, ethylene, propylene, cyclopropylene, cyclobutylene, alkyleneoxy, alkylenethio, vinylene, ethynylene may be substituted with one or more substituents selected from deuterium, halogen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, oxo, -CN, -OH, and -NH;
[0133] Alternatively, L is a bond, -O-, -S-, cyclopropylene, methylenemethoxy, methylenemethyl, methylene-OH, methylene-NH2, ethylene, propylene;
[0134] [ka]
[0135] In a third aspect of the present invention, there is provided a compound of formula (Ia), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0136] wherein Y1 and Y2 are independently selected from C, O, or S, and Y1 and Y2 are not the same; n5 is selected from 1 or 2; when Y2 is not C, n6 is 1, and when Y2 is C, n6 is selected from 1 or 2; X1 to X4, Y, R A , R B , R C , R D , R E , L, ring B, and n1 to n4 are as described in the compounds of formula (I) in any of the above-mentioned embodiments of the first and second aspects of the present invention; In a preferred embodiment of the third aspect of the present invention, Y1 is O and Y2 is C; In a preferred embodiment of the third aspect of the present invention, Y1 is S and Y2 is C; In a preferred embodiment of the third aspect of the present invention, Y2 is O and Y1 is C; In a preferred embodiment of the third aspect of the present invention, Y2 is S and Y1 is C;
[0137] In a preferred embodiment of the invention relating to the third aspect, in any of the preceding embodiments of the third aspect: [ka]
[0138] In a preferred embodiment of the invention relating to the third aspect, in any of the preceding embodiments of the third aspect, at least one R C is oxo.
[0139] In a fourth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-a1): [ka]
[0140] In a fifth aspect, the present invention further provides a compound represented by the following formula (Ib), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0141] wherein Y1 and Y2 are independently selected from C, O, or S, and Y1 and Y2 are not the same; n5 is selected from 1 or 2; when Y2 is not C, n6 is 1, and when Y2 is C, n6 is selected from 1 or 2; X1 to X4, Y, R A , R B , R C, R D , R E , L, ring B, and n1 to n4 are as described in the compounds of formula (I) in any of the above-mentioned embodiments of the first and second aspects of the present invention; In a preferred embodiment of the fifth aspect of the present invention, Y1 is O and Y2 is C; In a preferred embodiment of the fifth aspect of the present invention, Y1 is S and Y2 is C; In a preferred embodiment of the fifth aspect of the present invention, Y2 is O and Y1 is C; In a preferred embodiment of the fifth aspect of the present invention, Y2 is S and Y1 is C;
[0142] In a preferred embodiment of the invention relating to the fifth aspect, in any of the preceding embodiments of the fifth aspect: [ka]
[0143] In a preferred embodiment of the invention relating to the fifth aspect, in any of the preceding embodiments of the fifth aspect, at least one R C is oxo.
[0144] In a sixth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-b1): [ka]
[0145] In a seventh aspect of the present invention, the present invention further provides a compound represented by the following formula (Ic), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0146] In a preferred embodiment of the seventh aspect of the present invention, Y1 is N and Y2 is C; In a preferred embodiment of the seventh aspect of the present invention, Y1 is C and Y2 is N; In a preferred embodiment of the seventh aspect of the present invention, Y1 is C and Y2 is C;
[0147] In a preferred embodiment of the invention relating to the seventh aspect, in any of the preceding embodiments of the seventh aspect: [ka]
[0148] In a preferred embodiment of the invention relating to the seventh aspect, in any of the preceding embodiments of the seventh aspect, at least one R C is oxo.
[0149] In an eighth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-c1): [ka]
[0150] In a ninth aspect of the present invention, the present invention further provides a compound represented by the following formula (Id), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0151] In a preferred embodiment of the ninth aspect of the present invention, Y1 is N and Y2 is C; In a preferred embodiment of the ninth aspect of the present invention, Y1 is C and Y2 is N;
[0152] In a preferred embodiment of the invention relating to the ninth aspect, in any of the preceding embodiments of the ninth aspect: [ka]
[0153] In a preferred embodiment of the invention relating to the ninth aspect, in any of the preceding embodiments of the ninth aspect, at least one R C is oxo.
[0154] In a tenth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-d1): [ka]
[0155] In an eleventh aspect of the present invention, the present invention further provides a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0156] In a preferred embodiment of the eleventh aspect of the present invention, Y1 is N and Y2 is C; In a preferred embodiment of the eleventh aspect of the present invention, Y1 is C and Y2 is N;
[0157] In a preferred embodiment of the invention relating to the eleventh aspect, in any of the preceding embodiments of the eleventh aspect, [ka]
[0158] In a preferred embodiment of the invention relating to the eleventh aspect, in any of the preceding embodiments of the eleventh aspect, RC At least one of is oxo.
[0159] In a twelfth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-e1): [ka]
[0160] In a thirteenth aspect of the present invention, the present invention further provides a compound represented by the following formula (If), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0161] In the formula, Y1, Y2, and Y3 are independently selected from C or N, and Y1, Y2, and Y3 are not simultaneously C or N, and X1 to X4, Y, R A , R B , R C , R D , R E , L, ring B, n1 to n4 are as described in the compounds of formula (I) in any of the above-described embodiments of the first and second aspects of the present invention.
[0162] In a preferred embodiment of the thirteenth aspect of the present invention, one of Y1, Y2 and Y3 is N and the rest are C; In a preferred embodiment of the thirteenth aspect of the present invention, Y1 and Y3 are N and Y2 is C; In a preferred embodiment of the thirteenth aspect of the present invention, Y1 and Y2 are N and Y3 is C; In a preferred embodiment of the thirteenth aspect of the present invention, Y2 and Y3 are N and Y1 is C;
[0163] In a preferred embodiment of the invention relating to the thirteenth aspect, in any of the preceding embodiments of the thirteenth aspect, [ka]
[0164] In a fourteenth aspect of the present invention, the present invention further provides a compound represented by the following formula (I-f1): [ka]
[0165] In a fifteenth aspect of the present invention, the present invention further provides a compound represented by the following formula (II), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0166] In the formula, X1, X2, X3, X4, R A , R D , R E wherein rings B, L, n1 and n4 are as described in the compounds of formula (I) in any of the above embodiments of the first and second aspects of the present invention; Y1 is N and Y2 is CR B , or N;
[0167] Each R B , and R Y are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -Z-OR1, -Z-SR1, -Z-NR2R3, -Z-NR2C(O)R4, -Z-NR2C(O)OR1, -ZC(O)R4, -ZC(O)OR1, -ZC(O)(CR5R6) n C(O)R4, -ZC(O)(CR5R6)n C(O)OR1, -ZC(O)NR2R3, -ZS(O)2R4, -ZS(O)2NR2R3, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3- to 20-membered heterocyclyl, and 5- to 16-membered heteroaryl; and the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; n is 0, 1, 2 or 3;
[0168] In a preferred embodiment of the fifteenth aspect of the present invention, X1 is N, and X2, X3 and X4 are all CH.
[0169] In a preferred embodiment of the fifteenth aspect of the present invention, X3 is N and X1, X2 and X4 are all CH.
[0170] In a preferred embodiment of the fifteenth aspect of the present invention, X1 and X3 are both N and X2 and X4 are both CH.
[0171] In a preferred embodiment of the fifteenth aspect of the present invention, X1, X2, X3 and X4 are all CH.
[0172] In a preferred embodiment of the invention relating to the fifteenth aspect, in any of the preceding embodiments of the fifteenth aspect, Y2 is CH; or Y2 is N.
[0173] In a preferred embodiment of the invention relating to the fifteenth aspect, in any of the preceding embodiments of the fifteenth aspect, R B , are hydrogen, deuterium, halogens, oximes, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0174] Or, R B , is hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO2, -NH2, cyano, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl, vinyl, ethynyl;
[0175] Alternatively, R B , is hydrogen, F, Cl, Br, -OH, cyano, methyl, ethyl, methoxy, ethoxy, vinyl, ethynyl; Alternatively, R B , is selected from hydrogen.
[0176] In a preferred embodiment of the invention relating to the fifteenth aspect, in any of the preceding embodiments of the fifteenth aspect, each R Y are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, where alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl are substituted with deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy, halophenyl;
[0177] Or, each R Y are independently hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO2, -NH2, cyano, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl, vinyl, ethynyl, propenyl, propynyl;
[0178] Or, each R Y are independently hydrogen, deuterium, F, Cl, Br, -OH, cyano, amine, methyl, ethyl, methoxy, ethoxy, methylthio, ethylthio, vinyl, ethynyl, propenyl, propynyl; Alternatively, R Y is selected from hydrogen, amine, methyl, vinyl, ethynyl.
[0179] In a preferred embodiment of the invention relating to the fifteenth aspect, in any of the preceding embodiments of the fifteenth aspect: [ka]
[0180] In a sixteenth aspect, the present invention further provides a compound represented by the following formula (III), a stereoisomer, tautomer, or mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0181] In the formula, R A , R B , R C , R D , R E wherein rings B, L, n2, n3 and n4 are as described in the compounds of formula (I) in any of the above embodiments of the first and second aspects of the present invention; X1, X2, X3, and Y are each independently CH or N; and if X1, X2, and X3 are all CH, then Y is not CH; n1 is 1, 2, 3 or 4; Ring A is a 5-10 membered heterocyclyl or a 5-12 membered heteroaryl; In a preferred embodiment of the sixteenth aspect of the present invention, X1 is N, and X2 and X3 are both CH.
[0182] In a preferred embodiment of the sixteenth aspect of the present invention, X3 is N, and X1 and X2 are both CH.
[0183] In a preferred embodiment of the sixteenth aspect of the present invention, X1 and X3 are both N and X2 is CH.
[0184] In a preferred embodiment of the sixteenth aspect of the present invention, X1, X2, and X3 are all CH.
[0185] In a preferred embodiment of the invention relating to the sixteenth aspect, in any of the preceding embodiments of the sixteenth aspect, Y is CH; or Y is N.
[0186] In a preferred embodiment of the invention relating to the sixteenth aspect, in any of the preceding embodiments of the sixteenth aspect: [ka]
[0187] In a seventeenth aspect of the present invention, the present invention further provides a compound represented by the following formula (IV-1), (IV-2), (IV-3), or (IV-4), a stereoisomer, a tautomer, or a mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0188] In the formula, X1, R A , R D , R E , R C wherein ring B, n1 and n4 are as described in the compounds of formula (I) in any of the foregoing embodiments of the first and second aspects of the present invention; Y2 is C or N;
[0189] In a preferred embodiment of the present invention relating to formula (IV-1), (IV-2), (IV-3) or (IV-4), in any of said formulas (IV-1), (IV-2), (IV-3) and (IV-4), each Rc is independently hydrogen, oxo, -OH, -SH, -NH2, -Boc, -C(O)CH2OH, -NHC(O)CH3, carboxy, -S(O)2CH3, -S(O)2NH2, -methoxy, methylthio, -CH2CF3, cyclopropyl;
[0190] In a preferred embodiment of the present invention relating to formula (IV-1), (IV-2), (IV-3) or (IV-4), in any of formulas (IV-1), (IV-2), (IV-3) and (IV-4), each Rc is independently hydrogen, oxo, -Boc, -C(O)CHOH, -CHCF, cyclopropyl;
[0191] In a preferred embodiment of the present invention relating to formula (IV-1), (IV-2), (IV-3) or (IV-4), in any of formulas (IV-1), (IV-2), (IV-3) and (IV-4), each Rc is independently hydrogen, oxo;
[0192] [ka]
[0193] [ka]
[0194] In a preferred embodiment of the present invention relating to formula (IV-1), (IV-2), (IV-3) or (IV-4), in any of said formulas (IV-1), (IV-2), (IV-3) and (IV-4), R D is -SO2NH2.
[0195] In an eighteenth aspect of the present invention, the present invention further provides a compound represented by the following formula (V-1), a stereoisomer, a tautomer, or a mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0196] In the formula, X1, R A , R E , R C , n1 and n4 are described as any of formula (I) or formula (IV-1), (IV-2), (IV-3) or (IV-4) in any of the foregoing embodiments of the first and second aspects of the present invention; Q is C or N; In one preferred embodiment of formula (V-1) of the present invention, in any of the formulas (V-1), Q is C;
[0197] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0198] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0199] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0200] In a preferred embodiment of the present invention relating to formula (V-1), in any of the above formulas (V-1), R A is selected from hydrogen, F, Cl, methoxy, ethoxy; In a preferred embodiment of the present invention relating to formula (V-1), in any of the above formulas (V-1), R A is selected from hydrogen, F, and methoxy;
[0201] In a preferred embodiment of the present invention relating to formula (V-1), in any of the above formulas (V-1), R E is selected from hydrogen, deuterium, F, and Cl; In a preferred embodiment of the present invention relating to formula (V-1), in any of the above formulas (V-1), R E is hydrogen, F;
[0202] In a preferred embodiment of formula (V-1) of the present invention, in any of the formulas (V-1), n1 is 1 or 2; In a preferred embodiment of formula (V-1) of the present invention, in any of the formulas (V-1), n4 is 1 or 2; In a preferred embodiment of formula (V-1) of the present invention, in any of the formulas (V-1), n4 is 2;
[0203] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0204] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0205] In a preferred embodiment of the formula (V-1) of the present invention, in any of the formulas (V-1), [ka]
[0206] In a nineteenth aspect of the present invention, the present invention further provides a compound represented by the following formula (V-2), a stereoisomer, a tautomer, or a mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0207] In a preferred embodiment of the formula (V-2) of the present invention, in any of the formulas (V-2), [ka]
[0208] In a preferred embodiment of the formula (V-2) of the present invention, in any of the formulas (V-2), [ka]
[0209] In a preferred embodiment of the formula (V-2) of the present invention, in any of the formulas (V-2), [ka]
[0210] In a preferred embodiment of the formula (V-2) of the present invention, in any of the formulas (V-2), [ka]
[0211] In a twentieth aspect of the present invention, the present invention further provides a compound represented by the following formula (V-3), a stereoisomer, a tautomer, or a mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0212] In a preferred embodiment of the formula (V-3) of the present invention, in any of the formulas (V-3), R C is hydrogen;
[0213] In a preferred embodiment of formula (V-3) of the present invention, in any of the formulas (V-3), [ka]
[0214] In a preferred embodiment of formula (V-3) of the present invention, in any of the formulas (V-3), [ka]
[0215] In a preferred embodiment of formula (V-3) of the present invention, in any of the formulas (V-3), [ka]
[0216] In a twenty-first aspect of the present invention, the present invention further provides a compound represented by the following formula (V-4), a stereoisomer, a tautomer, or a mixture thereof of said compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound: [ka]
[0217] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0218] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0219] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0220] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0221] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0222] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0223] In a preferred embodiment of the formula (V-4) of the present invention, in any of the formulas (V-4), [ka]
[0224] In a 22nd aspect of the present invention, X2 and X4 are R A and more preferably X2 is R A This relates to a preferred embodiment of any of the first to twenty-first aspects of the invention, wherein
[0225] In a preferred embodiment of the present invention, the compound of the present invention is selected from the following group: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10]
[0226] The present invention also aims to provide a method for producing a compound represented by formula (I), (Ia) to (If), a stereoisomer, a tautomer, or a mixture thereof of the compound, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of the compound, or a stable isotope derivative, metabolite, or prodrug of the compound.
[0227] The compounds can be prepared by a number of methods, including but not limited to: [ka] [ka]
[0228] In a preferred embodiment of the present invention, [ka]
[0229] In a preferred embodiment of the present invention, [ka] [ka]
[0230] In a preferred embodiment of the present invention, [ka] [ka]
[0231] In a preferred embodiment of the present invention, [ka] [ka]
[0232] In a preferred embodiment of the present invention, [ka]
[0233] In a preferred embodiment of the present invention, [ka]
[0234] In a preferred embodiment of the present invention, [ka]
[0235] In a preferred embodiment of the present invention, [ka]
[0236] In a preferred embodiment of the present invention, [ka]
[0237] In a preferred embodiment of the present invention, [ka]
[0238] In the above scheme, Hal in the compound represents halogen, and each substituent is as defined above. Those skilled in the art can easily determine reaction conditions such as temperature, time, solvent, etc. suitable for use in the above scheme after reading this disclosure.
[0239] The present invention also provides pharmaceutical compositions comprising a compound of the present invention, its stereoisomer, tautomer, or mixtures thereof, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
[0240] The present invention further provides a pharmaceutical composition comprising a compound according to the present invention, a stereoisomer, a tautomer, or a mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound, and a pharmaceutically acceptable adjuvant.
[0241] The present invention is also directed to the use of a compound according to the present invention, a stereoisomer, a tautomer, or a mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound, in the manufacture of a medicament for the treatment or prevention of a disease mediated by ENPP1.
[0242] In some embodiments, the ENPP1-mediated disease is cancer or a tumor-related disease, such as pancreatic cancer.
[0243] In some embodiments, the ENPP1-mediated disease is a cardiovascular disease, such as heart failure or myocardial infarction.
[0244] The present invention also aims to provide a method for the prevention and / or treatment of diseases mediated by ENPP1, which method comprises administering to a patient a therapeutically effective amount of a compound according to the present invention, a stereoisomer, a tautomer, or a mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound, or a pharmaceutical composition according to the present invention.
[0245] The compounds of the present invention, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative, or a pharmaceutically acceptable salt thereof, can be administered in combination with another anti-cancer agent or immune checkpoint inhibitor for use in the treatment or prevention of a disease mediated by ENPP1 (e.g., cancer or tumor).
[0246] When the compounds of the present invention, or their prodrugs, tautomers, stereoisomers, solvates, isotopic derivatives, or pharmaceutically acceptable salts thereof, are administered in combination with another anti-cancer agent or immune checkpoint inhibitor for use in treating cancer or tumors, the compounds of the present invention, or their pharmaceutically acceptable salts, can provide an enhanced anti-cancer effect.
[0247] definition The term "alkyl," unless otherwise defined, refers to a monovalent saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms (i.e., C 1-10 alkyl group), more preferably 1 to 8 carbon atoms (C 1-8 alkyl group), more preferably 1 to 6 carbon atoms (i.e., C 1-6 alkyl group), e.g., "C 1-6 An "alkyl group" refers to an alkyl group having 1 to 6 carbon atoms in the carbon chain (specifically, 1, 2, 3, 4, 5, or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0248] The term "alkenyl," unless otherwise defined, refers to a straight- or branched-chain unsaturated aliphatic hydrocarbon group consisting of carbon and hydrogen atoms and having at least one double bond. An alkenyl group has 2 to 20 carbon atoms, preferably 2-10 carbon atoms (i.e., C 2-10 alkenyl group), more preferably 2 to 8 carbon atoms (C 2-8 alkenyl groups), more preferably 2 to 6 carbon atoms (i.e., C 2-6 alkenyl groups), 2 to 5 carbon atoms (i.e., C 2-5 alkenyl groups), 2 to 4 carbon atoms (i.e., C 2-4 alkenyl groups), 2-3 carbon atoms (i.e., C 2-3 alkenyl group), may contain two carbon atoms (i.e., a C alkenyl group), e.g., "C 2-6 An "alkenyl group" means that the group is an alkenyl group having 2 to 6 (specifically, 2, 3, 4, 5, or 6) carbon atoms in the carbon chain. Non-limiting examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, and 1,3-butadienyl.
[0249] The term "alkynyl," unless otherwise defined, refers to a straight- or branched-chain unsaturated aliphatic hydrocarbon group consisting of carbon and hydrogen atoms and having at least one triple bond. An alkynyl group has 2 to 20 carbon atoms, preferably 2-10 carbon atoms (i.e., C 2-10 alkynyl), more preferably 2 to 8 carbon atoms (C 2-8 alkynyl), more preferably 2 to 6 carbon atoms (i.e., C 2-6 alkynyl), 2 to 5 carbon atoms (i.e., C 2-5 alkynyl), 2 to 4 carbon atoms (i.e., C 2-4 alkynyl), 2-3 carbon atoms (i.e., C 2-3 alkynyl), may contain two carbon atoms (i.e., C2 alkynyl), e.g., "C 2-6"Alkynyl" means that the group is alkynyl and the carbon chain contains 2 to 6 carbon atoms (specifically, 2, 3, 4, 5, or 6 carbon atoms). Non-limiting examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, and 1-butynyl.
[0250] The term "cycloalkyl," unless otherwise defined, refers to a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms, preferably 3 to 12 carbon atoms (i.e., C 3-12 cycloalkyl), more preferably 3 to 10 carbon atoms (C 3-10 cycloalkyl), more preferably 3 to 6 carbon atoms (C 3-6 cycloalkyl), 4 to 6 carbon atoms (C 4-6 cycloalkyl), 5-6 carbon atoms (C 5-6 Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, and the like.
[0251] The term "alkoxy," unless otherwise defined, refers to an -O-alkyl group, wherein the alkyl group is as defined above, i.e., containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 (specifically, 1, 2, 3, 4, 5, or 6) carbon atoms. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, and the like.
[0252] The term "alkylthio", unless otherwise specified, refers to replacing the oxygen in the above "alkoxy" with a sulfur.
[0253] The term "halogen" or "halo," unless otherwise specified, refers to F, Cl, Br, or I. The term "haloalkyl" means that one, two, or more hydrogen atoms, or all hydrogen atoms in an alkyl group, as defined above, are replaced with halogen. Representative examples of haloalkyl groups include CCl, CF, CHCl, CHCl, CHBr, CHI, CHCF, CFCF, and the like.
[0254] The term "heterocyclic group," unless otherwise defined, refers to a saturated or partially unsaturated monocyclic, bicyclic, or polycyclic hydrocarbon substituent, having a non-aromatic structure and containing 3 to 20 ring atoms, of which 1, 2, 3, or more ring atoms are selected from N, O, or S, and the remaining ring atoms are C. Preferably, the heterocyclic group contains 3 to 12 ring atoms, more preferably 3 to 10 ring atoms, or 3 to 8 ring atoms, or 3 to 6 ring atoms, or 4 to 6 ring atoms, or 5 to 6 ring atoms. The number of heteroatoms is preferably 1 to 4, and more preferably 1 to 3 (i.e., 1, 2, or 3). Examples of monocyclic heterocyclic groups include pyrrolidyl, imidazolidinyl, tetrahydrofuran, dihydropyrrole, piperidinyl, piperazinyl, and pyranyl. Polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-fused-ring heterocyclic groups.
[0255] The term "fused heterocyclyl," unless otherwise defined, refers to a 5- to 20-membered polycyclic heterocyclyl in which each ring in the system shares an adjacent pair of atoms with another ring in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron system, and in which one or more ring atoms are selected from N, O, or S heteroatoms, and the remaining ring atoms are C. Preferably, it is 6- to 14-membered, and more preferably, it is 7- to 10-membered. Depending on the number of rings, heterocyclyls can be classified as bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyls, preferably bicyclic or tricyclic, and more preferably 4-membered / 4-membered fused heterocyclyl, 4-membered / 5-membered fused heterocyclyl, 5-membered / 4-membered fused heterocyclyl, 5-membered / 5-membered fused heterocyclyl, 5-membered / 6-membered fused heterocyclyl, 6-membered / 5-membered fused heterocyclyl, 4-membered / 6-membered fused heterocyclyl, 6-membered / 4-membered fused heterocyclyl, and 6-membered / 6-membered fused heterocyclyl. Non-limiting examples of fused heterocyclyls include: [ka]
[0256] Examples include:
[0257] The term "spiroheterocyclyl," unless otherwise defined, refers to a 5- to 20-membered polycyclic heterocyclyl that shares one atom (called a spiro atom) between monocyclic rings, in which one or more ring atoms are selected from N, O, or S heteroatoms, and the remaining ring atoms are C. It may contain one or more double bonds, but no ring has a completely conjugated π-electron system. It is preferably 6- to 14-membered, more preferably 7- to 10-membered. Based on the number of spiro atoms shared between the rings, spiroheterocyclyls can be classified as monospiroheterocyclyls, bispiroheterocyclyls, or polyspiroheterocyclyls, with monoheterocyclyls and bispiroheterocyclyls being preferred. More preferred are 4-membered / 4-membered spiroheterocyclyl, 4-membered / 5-membered spiroheterocyclyl, 5-membered / 4-membered spiroheterocyclyl, 5-membered / 5-membered spiroheterocyclyl, 4-membered / 6-membered spiroheterocyclyl, 6-membered / 4-membered spiroheterocyclyl, 5-membered / 6-membered spiroheterocyclyl, 6-membered / 5-membered spiroheterocyclyl, and 6-membered / 6-membered spiroheterocyclyl. Non-limiting examples of spiroheterocyclyl include: [ka]
[0258] Examples include:
[0259] The term "aryl," unless otherwise specified, refers to monocyclic, bicyclic, and tricyclic aromatic carbocyclic ring systems containing 6 to 16 carbon atoms, or 6 to 14 carbon atoms, or 6 to 12 carbon atoms, or 6 to 10 carbon atoms, preferably 6 to 10 carbon atoms. The term "aryl" can be used interchangeably with the term "aromatic ring." Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrene, pyrenyl, and the like.
[0260] The term "heteroaryl group," unless otherwise specified, refers to an aromatic monocyclic, bicyclic, or polycyclic ring system containing 5-16 membered structures, or 5-14 membered structures, 5-12 membered structures, 5-10 membered structures, 5-8 membered structures, or 5-6 membered structures, in which one, two, three, or more of the ring atoms are heteroatoms and the remaining atoms are carbon. The heteroatoms are independently selected from O, N, or S, with the number of heteroatoms preferably being one, two, or three. Examples of heteroaryl groups include furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothienyl, benzopyridinyl, and benzopyrimidinyl. , benzopyrazinyl, benzimidazolyl, benzophthalazinyl, pyrroly[2,3-b]pyridinyl, imidazolyl[1,2-a]pyridinyl, pyrazolyl[1,5-a]pyridinyl, pyrazolyl[1,5-a]pyrimidinyl, imidazolyl[1,2-b]pyridazinyl, [1,2,4]triazolyl[4,3-b]pyridazinyl, [1,2,4]triazolyl[1,5-a]pyrimidinyl, [1,2,4]triazolyl[1,5-a]pyridinyl and the like.
[0261] The term "fused heteroaryl," unless otherwise specified, refers to an unsaturated fused ring system having aromaticity, containing 5 to 14 ring atoms (including at least one heteroatom) and formed by two or more ring systems linked together by sharing two adjacent atoms, provided that one, two, three, or more of the ring atoms are heteroatoms, and the remaining atoms are carbon. The heteroatoms are independently selected from O, N, or S, and the number of heteroatoms is preferably 1, 2, or 3. Preferred examples include 5- to 12-membered fused heteroaryls, 7- to 12-membered fused heteroaryls, and 9- to 12-membered fused heteroaryls, and more preferably 5-membered / 5-membered fused heteroaryls, 5-membered / 6-membered fused heteroaryls, 6-membered / 5-membered fused heteroaryls, and 6-membered / 6-membered bicyclic fused heteroaryls. Examples of fused heteroaryl groups include, but are not limited to, benzofuranyl, benzisofuranyl, benzothiophenyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, 2-quinolinone, 4-quinolinone, 1-isoquinolinone, isoquinolyl, acridinyl, phenanthridinyl, benzopyridazinyl, phthalazinyl, quinazolinyl, quinoxalinyl, phenazinyl, pteridinyl, purinyl, naphthyridinyl, phenazinyl, and phenothiazinyl groups.
[0262] The term "pharmaceutically acceptable salt" or "medicinal salt," unless otherwise specified, refers to a salt that is suitable, within the scope of reasonable medical judgment, for contact with the tissues of mammals, particularly humans, without undue toxicity, irritation, allergic response, etc., and that is commensurate with a reasonable benefit / risk ratio; for example, pharmaceutically acceptable salts of amines, carboxylic acids, and other compounds are well known to those skilled in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or can be prepared by reacting the free base or free acid alone with a suitable reagent.
[0263] The term "isotopically labeled analogs," unless otherwise specified, refers to isotopically labeled molecules in compounds of Formula I-II, thereby providing isotopically labeled analogs that may have improved pharmacological activity. Isotopes commonly used for isotopic labels are hydrogen isotopes. 2 H and 3 H, a carbon isotope 11 C. 13 C and 13 C, a chlorine isotope 35 Cl and 37 Cl, a fluorine isotope 18 F, an iodine isotope 123 I and 125 I, a nitrogen isotope 13 N and 15 N, an oxygen isotope 15 O. 17 O and 18 O and sulfur isotopes 35 These isotopically labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. 2 H), 3 H and carbon 13 C is widely used because it is easy to label and detect. 2 Substitution of heavy isotopes such as H can increase metabolic stability, prolong half-life, and reduce dosage, providing therapeutic advantages. Generally, isotope-labeled compounds are synthesized from labeled starting compounds using known synthetic techniques, similar to the synthesis of non-isotopically labeled compounds.
[0264] The term "isotopic derivative" means that, unless otherwise specified, the compounds of the present invention can exist in isotopically labeled or isotopically enriched forms, which have one or more atoms whose atomic mass or mass number differs from the atomic mass or mass number of many atoms commonly found in nature. The isotopes can be radioactive or non-radioactive. Isotopes commonly used as isotopic labels include hydrogen isotopes, 2 H and 3 H, carbon isotope: 13 C and 14 C, chlorine isotope:35 Cl and 37 Cl, fluorine isotopes: 18 F, an iodine isotope: 123 I and 125 I, nitrogen isotope: 13 N and 15 N, oxygen isotopes: 15 O. 17 O and 18 O and sulfur isotopes 35 These isotope-labeled compounds can be used to investigate the distribution of pharmaceutical molecules in tissues. 3 H and 13 C is more widely used because it is easy to label and detect. Certain heavy isotopes, such as deuterium ( 2 The substitution of H) increases metabolic stability and half-life, thereby allowing for lower doses to provide therapeutic benefit. Isotopically labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques, similar to the synthesis of non-isotopically labeled compounds.
[0265] The term "solvate," unless otherwise specified, refers to a physical association of a compound of the present invention with one or more solvent molecules (whether organic or inorganic). Such physical association includes hydrogen bonding. In some cases, the solvate can be isolated, for example, when one or more solvent molecules are incorporated into the lattice of a crystalline solid. The solvent molecules in the solvate can exist in an ordered and / or disordered arrangement. The solvate can contain stoichiometric or non-stoichiometric solvent molecules. "Solvate" includes solvates that are separable from the solution phase. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are known in the art.
[0266] The term "stereoisomers," unless otherwise specified, refers to compounds that have identical chemical constitution but differ with regard to the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereoisomers, conformational isomers (rotational isomers), geometric (cis / trans) isomers, atropisomers, and the like. Any resulting mixture of stereoisomers may be separated into neat or substantially neat geometric isomers, enantiomers, and diastereomers on the basis of differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization techniques.
[0267] The term "tautomer," unless otherwise specified, refers to structural isomers of different energies that are interconvertible via a low energy barrier. When tautomerism is possible (e.g., in solution), chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also called prototropic tautomers) include interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions via reorganization of some of the bonding electrons.
[0268] Unless otherwise specified, structures depicted in the present invention are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure: for example, R and S configurations about asymmetric centers, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Thus, individual stereochemical isomers, enantiomeric, diastereomeric, or geometric (or conformational) mixtures are within the scope of the presently disclosed invention.
[0269] The term "cocrystal," unless otherwise specified, is used to describe a situation in which neutral molecular components exist in a defined stoichiometric ratio within a crystalline compound. The preparation of pharmaceutical cocrystals allows for modifications to be made to an active pharmaceutical ingredient in crystalline form, which may in turn alter its physicochemical properties without impairing its intended biological activity (see Pharmaceutical Salts and Co-crystals, edited by J. Wouters & L. Quere, RSC Publishing, 2012).
[0270] The term "polymorph," unless otherwise specified, refers to different arrangements of chemical drug molecules, generally manifested as the form in which a drug substance exists in the solid state. Drugs can exist in multiple crystalline forms, and different crystalline forms of the same drug may dissolve and be absorbed differently in the body, thereby affecting the dissolution and release of the drug product.
[0271] The term "metabolite," unless otherwise specified, refers to a product produced through metabolism in the body of the specified compound or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art and activity measured using tests such as those described herein. Such products may result, for example, from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of an administered compound. Thus, the present invention includes metabolic products of the compounds disclosed herein, including metabolic products produced by contacting a compound disclosed herein with a mammal for a sufficient period of time.
[0272] The term "prodrug," unless otherwise specified, refers to a drug that is converted into the parent drug in vivo. Prodrugs are often useful because they improve undesirable physical or biological properties. Physical properties typically relate to solubility (too much or too little in lipids or water) and stability, while problematic biological properties include rapid metabolism or low bioavailability, but may themselves be related to physicochemical properties. For example, a prodrug may be made bioavailable by oral administration, whereas the parent drug is not. A prodrug may have higher solubility than the parent drug in pharmaceutical compositions. An example of a prodrug may be, but is not limited to, any compound of the present invention that is administered as an ester ("prodrug") to facilitate transport across cell membranes. However, while water solubility is detrimental to transport, water solubility is beneficial once inside cells, where it is subsequently metabolized and hydrolyzed to a carboxylic acid, i.e., the active form. Another example of a prodrug is a short peptide (polyamino acid) attached to an acid group. The peptide is metabolized to reveal the active moiety.
[0273] The term "optionally substituted" means that, unless otherwise specified, the hydrogen atoms at substitutable positions of the group are not substituted or are substituted with one or more substituents, such as halogen, hydroxy, mercapto, cyano, nitro, amino, azide, oxo, carboxyl, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 Cycloalkyl groups, C 3-10 Cycloalkylsulfonyl group, 3-10 membered heterocycloalkyl group, C 6-14 It is preferable that the C is selected from the group consisting of an aryl group and a 5- to 10-membered heteroaryl ring group. 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkyl group, C 3-10 Cycloalkyl groups, C 3-10Cycloalkylsulfonyl group, 3-10 membered heterocycloalkyl group, C 6-14 The aryl group or the 5- to 10-membered heteroaryl ring group is not particularly limited to halogen, hydroxyl group, amino group, cyano group, C 1-6 Alkyl group or C 1-6 The oxo group may be optionally substituted with one or more selected from alkoxy groups. The oxo group refers to a group in which two H atoms at the same substitution site are substituted with the same O atoms to form a double bond.
[0274] The advantageous effects of the present invention are: This invention provides a new direction for the development of novel ENPP1 inhibitors. In vitro biochemical and MDA-MB-231 cell enzyme activity studies demonstrated that these compounds possess potent inhibitory effects against both recombinant and endogenously expressed ENPP1 enzymes, with low inhibitory activity and good selectivity against ENPP2. In vitro ADME studies demonstrated high stability in liver microsomes, no risk of hERG inhibition, and good cell permeability. Pharmacokinetic studies in mice demonstrated favorable bioavailability and exposure, and excellent metabolic properties, making these compounds promising compounds for the treatment of ENPP1-mediated diseases.
[0275] MODE FOR CARRYING OUT THE INVENTION The present invention will be further described below based on specific examples. It should be understood that these examples are used only to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which specific conditions are not specified in the following examples are generally performed according to conventional conditions or the manufacturer's recommended conditions. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, methods and materials similar or equivalent to those described herein can all be applied to the method of the present invention. The preferred methods and materials described herein are for illustrative purposes only.
[0276] The structures of the compounds of the present invention were identified by nuclear magnetic resonance (NMR) and / or liquid chromatography / mass spectrometry (LC-MS) and / or high performance liquid chromatography (HPLC). The NMR was measured using a Bruker 400 MHz or / and a Varian 400 MHz spectrometer, the LC-MS was measured using an Agilent 1260 Infinity II-6120 / 6125MSD spectrometer, and the HPLC was measured using a Waters Acquity UPLC_2 or / and a Shimadzu LC2030 or / and an Agilent 1260 Infinity II spectrometer.
[0277] Starting materials in the examples of the present invention are known, commercially available, or can be synthesized using or according to methods known in the art.
[0278] The present invention provides a method for producing the compound. The compound of the present invention can be produced by the following procedure.
[0279] In the examples below, the abbreviations have the following meanings: [Table 2]
[0280] The example compounds were named using PerkinElmer's Chemdraw® (version 20.0.0.41).
[0281] Preparation Example 1 Preparation of (4-bromo-2,6-difluorophenyl)methylamine: [ka]
[0282] Step 1: Preparation of (E)-4-bromo-2,6-difluorobenzene(methyl)aldoxime 4-Bromo-2,6-difluorobenzaldehyde (50 g, 0.23 mol, 1.0 eq.), hydroxylamine hydrochloride (78.61 g, 1.13 mol, 5.0 eq.), and sodium acetate (79.1 g, 1.13 mol, 5.0 eq.) were added to ethanol (2 L), stirred, heated to 90 °C, and refluxed for 4 h. The reaction was monitored for completion by LCMS. After cooling, the ethanol solvent was removed under reduced pressure. 1 L of water was added. The mixture was extracted with ethyl acetate (×2). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the desired compound (50 g, 93.64% yield). LCMS (ESI): [M+H] + = 236.0.
[0283] Step 2: Preparation of (4-bromo-2,6-difluorophenyl)methylamine (E)-4-Bromo-2,6-difluorobenzene(methyl)aldoxime (12.0 g, 93.22 mmol, 1.0 eq.) and zinc powder (60.9 g, 932.2 mmol, 10.0 eq.) were dissolved in acetic acid solution (300 mL), and the mixture was stirred at room temperature (20°C) for 4 hours.
[0284] The reaction was monitored for completion by LCMS. The reaction mixture was filtered, the filtrate was concentrated, the residue was dissolved in water (200 mL), the filtrate was adjusted to basicity with saturated sodium hydroxide solution, and extracted with ethyl acetate (3 × 200 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash chromatography (Silica gel, DCM / MeOH = 20:1) to obtain the target compound (11.8 g, yield 57%). LCMS (ESI): [M+H] + = 222.0; 1 HNMR (400MHz, DMSO-d6) δ 7.57-7.30 (m, 2H), 3.66 (s, 2H).
[0285] Preparation Example 2 Preparation of 7-methoxy-1,8-naphthyridin-4-ol: [ka]
[0286] First step: Preparation of 5-(((6-methoxypyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 2,2-Dimethyl-1,3-dioxane-4,6-dione (23.82 g, 165.3 mmol, 0.9 eq.) was dissolved in triethyl orthoformate (91 mL, 615.27 mmol, 3.35 eq.) and reacted at 90 °C for 1.5 h. The mixture was then cooled to 70 °C. 2-Amino-6-methoxypyridine (22.8 g, 183.66 mmol, 1.0 eq.) was added slowly in portions, and the reaction was continued at 70 °C for 30 min. The reaction was monitored for completion using TLC and LCMS. The mixture was cooled to room temperature, filtered, and the filter cake was washed with petroleum ether and dried to give the target compound (38.3 g, 74.94% yield). LCMS (ESI) [2M+Na] + = 579.1; 1 H NMR (400 MHz, DMSO- d6) δ 11.33 (d, J = 13.6 Hz, 1H), 9.18 (d, J = 14.0 Hz, 1H), 7.78 (q, J = 8.0 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 3.91 (s, 3H), 1.69 (s, 6H).
[0287] Second step: Preparation of 7-methoxy-1,8-naphthyridin-4-ol 5-(((6-Methoxypyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (20 g, 71.88 mmol, 1.0 eq.) was dissolved in diphenyl ether (95.3 mL) and reacted at 200°C for 6 hours. After the reaction was completed, the mixture was cooled to room temperature, and a large amount of petroleum ether was added to precipitate a solid. The solid was filtered, and the filter cake was washed with petroleum ether and dried to obtain the target compound (10.3 g, yield 81.34%). LCMS (ESI) [M+H] + = 177.1; 1 H NMR (400 MHz, DMSO- d6) δ 11.98 (s, 1H), 8.29 (d, J = 8.8 Hz, 1H), 7.78 - 7.75 (m, 1H), 6.79 (d, J = 8.4 Hz, 1H), 6.05 - 6.03 (m, 1H), 3.96 (s, 3H)
[0288] Example 1 Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-3-oxo-4-(2,2,2-trifluoroethyl)-3,4-dihydropyrimido[4,5-c]quinolin-2(1H)-yl)methyl)benzenesulfonamide (Compound 1): [ka]
[0289] Step 1: Preparation of diethyl 2-(((4-fluoro-3-methoxyphenyl)amino)methylene)malonate 4-Fluoro-3-methoxyaniline (9.79 g, 0.07 mol, 1.5 eq.) and 1,3-diethyl 2-(ethoxymethylene)malonate (10 g, 0.05 mol, 1 eq.) were added to ethanol (200 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the product was purified by flash silica gel column chromatography (Silica gel, PE:EA = 5:95) to obtain the target compound (12.8 g, yield 88.91%). LCMS (ESI) [M+H] + =312.1; 1H NMR (400 MHz, DMSO-d6) δ 10.70 (d, J = 13.6 Hz, 1H), 8.36 (d, J = 13.6 Hz, 1H), 7.24 (m, J = 5.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 1H), 4.21 (m, J = 7.2 Hz, 2H), 4.13 (m, J = 7.2 Hz, 2H), 3.88 (s, 3H), 1.26 (m, J = 8.6 Hz, 6H).
[0290] Step 2: Preparation of ethyl 4-chloro-6-fluoro-7-methoxyquinoline-3-carboxylate Diethyl 2-(((4-fluoro-3-methoxyphenyl)amino)methylene)malonate (5 g, 16.06 mmol) and phosphorus oxychloride (8 mL) were placed in a 100 mL flask, the temperature was raised to 100° C., and the reaction was stirred for 5 hours. The reaction was monitored for completion by LCMS. After cooling to room temperature, the mixture was slowly added dropwise to 200 mL of water in a flask. After cooling, the mixture was neutralized by gradually adding aqueous sodium bicarbonate solution, and extracted with ethyl acetate (200 mL × 2). The organic phases were combined and washed with salt. The solvent was then evaporated under reduced pressure to give the target compound (4.2 g, yield 92.19%). LCMS (ESI) [M + H] + = 284.0.
[0291] Step 3: Preparation of ethyl 4-cyano-6-fluoro-7-methoxyquinoline-3-carboxylate Ethyl 4-chloro-6-fluoro-7-methoxyquinoline-3-carboxylate (3.1 g, 10.93 mmol, 1.0 eq.) and copper cyanide (3.9 g, 43.72 mmol, 4.0 eq.) were added to 20 mL of NMP and reacted at 150 °C for 15 hours. The mixture was filtered while still hot, water (100 mL) was added, and the mixture was extracted with ethyl acetate (200 mL × 2). The organic phase was washed five times with brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to remove the solvent. Silica gel was added to prepare a sample, which was then isolated and purified using a flash silica gel column (Silica gel, PE:EA = 8:92) to obtain the target compound (950 mg, yield 31.7%). LCMS (ESI) [M+H] + = 275.0; 1 H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 7.89 (m, J = 9.6 Hz, 2H), 4.47 (q, J = 7.2 Hz, 2H), 4.11 (s, 3H), 1.42 (t, J = 7.2 Hz, 3H)
[0292] Step 4: Preparation of 4-cyano-6-fluoro-7-methoxyquinoline-3-carboxylic acid Ethyl 4-cyano-6-fluoro-7-methoxyquinoline-3-carboxylate (950 mg, 3.46 mmol, 1.0 eq.) was added to methanol (50 mL), and sodium hydroxide (2M, 3 mL) solution was added. The mixture was stirred at room temperature for 1 hour. After the reaction was completed, the methanol was removed under vacuum, 20 mL of water was added, the pH was adjusted to acidic, and the mixture was extracted with ethyl acetate (200 mL × 2). The organic phase was washed twice with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to give the target compound (606 mg, yield 75.27%). LCMS (ESI) [M + H] + = 247.1.
[0293] Fifth step: Preparation of tert-butyl (4-cyano-6-fluoro-7-methoxyquinolin-3-yl)carbamate 4-Cyano-6-fluoro-7-methoxyquinoline-3-carboxylic acid (330 mg, 1.34 mmol, 1.0 eq.), triethylamine (1353.4 mg, 13.4 mmol, 10 eq.), diphenylphosphoryl azide (1105 mg, 4.02 mmol, 3.0 eq.), and t-butanol (5 mL) were added to DMF (5 mL) and stirred at 80 °C for 2 hours. After the reaction was completed, the solvent was removed by vacuum distillation, 20 mL of water was added, and the mixture was extracted with ethyl acetate (1000 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by vacuum distillation. Silica gel was added to prepare a sample, which was then isolated and purified using a chromatographic column (silica gel, PE:EA = 85:15) to obtain the target compound (180 mg, yield 42.55%). LCMS (ESI) [M + H] + = 318.1.
[0294] Step 6: Preparation of tert-butyl (4-cyano-6-fluoro-7-methoxyquinolin-3-yl)(2,2,2-trifluoroethyl)carbamate tert-Butyl (4-cyano-6-fluoro-7-methoxyquinolin-3-yl)carbamate (20 mg, 0.13 mmol, 1.0 eq.) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (60.3 mg, 0.26 mmol, 2.0 eq.) were added to DMF (2 mL), potassium carbonate (35.8 mg, 0.26 mmol, 2.0 eq.) was added, and the mixture was stirred at 60 ° C for 1 hour. After the reaction was completed, 20 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL × 2). The organic phase was washed five times with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to obtain the crude product. Silica gel was added to prepare a sample, and the product was isolated and purified by silica gel column chromatography (Silica gel, PE:EA = 13:87) to obtain the target compound (20 mg, yield 39.73%). LCMS (ESI) [M+H] + = 400.0; 1H NMR (400 MHz, DMSO-d6) δ 9.10 (s, 1H), 7.88 (d, J = 10.8 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 4.72 (s, 3H), 4.08 (s, 3H), 1.37 (d, J = 35.8 Hz, 6H), 1.28 - 1.05 (m, 2H)
[0295] Seventh step: Preparation of tert-butyl (4-(aminomethyl)-6-fluoro-7-methoxyquinolin-3-yl)(2,2,2-trifluoroethyl)carbamate tert-Butyl (4-cyano-6-fluoro-7-methoxyquinolin-3-yl) (2,2,2-trifluoroethyl) carbamate (190 mg, 0.12 mmol, 1.0 eq.) was added to acetic acid (5 mL), palladium carbon (40 mg) was added, and the mixture was reacted at room temperature under hydrogen protection for 2 hours. After the reaction was completed, the palladium carbon was filtered off, 20 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure to obtain the target compound (190 mg, yield 99%). LCMS (ESI) [M + H] + = 404.1.
[0296] Eighth step: Preparation of tert-butyl (4-(((4-bromo-2,6-difluorobenzyl)amino)methyl)-6-fluoro-7-methoxyquinolin-3-yl)(2,2,2-trifluoroethyl)carbamate tert-Butyl (4-(aminomethyl)-6-fluoro-7-methoxyquinolin-3-yl)(2,2,2-trifluoroethyl)carbamate (160 mg, 0.4 mmol, 1.0 eq.) and 4-bromo-2,6-difluorobenzaldehyde (32.8 mg, 0.48 mmol, 1.2 eq.) were added to dichloromethane (10 mL), followed by the addition of one drop of acetic acid, sodium borohydride acetate (420 mg, 1.6 mmol, 4.0 eq.), and molecular sieves. The mixture was stirred at room temperature for 2 h and monitored for completion by LCMS. Silica gel was added, and the mixture was purified by flash silica gel column chromatography (silica gel, PE:EA = 75:25) to give the desired compound (170 mg, 70.45% yield). LCMS (ESI) [M+H] + = 609.1; 1 H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.11 (s, 1H), 7.60 (s, 1H), 7.50 (s, 2H), 4.46 (s, 2H), 4.10 - 3.99 (m, J = 1.6 Hz 4H), 3.87 (s, 3H), 3.78 (s, 1H), 1.44 (s, 3H), 1.21 (d, J = 16.2 Hz, 6H)
[0297] Ninth step: Preparation of 4-(((4-bromo-2,6-difluorobenzyl)amino)methyl)-6-fluoro-7-methoxy-N-(2,2,2-trifluoroethyl)-quinolin-3-amine tert-Butyl (4-(((4-bromo-2,6-difluorobenzyl)amino)methyl)-6-fluoro-7-methoxyquinolin-3-yl)(2,2,2-trifluoroethyl)carbamate (200 mg, 0.32 mmol, 1.0 eq.) was added to hydrochloric acid in dioxane (1 M, 5 mL), stirred at room temperature for 2 hours, and the solvent was evaporated under reduced pressure to give the crude target compound (160 mg). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H]+ = 509.1.
[0298] Tenth step: Preparation of 2-(4-bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrimidine[4,5-c]quinolin-3(2H)-one 4-(((4-Bromo-2,6-difluorobenzyl)amino)methyl)-6-fluoro-7-methoxy-N-(2,2,2-trifluoroethyl)-quinolin-3-amine (160 mg, crude product) was added to a 10 mL solution of tetrahydrofuran, triphosgene (60 mg) was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was extracted with ethyl acetate (100 mL × 2), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and silica gel was added to prepare a sample. The sample was isolated and purified by flash silica gel column chromatography (Silica gel, PE:EA = 70:30) to obtain the target compound (140 mg, yield 87.35%). LCMS (ESI) [M + H] + = 534.0.
[0299] Eleventh step: Preparation of 2-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrimidine[4,5-c]quinolin-3(2H)-one 2-(4-Bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrimidine[4,5-c]quinolin-3(2H)-one (140 mg, 0.26 mmol, 1 eq.) and benzenemethanethiol (39 mg, 0.31 mmol, 1.2 eq.) were added to 10 mL of dioxane, followed by tris(dibenzylideneacetone)dipalladium (24 mg, 0.026 mmol, 0.1 eq.) and cesium carbonate (169 mg, 0.52 mmol, 2 eq.). The mixture was reacted under nitrogen protection at 100°C for 3 hours. After the reaction was completed, the mixture was extracted with ethyl acetate (100 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and silica gel was added to prepare a sample. The sample was then purified by flash silica gel column chromatography (Silica gel, PE:EA = 65:35) to obtain the target compound (85 mg, yield 56.61%). LCMS (ESI) [M + H] + = 578.1.
[0300] Step 12: Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-3-oxo-4-(2,2,2-trifluoroethyl)-3,4-dihydropyrimido[4,5-c]quinolin-2(1H)-yl)methyl)benzenesulfonamide 2-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrimidine [4,5-c] quinolin-3 (2H) -one (80 mg, 0.14 mmol, 1.0 eq.) was added to 2 mL of tetrahydrofuran and 1 mL of acetonitrile solution, and at 0 ° C., 1 drop of acetic acid, 1 drop of water and 1,3-dichloro-5,5-dimethylhydantoin (110 mg, 0.56 mmol, 4 eq.) were added, and the mixture was allowed to react for 2 hours at 0 ° C. After the reaction was completed, 2 mL of aqueous ammonia was added dropwise at 0 ° C., and extracted with ethyl acetate (100 mL × 2). The organic phase was washed with saturated brine, then dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the crude product. Purification gave the title compound (12 mg, yield 13.33%). LCMS (ESI) [M+H] + = 535.1; 1 HNMR (400MHz, DMSO-d6) δ 8.90 (s, 1H), 7.69 (d, J = 12.6 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 6.8 Hz, 2H), 7.18 (s, 2H), 5.04 (d, J = 9.2 Hz, 2H), 4.96 (s, 2H), 4.79 (s, 2H), 3.99 (s, 3H)
[0301] Example 2 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxopyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (Compound 2): [ka]
[0302] First step: Preparation of 7-methoxy-3-nitro-1,8-naphthyridin-4-ol 7-Methoxy-1,8-naphthyridin-4-ol (14 g, 79.47 mmol, 1.0 eq.) was dissolved in acetic anhydride (100 mL), and nitric acid (8.41 mL, 133.51 mmol, 1.68 eq.) was slowly added dropwise in an ice bath. The mixture was then heated to 90°C and reacted at 90°C for 2 hours. After completion of the reaction, the mixture was cooled to room temperature and filtered. The filtered cake was washed with petroleum ether and dried to obtain the target compound (5.8 g, 33% yield). LCMS (ESI) [M+H] + = 222.1; 1 H NMR (400 MHz, DMSO-d6) δ 13.27 (s, 1H), 8.95 (s, 1H), 8.45 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 4.01 (s, 3H).
[0303] Step 2: Preparation of 5-chloro-2-methoxy-6-nitro-1,8-naphthyridine 7-Methoxy-3-nitro-1,8-naphthyridin-4-ol (8.8 g, 39.79 mmol, 1.0 eq.) was dissolved in dichloromethane (50 mL), a catalytic amount of N,N-dimethylformamide (1 mL) was added, and then thionyl chloride (9 mL, 75.69 mmol, 1.9 eq.) was slowly added dropwise under ice bath conditions, and the mixture was heated to 40 ° C. and reacted at 40 ° C. for 2 hours. After the reaction was completed, the mixture was quenched with ice water, extracted with dichloromethane (100 mL × 3), the organic phase was collected, dried, filtered, concentrated, and purified by column chromatography (Silica gel, PE:EA = 2:1) to obtain the target compound (7.2 g, yield 75.52%). LCMS (ESI) [M+H] + = 239.9; 1 H NMR (400 MHz, DMSO-d6) δ 8.95-8.94 (m, 1H), 8.44 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 4.01 (s, 3H).
[0304] Third step: Preparation of N-(4-bromo-2,6-difluorobenzyl)-7-methoxy-3-nitro-1,8-naphthyridin-4-amine 5-Chloro-2-methoxy-6-nitro-1,8-naphthyridine (600 mg, 2.5 mmol, 1 eq.) and 1-(4-bromo-2,6-difluorophenyl)methylamine (610.6 mg, 2.75 mmol, 1.1 eq.) were dissolved in acetonitrile (100 mL), potassium carbonate (1.04 g, 7.5 mmol, 3 eq.) was added, and the mixture was reacted at 40 °C for 2 h. After the reaction was completed, the mixture was concentrated, washed with water and ethyl acetate (20 mL × 3). After extraction, the organic phase was collected, dried, filtered, concentrated, and purified by column chromatography (silica gel, PE:EA = 1:1) to obtain the target compound (700 mg, 65.9% yield). LCMS (ESI) [M+H] + = 427.0; 1 H NMR (400 MHz, DMSO- d6) δ 9.14 (s, 1H), 8.84 - 8.67 (m, 2H), 7.51 (d, J = 6.8 Hz, 2H), 7.10 (d, J = 8.6 Hz, 1H), 4.69 (s, 2H), 4.02 (s, 3H)
[0305] 4th step:N 4 Preparation of -(4-bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine N-(4-bromo-2,6-difluorobenzyl)-7-methoxy-3-nitro-1,8-naphthyridin-4-amine (660 mg, 1.55 mmol, 1.0 eq.) was dissolved in methanol (50 mL), followed by the addition of tin chloride (2943 mg, 15.52 mmol, 10 eq.) and the reaction mixture was allowed to react for 2 hours at 20 °C. After the reaction was complete, the solvent was partially concentrated, the mixture was washed with saturated aqueous sodium bicarbonate to a weak base, and then extracted with water and ethyl acetate (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, DCM:MeOH = 20:1) to give the target compound (700 mg, crude product). LCMS (ESI) [M+H] + = 397.0; 1 H NMR (400 MHz, DMSO- d6) δ 8.70 (d, J = 9.6 Hz, 1H), 8.08 (s, 1H), 7.51 (d, J = 7.2 Hz, 2H), 7.06 (d, J = 9.2 Hz, 1H), 5.00 (s, 2H), 4.07 - 3.94 (m, 6H).
[0306] Fifth step: Preparation of ethyl 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-2-oxo-1,2-dihydropyrazino[2,3-c][1,8]naphthyridine-3-carboxylate Add N 4 -(4-Bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine (300 mg, crude), diethyl 2-oxomethacrylate (264 mg, 1.51 mmol), and 10 mL of toluene were added to a reactor equipped with a water separator. The reaction was carried out at 130°C for 16 hours, and the product was monitored. The reaction mixture was concentrated, and the resulting crude product was purified by flash silica gel column chromatography (petroleum ether:ethyl acetate = 100:0 to 100:70) to obtain the target compound (220 mg). LCMS (ESI) [M+H] + = 505 / 507; 1HNMR (400MHz, CDCl3) δ 9.33 (s, 1H), 8.37 (d, J = 12.0 Hz, 1H), 7.19-6.95(m, 3H), 5.69 (s, 2H), 4.44-4.42 (m, 2H), 4.06 (s, 3 H), 1.17 (t, J= 6.4 Hz, 3 H).
[0307] Sixth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-2-oxo-1,2-dihydropyrazino[2,3-c][1,8]naphthyridine-3-carboxylic acid Ethyl 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-2-oxo-1,2-dihydropyrazino[2,3-c][1,8]naphthyridine-3-carboxylate (220 mg, 0.43 mmol, 1.0 eq.), 5 mL of ethanol, triethylamine (176 mg, 1.74 mmol, 4.0 eq.), and 2 mL of water were added to a single-neck round-bottom flask. The reaction mixture was heated to 50 °C and stirred for 16 h. The reaction mixture was partially concentrated at room temperature, and the remainder was diluted with ethyl acetate. The pH of the solution was adjusted to 4 with 1 mol / L dilute hydrochloric acid. The ethyl acetate layer was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the desired compound (180 mg, 90% yield). LCMS (ESI) [M+H] + = 477.0 / 479.0; 1 HNMR (400MHz, CDCl3) δ 9.54 (s, 1H), 8.45 (d, J = 6.4 Hz, 1H), 7.28 (d, J = 6.4 Hz, 1H), 7.05-7.01 (m, 3 H), 5.75 (s, 2H), 4.06 (s, 3 H).
[0308] Seventh step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-2-oxo-1,2-dihydropyrazino[2,3-c][1,8]naphthyridine-3-carboxylic acid (150 mg, 0.31 mmol, 1.0 eq.) and 3 mL of nitrobenzene were added to a microwave tube, and the reaction mixture was heated to 160 °C and stirred for 2 h. After the reaction was complete, the target compound (80 mg, 59% yield) was obtained by direct column chromatography (petroleum ether:ethyl acetate = 100:0 to 0:100). LCMS (ESI): [M+H] + = 432.9 / 433.9; 1 HNMR (400MHz, CDCl3) δ 9.33 (s, 1H), 8.40 (d, J=8.0 Hz, 1H), 8.32 (s, 1H), 7.19-6.98 (m, 3H), 5.69 (s, 2 H), 4.21 (s, 3H).
[0309] Eighth step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one A microwave tube was charged with 1-(4-bromo-2,6-difluorobenzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one (52 mg, 0.12 mmol, 1.0 eq.), p-methoxybenzylthiol (55 mg, 0.36 mmol, 3.0 eq.), cesium carbonate (84 mg, 0.26 mmol, 2.2 eq.), tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol, 0.1 eq.), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (10 mg, 0.02 mmol, 0.2 eq.). The reaction was sparged with nitrogen for 1 min, sealed, and heated to 90 °C for 4 h. After the reaction was completed, the reaction mixture was partitioned between water and ethyl acetate, and the ethyl acetate layer was dried and concentrated to give a crude product, which was purified (petroleum ether:ethyl acetate=1:1) to give the target compound (20 mg, yield 32%). LCMS (ESI): [M+H] + = 507.1;1 HNMR (400MHz, CDCl3) δ 9.33 (s, 1H), 8.44 (d, J=8.0 Hz, 1H), 8.32 (s, 1H), 7.19 (d, J=8.0 Hz, 2H), 6.78 (d, J=8.0 Hz, 1H), 6.69 (d, J=8.0 Hz, 2H), 6.55 (d, J=8.0 Hz, 2H), 5.69 (s, 2H), 4.17(s, 3H), 4.01(s, 2H), 3.74(s, 3H).
[0310] Step 9: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxopyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide A round-bottom flask was charged with 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one (15 mg, 0.029 mmol, 1.0 eq.), 2 mL of tetrahydrofuran, 1 mL of acetonitrile, acetic acid (2 mg, 0.033 mmol, 1.1 eq.), and water (2 mg, 0.11 mmol, 3.7 eq.). The solution was cooled with ice water while 1,3-dichloro-5,5-dimethylhydantoin (12 mg, 0.058 mmol, 2.0 eq.) was added, and the reaction was stirred for 60 minutes. 1 mL of aqueous ammonia was added, and stirring was continued for 60 minutes. After the reaction was completed, the water and ethyl acetate layers were separated, the ethyl acetate layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was then purified by liquid phase isolation to obtain the target compound (4.5 mg, yield 35%). LCMS (ESI) [M+H] + = 434.0; 1 HNMR (400MHz, DMSO-d6) δ 9.24 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.35 (s, 1H), 7.63 (s, 2H), 7.47 (d, J=8.0 Hz, 2H), 7.17 (d, J=8.0 Hz, 1H), 5.83 (s, 2H), 4.06 (s, 3H).
[0311] Example 3 Preparation of 4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepane-1-sulfonamide (compound 3): [ka]
[0312] Step 1: Preparation of 4-chloro-7-methoxy-1,8-naphthyridin-3-amine 5-Chloro-2-methoxy-6-nitro-1,8-naphthyridine (5.0 g, 20.87 mmol, 1.0 eq.) was dissolved in acetic acid (20 mL) in a single-neck flask, and zinc powder (2.7 g, 41.74 mmol, 2.0 eq.) was added to the reaction solution. The reaction mixture was stirred at room temperature for 16 hours. The product was monitored, and the reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to give the desired compound (400 mg, 9% yield). LCMS (ESI) [M+H] + = 210.1; 1 H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.24 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 4.01 (s, 2H), 3.96 (s, 3H).
[0313] Second step: Preparation of tert-butyl (4-chloro-7-methoxy-1,8-naphthyridin-3-yl)carbamate 4-Chloro-7-methoxy-1,8-naphthyridin-3-amine (800 mg, 3.82 mmol, 1.0 eq.) and 4-dimethylaminopyridine (233 mg, 1.91 mmol, 0.5 eq.) were dissolved in dichloromethane (20 mL) in a single-neck round-bottom flask, followed by di-tert-butyl dicarbonate (1.7 g, 7.63 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 4 h. The product was monitored, the reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 3:1) to give the desired compound (380 mg, 23% yield). LCMS (ESI) [M + H] + = 410.2.
[0314] Third step: Preparation of methyl 3-((tert-butoxycarbonyl)amino)-7-methoxy-1,8-naphthyridine-4-carboxylate To a single-necked round-bottom flask were added tert-butyl (tert-butoxycarbonyl) (4-chloro-7-methoxy-1,8-naphthyridin-3-yl)carbamate (800 mg, 2.02 mmol, 1.0 eq.) and 4-dimethylaminopyridine (247 mg, 2.02 mmol, 1.0 eq.), palladium acetate (23.0 mg, 0.1 mmol, 0.05 eq.), and methanol (10 mL), followed by 4,5-bis(diphenylphosphine)-9,9-dimethylxanthine (1169 mg, 2.02 mmol, 1.0 eq.), octacarbonylbiscobalt (CAS: 10210-68-1) (765 mg, 2.22 mmol, 1.1 eq.), and the reaction was refluxed at 90° C. for 5 hours. After monitoring the completion of the reaction by LCMS, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=7:3) to give the target compound (400 mg, yield 46%). LCMS (ESI): [M+H] + = 334.1; 1H NMR (400 MHz, CD3OD) δ 9.04 (s, 1H) , 8.47 (d, J = 9.2 Hz, 1H), 7.12 (d, J = 9.2 Hz, 1H), 4.09 (s, 3H), 4.01 (s, 3H), 1.53 (s, 9H).
[0315] Step 4: Preparation of methyl 3-amino-7-methoxy-1,8-naphthyridine-4-carboxylate Methyl 3-((tert-butoxycarbonyl)amino)-7-methoxy-1,8-naphthyridine-4-carboxylate (400 mg, 1.2 mmol, 1.0 eq.) was dissolved in methanolic hydrochloride (4M, 10 mL) and the reaction was stirred at room temperature for 16 hours. After monitoring the completion of the reaction by LCMS, the reaction mixture was evaporated under reduced pressure to give the crude target compound (250 mg). LCMS (ESI): [M+H] + = 234.1; 1 H NMR (400 MHz, DMSO-d6) δ 8.81 - 8.66 (m, 2H), 7.16 (d, J = 9.2 Hz, 1H), 6.28 (s, 3H), 4.00 (s, 3 H), 3.99 (s, 3 H).
[0316] Fifth step: Preparation of 8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-ol 8-methoxypyrimido [4,5-c][1,8]naphthyridin-1-ol To a round-bottom flask was added methyl 3-amino-7-methoxy-1,8-naphthyridine-4-carboxylate (310 mg, crude), formamidine acetate (831 mg, 7.98 mmol) and formamide (5 mL), and the reaction was stirred at 130° C. for 16 hours. After monitoring the completion of the reaction by LCMS, the temperature was lowered to room temperature, the reaction mixture was washed with water to precipitate a solid, which was then filtered, and the filter cake was dried to obtain the target compound (200 mg, yield 66%). LCMS (ESI) [M+H]+ = 229.2; 1 H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 9.84 (d, J = 9.2 Hz, 1H), 9.31 (s, 1H), 8.31 (s, 1H) , 7.30 (d, J = 9.2 Hz, 1H), 4.08 (s, 3H).
[0317] Step 6: Preparation of tert-butyl 4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepane-1-carboxylate 8-Methoxypyrimido[4,5-c][1,8]naphthyridin-1-ol (50 mg, 0.22 mmol, 1.0 eq.) was placed in a single-necked round-bottom flask, and 2 mL of acetonitrile was added. While stirring, 1,8-disazobisspiro[5.4.0]undec-7-ene (100 mg, 0.66 mmol, 3.0 eq.) was added to the reaction system to clarify it. One drop of diphenyl ether, carbitol condensing agent (290 mg, 0.66 mmol, 3 eq.) was added to the reaction system, and after stirring for 10 minutes, tert-butyl 1,4-diazepane-1-carboxylate (130 mg, 0.66 mmol, 3 eq.) was added to the above stirring solution, and the reaction was stirred for another 16 hours to complete the reaction. The reaction solution was concentrated, and the resulting crude product was isolated and purified using a preparative plate to obtain the target compound (20 mg, 22% yield). LCMS (ESI) [M+H] + = 411.2; 1 HNMR (400MHz, DMSO-d6) δ 9.35 (s, 1H) , 8.71 (s, 1H) , 8.57 (t, J = 8.0 Hz, 1H) , 7.24 (d, J = 8.0 Hz, 1H), 4.25-4.22 (m, 1H), 4.06 (s, 3H), 3.75-3.30 (m, 5H), 2.10-2.02 (m, 1H), 1.75-1.52 (m, 1H), 1.37 (s, 4.5H), 1.17 (s, 4.5H), 0.88-0.85 (m, 2H).
[0318] Seventh step: Preparation of 1-(1,4-diazepan-1-yl)-8-methoxypyrimido[4,5-c][1,8]naphthyridine hydrochloride A single-necked round-bottom flask was charged with tert-butyl 4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepane-1-carboxylate (20 mg, 0.05 mmol, 1.0 eq.) and 2 mL of methanol. Hydrogen chloride / ethanol solution (2 mol / L, 1.0 mL, 40 eq.) was added to the solution, and the reaction mixture was stirred at room temperature for 16 hours. Upon completion of the reaction, 20 mg of the crude target compound was obtained. This was concentrated and used directly in the next reaction. LCMS (ESI) [M + H] + = 311.2.
[0319] Eighth step: Preparation of tert-butyl 4-((4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepan-1-yl)sulfonyl)carbamate A single-necked round-bottom flask was charged with tert-butyl (chlorosulfonyl)carbamate (40 mg, 0.29 mmol, 5 eq.) and 2 mL of methylene chloride. tert-Butanol (20 mg, 0.29 mmol, 5 eq.) was added under ice cooling and stirred for 30 min. Then, a solution of 1-(1,4-diazepan-1-yl)-8-methoxypyrimido[4,5-c][1,8]naphthyridine hydrochloride (20 mg, 0.06 mmol, 40% purity, 1.0 eq.) and diisopropylethylamine (39 mg, 0.3 mmol, 5 eq.) in 2 mL of methylene chloride was added to another stirred round-bottom flask, and the reaction mixture was stirred at room temperature for 2 h. After completion of the reaction, the reaction mixture was concentrated to give the crude target compound (80 mg), which was used directly in the next reaction. LCMS (ESI): [M + H] + = 490.0.
[0320] Step 9: Preparation of 4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepane-1-sulfonamide To a single-neck flask, tert-butyl (4-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)-1,4-diazepan-1-yl)sulfonyl)carbamate (80 mg, crude product) obtained in the previous reaction, 1 mL of dichloromethane, and 1 mL of trifluoroacetic acid were added, and the reaction mixture was stirred for 1 hour. After the reaction was completed, the reaction mixture was concentrated, and the crude product was directly purified by preparative HPLC to obtain the target compound (1.6 mg, total yield for three steps: 8%). LCMS (ESI): [M+H] + = 390.1; 1 HNMR (400MHz, MeOD) δ 9.36 (s, 1H), 8.75 (s, 1H), 8.67 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 4.15-4.10 (m, 4H), 3.95-3.80 (m, 5H), 3.60-3.50 (m, 2H), 2.01-1.98 (m, 2H).
[0321] Example 4 Preparation of N-((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)sulfonamide (Compound 4): [ka]
[0322] Step 1: Preparation of tert-butyl 4-cyanoazepane-1-carboxylate tert-Butyl 4-oxoazepane-1-carboxylate (6 g, 28.13 mmol, 1 eq.) was dissolved in DMF (30 mL). A solution of 1-((isocyanatomethyl)sulfonyl)-4-methylbenzene (6.87 g, 35.16 mmol, 1.25 eq.), potassium tert-butoxide (6.31 g, 56.26 mmol, 2 eq.) in tert-butanol (30 mL), and 1,2-dimethoxyethane (24.05 mL) was added at 0 °C. The mixture was then warmed to 20 °C and reacted at 20 °C for 3 h. The reaction was monitored for completion by TLC. The organic layers were extracted with ethyl acetate, washed with water, combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate = 10:1) to obtain the target compound (4.2 g, 66.57% yield). LCMS (ESI) [M+Na] + = 247.1; 1 H NMR (400 MHz, DMSO-d6) δ 3.45-3.20 (m, 4H), 3.15-3.05 (m, 1H), 1.95-1.82 (m, 2H), 1.80-1.65 (m, 4H), 1.40 (s, 9H).
[0323] Step 2: Preparation of azepane-4-carbonitrile A single-necked round-bottom flask was charged with tert-butyl 4-cyanoazepane-1-carboxylate (3.00 g, 13.37 mmol, 1 eq.), and trifluoroacetic acid (30 mL) and dichloromethane (5 mL) were added. The reaction solution was stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated to give the crude target compound (1.5 g), which was used directly in the next reaction. LCMS (ESI) [M+H] + = 125.2; 1 H NMR(400 MHz, CDCl3)δ 3.75-3.70 (m, 4H), 3.15-3.05 (m, 1H), 2.36-2.34 (m, 2H), 2.33-2.00 (m, 4H).
[0324] Step 3: Preparation of benzyl 4-cyanoazepane-1-carboxylate A single-necked round-bottom flask was charged with azepane-4-carbonitrile (1500 mg, crude), diisopropylethylamine (4.7 g, 36.24 mmol), and 30 mL of tetrahydrofuran. Benzyl chloroformate (2060 mg, 12.08 mmol) was slowly added dropwise under stirring, and the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the crude product was concentrated, and the target compound (2.3 g, 74% yield) was obtained by column chromatography (petroleum ether:ethyl acetate = 10:1). LCMS (ESI): [M+Na] + = 281.1; 1 H NMR (400 MHz, CDCl3) δ 7.39-7.23 (m, 5H), 5.13 (s, 2H), 3.75-3.25 (m, 4H), 2.87-2.82 (m, 1H), 1.99-1.65(m, 6H).
[0325] Step 4: Preparation of benzyl 4-(aminomethyl)azepane-1-carboxylate Benzyl 4-cyanoazepane-1-carboxylate (2200 mg, 8.52 mmol, 1 eq.) and a solution of borane in tetrahydrofuran (1 M, 30 mL) were added to a single-necked round-bottom flask, and the reaction solution was stirred at 70°C for 16 hours to complete the reaction. The reaction solution was concentrated to give the crude target compound (2.0 g), which was used directly in the next reaction. LCMS (ESI): [M + H] + = 263.1.
[0326] Step 5: Preparation of benzyl 4-(((tert-butoxycarbonyl)amino)methyl)azepane-1-carboxylate In a single-necked round-bottom flask, 4-(aminomethyl)azepane-1-carboxylic acid benzyl ester (2000 mg, crude product) was dissolved in 10 mL of dichloromethane, and 4-dimethylaminopyridine (465.68 mg, 3.81 mmol) was added. Di-tert-butyl dicarbonate (3327.62 mg, 15.25 mmol) was slowly added with stirring. After stirring at room temperature for 2 hours, the reaction was terminated and the reaction solution was concentrated to obtain a crude product. This was purified by column chromatography (petroleum ether:ethyl acetate=100:20) to obtain the target compound (900 mg, total yield for two steps: 30%). LCMS (ESI) [M+Na] + = 385.2; 1 H NMR (400 MHz, CDCl3) δ 7.28-7.23 (m, 5H), 5.15 (s, 2H), 4.59-4.55 (m, 1H), 3.55-3.05 (m, 4H), 3.05-2.95 (m, 2H), 1.95-1.44 (m, 7H), 1.42 (s, 9H).
[0327] Step 6: Preparation of tert-butyl (azepan-4-ylmethyl)carbamate Benzyl 4-(((tert-butoxycarbonyl)amino)methyl)azepane-1-carboxylate (900 mg, 2.48 mmol, 1 eq.) was dissolved in 10 mL of methanol in a single-neck round-bottom flask, and palladium / carbon (10% content, 50% humidity) and two drops of aqueous ammonia were added. The reaction system was purged with a hydrogen balloon and reacted under a hydrogen atmosphere at 20°C for 16 hours. After completion of the reaction, the reaction solution was filtered, and the filtrate was concentrated to give 400 mg of the crude target compound, which was used directly in the next reaction. LCMS (ESI) [M+H] + = 229.2 ; 1 HNMR (400MHz, DMSO-d6) δ 6.88-6.83 (m, 1H), 2.70-2.59 (m, 4H), 2.67 (s, 2H), 2.58-2.52 (m, 1H), 1.66-1.51 (m, 5H), 1.40 (s, 9H), 1.20-1.15 (m, 2H).
[0328] Seventh step: Preparation of tert-butyl ((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)carbamate A single-neck round-bottom flask was charged with 8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-ol (60 mg, 0.026 mmol, 1.0 eq.) and 4 mL of N,N-dimethylformamide. One drop of DBU (160 mg, 1.05 mmol, 4.0 eq.) was added with stirring to clarify the reaction mixture. Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (220 mg, 0.5 mmol, 2 eq.) was added to the reaction mixture and stirred for 10 min. After stirring, tert-butyl (azepan-4-ylmethyl)carbamate (120 mg, crude, obtained from the previous reaction) was added to the stirred solution and the reaction was carried out at 90 °C for 16 h. After completion of the reaction, the reaction mixture was directly purified by reverse-phase preparative HPLC to give the desired compound (20 mg, 22% yield). LCMS (ESI) [M+H] + = 439.3; 1 HNMR (400MHz, DMSO-d6) δ 9.33 (s, 1H), 8.69 (s, 1H), 8.55-8.53 (m, 1H), 7.23 (d, J = 12.0 Hz, 1H), 6.85 (s, 1H), 4.06 (s, 3H), 3.83-3.75 (m, 2H), 3.23-3.05 (m, 2H), 2.83-2.74 (m, 2H), 1.85-1.52 (m, 7H), 1.37 (s, 9H).
[0329] Eighth Step: Preparation of (1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methanamine To a single-necked round-bottom flask were added tert-butyl ((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)carbamate (15 mg, 0.05 mmol, 1.0 eq.) and 1 mL of dichloromethane. To the solution was added trifluoroacetic acid (2.0 mL, 40 eq.), and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to give 20 mg of the crude target compound, which was used directly in the next reaction. LCMS (ESI) [M + H] + = 339.1.
[0330] Step 9: Preparation of tert-butyl (N-((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)sulfamoyl)carbamate A single-necked round-bottom flask was charged with tert-butyl (chlorosulfonyl)carbamate (40 mg, 0.29 mmol, 5 eq.) and 2 mL of dichloromethane. Tert-butanol (20 mg, 0.29 mmol) was added under ice cooling and stirred for 30 min. The reaction mixture was then added to a solution of 1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methylamine (20 mg, crude, obtained in the previous reaction) and diisopropylethylamine (39 mg, 0.3 mmol) in 2 mL of dichloromethane, and the mixture was stirred at room temperature for 3 h. After completion of the reaction, the reaction mixture was concentrated to give the crude target compound (20 mg), which was used directly in the next reaction. LCMS (ESI) [M + H] + = 518.3.
[0331] Tenth step: Preparation of N-((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)sulfonamide In a single-necked round-bottom flask, the crude tert-butyl (N-((1-(8-methoxypyrimido[4,5-c][1,8]naphthyridin-1-yl)azepan-4-yl)methyl)sulfamoyl)carbamate (20 mg) obtained in the previous step was dissolved in 2 mL of dichloromethane, 2 mL of trifluoroacetic acid was added, and the reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was concentrated to obtain the crude material, which was purified by HPLC to obtain the target compound (4.3 mg, total yield for three steps: 25%). LCMS (ESI) [M+H] + = 418.3; 1 HNMR (400MHz, MeOD) δ 9.32 (s, 1H) , 8.72 (s, 1H) , 8.44-8.41(m, 1H), 7.30 (d, J = 12 Hz, 1H), 4.30-3.95 (m, 5H), 3.78-3.70 (m, 2H), 2.90-2.81 (m, 2H), 2.01-1.88 (m, 4H), 1.55-1.23 (m, 2H), 0.99-0.95 (m, 1H).
[0332] Example 5 Preparation of 3,5-difluoro-4-((8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (compound 5): [ka]
[0333] First step: Preparation of 3-bromo-7-methoxy-1,8-naphthyridin-4-ol 7-Methoxy-1,8-naphthyridin-4-ol (12 g, 68.12 mmol, 1 eq.) was dissolved in N,N-dimethylformamide (50 mL), and then N-bromosuccinimide (7.3 g, 40.87 mmol, 0.6 eq.) was added at 0°C, followed by reaction at 0°C for 2 hours. The reaction was monitored for completion by LCMS, water was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phase was concentrated and purified by flash silica gel column chromatography (Silica gel, PE:EA = 50:50) to obtain the target compound (2.0 g, yield 11.5%). LCMS (ESI) [M + H] + =254.9.
[0334] Second step: Preparation of 6-bromo-5-chloro-2-methoxy-1,8-naphthyridine 3-Bromo-7-methoxy-1,8-naphthyridin-4-ol (500 mg, 1.96 mmol, 1 eq.) was dissolved in dichloromethane (50 mL), and then one drop of N,N-dimethylformamide was added. Sulfoxide chloride (2332 mg, 19.6 mmol, 10 eq.) was added, and the mixture was reacted at 40°C for 16 hours. The reaction was monitored for completion by LCMS, and the reaction mixture was slowly added dropwise to ice water for phase separation. The aqueous phase was extracted with dichloromethane (20 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, and concentrated to give the target compound (520 mg, 97% yield). LCMS (ESI) [M + H] + = 272.9.
[0335] Third step: Preparation of 2-((3-bromo-7-methoxy-1,8-naphthyridin-4-yl)amino)ethyl-1-ol 6-Bromo-5-chloro-2-methoxy-1,8-naphthyridine (500 mg, 1.83 mmol, 1 eq.) was dissolved in N-methylpyrrolidone (15 mL) and ethanolamine (2.2 g, 36.6 mmol, 20 eq.) was added. The reaction was carried out at 100°C for 2 hours and completion was monitored by LCMS. The reaction mixture was poured into water and extracted with ethyl acetate (20 mL x 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the desired compound (260 mg, 57% yield). LCMS (ESI) [M+H] + = 298.0;1 H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 9.2 Hz, 1H), 8.56 (s, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.22 (t, J = 5.6 Hz, 1H), 4.97 (t, J = 5.2 Hz, 1H), 3.97 (s, 3H), 3.76 - 3.67 (m, 2H), 3.65 - 3.57 (m, 2H).
[0336] Fourth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridine 2-((3-Bromo-7-methoxy-1,8-naphthyridin-4-yl)amino)ethyl-1-ol (200 mg, 0.67 mmol, 1 eq.) was dissolved in N,N-dimethylpyrrolidinone (5 mL) and copper iodide (128 mg, 0.67 mmol, 1.0 eq.), trans-1,2-cyclohexanediamine (77 mg, 0.67 mmol, 1.0 eq.), and potassium tert-butoxide (226 mg, 2.01 mmol, 3 eq.) were added. The reaction was performed in a microwave oven at 140 °C for 2 hours and monitored for completion by LCMS. 5-Bromo-2-(bromomethyl)-1,3-difluorobenzene (284 mg, 1.01 mmol, 1.5 eq.) was added to the reaction solution and the reaction was continued at 70 °C for 1 hour. The completion of the reaction was monitored by LCMS. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified using a silica gel column to obtain the target compound (100 mg, yield 36%). LCMS (ESI) [M+H] + = 422.0; 1H NMR (400 MHz, DMSO-d6) δ 8.91-8.82 (m, 1H), 8.75 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 9.2 Hz, 1H), 5.78 (s, 2H), 4.32 (t, J = 4.4 Hz, 2H), 3.93 (s, 3H), 3.74 (t, J = 4.0 Hz, 2H).
[0337] Fifth step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridine 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridine (100 mg, 0.24 mmol, 1 eq.) was dissolved in dioxane (10 mL) and 3-(4-methoxyphenyl)methanethiol (73 mg, 0.47 mmol, 2 eq.), (5-(diphenylphosphino)-9,9-dimethyl-9H-xant-4-yl)diphenylphosphine (27 mg, 0.05 mmol, 0.2 eq.), tris(1,5-diphenylpenta-1,4-dien-3-one)dipalladium (43 mg, 0.05 mmol, 0.2 eq.), and triethylamine (48 mg, 47 mmol, 2 eq.) were added. The reaction was carried out at 100 °C for 2 h under nitrogen protection. The reaction mixture was monitored for completion by LCMS. The reaction mixture was concentrated to dryness, silica gel was added, and a sample was prepared. The sample was purified by column chromatography (Silica gel, DCM:MeOH = 95:5) to obtain the target compound (70 mg, yield 60%). LCMS (ESI) [M + H] + = 496.1.
[0338] Step 6: Preparation of 3,5-difluoro-4-((8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-2,3-dihydro-1H-[1,4]oxazino[2,3-c][1,8]naphthyridine (60 mg, 0.12 mmol, 1.0 eq.), acetic acid (51 mg, 0.85 mmol, 7.0 eq.), and water (31 mg, 1.7 mmol, 14.0 eq.) were dissolved in tetrahydrofuran (15 mL), and 1,3-dichloro-5,5-dimethylhydantoin (72 mg, 0.36 mmol, 3 eq.) was added at 0°C. The mixture was reacted at 0°C for 2 hours. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. LCMS monitored the reaction of the feed material was complete. The reaction was concentrated and purified by preparative HPLC to give the desired compound (13.7 mg, 27% yield). LCMS (ESI) [M+H] + = 423.1; 1 HNMR (400MHz, MeOD-d4) δ 8.53 (s, 1H), 8.48 (d, J = 9.2 Hz, 1H), 7.53 (d, J = 7.2 Hz, 2H), 7.11 (d, J = 8.8 Hz, 1H), 5.92 (s, 2H), 4.36 (t, J = 4.4 Hz, 2H), 4.01 (s, 3H), 3.81 (t, J = 4.4 Hz, 2H).
[0339] Example 6 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide (Compound 6): [ka]
[0340] Step 1: Preparation of ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate 1,3-Diethyl 2-(((6-methoxypyridin-2-yl)amino)methylene)malonate (12 g, 22.7 mmol, 1 eq.) was dissolved in phosphorus oxychloride (60 mL) and the reaction was stirred at 110° C. under a nitrogen atmosphere for 4 hours. The reaction was monitored for completion by LCMS, the solvent was removed under reduced pressure, the resulting residue was dissolved in ethyl acetate (60 mL), quickly washed with water (20 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness. The crude product was purified by flash chromatography (Silica gel, DCM:EA = 1:1) to give the target compound (1.5 g, 12% yield). LCMS (ESI) [M + H] + = 266.0.
[0341] Second step: Preparation of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (3.0 g, 18.75 mmol, 1 eq.) was dissolved in acetonitrile (80 mL), and then potassium carbonate (5.2 g, 37.5 mmol, 2.0 eq.) and (4-bromo-2,6-difluorophenyl)methylamine (4.37 g, 19.69 mmol, 1.05 eq.) were added, and the mixture was reacted under a nitrogen atmosphere at 40° C. for 20 hours. The reaction was monitored for completion by LCMS, concentrated, diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness. The crude product was purified by flash chromatography (Silica gel, DCM:EA = 4:1) to give the target compound (3.5 g, 69.2% yield). LCMS (ESI) [M + H] + = 452.0.
[0342] Third step: Preparation of (4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol Ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (120 mg, 22.7 mmol, 1 eq.) was dissolved in ethanol (10 mL), sodium borohydride (134 mg, 5 eq.) was added slowly, and the reaction was stirred at 50° C. under a nitrogen atmosphere for 16 hours. The reaction was monitored for completion by LCMS, the solvent was evaporated, and the resulting residue was quenched with saturated sodium chloride solution (5 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated. The crude product was purified by flash chromatography (Silica gel, DCM:MeOH = 2:1) to give the target compound (120 mg, 38% yield). LCMS (ESI) [M+H] + = 410.0; 1 H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 8.35 (d, J = 9.2 Hz, 1H), 7.09 (d, J = 6.8 Hz, 2H), 6.90 (d, J = 9.2 Hz, 1H), 4.75 (s, 2H), 4.69 (s, 2H), 4.12 (s, 3H).
[0343] Fourth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (4-((4-Bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (300 mg, 0.73 mmol, 1 eq.) was dissolved in dichloromethane (15 mL), and N,N-diisopropylethylamine (473 mg, 3.66 mmol, 5 eq.) and triphosgene (651 mg, 2.19 mmol, 3 eq.) were added, followed by reaction at 0°C for 2 hours. The completion of the reaction was monitored by LCMS. The reaction mixture was washed with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness. The crude product was purified by flash silica gel column chromatography (Silica gel, MeOH:DCM = 5:95) to give the target compound (250 mg, yield 78.51%). LCMS (ESI) [M + H] + =436.0.
[0344] Fifth step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (200 mg, 0.46 mmol, 1 eq.) was dissolved in dioxane (10 mL), and (4-methoxyphenyl)methanethiol (141 mg, 0.92 mmol, 2 eq.), [5-(diphenylphosphino)-9,9-dimethyl-9H-xant-4-yl]diphenylphosphine (53 mg, 0.09 mmol, 0.2 eq.), tris(1,5-diphenylpenta-1,4-dien-3-one)dipalladium (84 mg, 0.09 mmol, 0.2 eq.), and N,N-diisopropylethylamine (178 mg, 1.38 mmol, 3 eq.) were added. The reaction was carried out at 90°C for 2 hours, and the completion of the reaction was monitored by LCMS. The reaction mixture was concentrated to dryness and then purified by flash silica gel column chromatography (Silica gel, MeOH:DCM = 5:95) to give the target compound as a yellow solid (110 mg, yield 47.09%). LCMS (ESI) [M + H] + = 510.1.
[0345] Step 6: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (100 mg, 0.2 mmol, 1.0 eq.), acetic acid (83 mg, 1.37 mmol, 7.0 eq.), and water (50 mg, 2.75 mmol, 14.0 eq.) were dissolved in tetrahydrofuran (15 mL). 1,3-Dichloro-5,5-dimethylhydantoin (116 mg, 0.59 mmol, 3 eq.) was added at 0°C, and the mixture was reacted at 25°C for 1 hour. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 25°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and then purified by preparative HPLC to give the desired compound (14.6 mg, yield 17.05%). LCMS (ESI) [M+H] + = 437.1; 1 HNMR (400MHz, MeOD-d4) δ 8.71 (s, 1H), 8.59 (d, J = 9.2 Hz, 1H), 7.46 (d, J = 7.6 Hz, 2H), 7.13 (d, J = 9.6 Hz, 1H), 5.57 (s, 2H), 5.30 (s, 2H), 4.12 (s, 3H).
[0346] Example 7 Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-2-oxo-3,4-dihydropyrimido[5,4-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide (Compound 7): [ka]
[0347] Step 1: Preparation of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxylate Ethyl 4-chloro-6-fluoro-7-methoxyquinoline-3-carboxylate (1 g, 3.6 mmol, 1 eq.), (4-bromo-2,6-difluorophenyl)methylamine (1.2 g, 5.4 mmol, 1.5 eq.) and potassium carbonate (1.47 g, 10.8 mmol, 3 eq.) were dissolved in acetonitrile (50 mL), heated to 90 ° C, and reacted for 12 hours. After the reaction was completed, the target compound (900 mg, yield 54.41%) was isolated and purified by flash silica gel chromatography (Silica gel, DCM:MEOH = 95:5). LCMS (ESI) [M+H] + = 469.0; 1 H NMR (400 MHz, DMSO-d6) δ 8.82 (s, 1H), 8.24 (t, J = 5.2 Hz, 1H), 8.19 (d, J = 13.4 Hz, 1H), 7.49 (dd, J = 8.0 Hz, 3H), 4.73 (d, J = 5.2 Hz, 2H), 4.28 (d, J = 7.2 Hz, 2H), 4.00 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H).
[0348] Second step: Preparation of 4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxylic acid Ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxylate (500 mg, 1.07 mmol, 1 eq.) was added to methanol (5 mL) and tetrahydrofuran (5 mL), 3 mL of a 2M aqueous solution of sodium hydroxide was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was evaporated under reduced pressure, 20 mL of water was added, the pH was adjusted to acidic, and a solid was precipitated and filtered. The filter cake was washed with petroleum ether, and the solid was dried under vacuum to obtain the target compound (400 mg, yield 75.27%). LCMS (ESI) [M + H] + = 440.9.
[0349] Step 3: Preparation of 4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxamide 4-((4-Bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxylic acid (380 mg, 0.76 mmol, 1 eq.), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.8 g, 7.6 mmol, 10 eq.), and ammonia in tetrahydrofuran (19 mL, 7.6 mmol, 10 eq.) were added to N,N-dimethylformamide (10 mL), N,N-diisopropylethylamine (98.0 mg, 0.76 mmol, 1 eq.) was added dropwise, and the mixture was reacted at room temperature for 40 hours. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (100 mL × 2). The organic phase was washed five times with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure. Silica gel was added, and the mixture was loaded onto a flash silica gel column (Silica The target compound (250 mg, yield 65.94%) was obtained using a solvent mixture of 100% ethanol, 1% DCM, 1% MeOH (70:30), and 1% DCM. LCMS (ESI) [M + H] + = 440.0.
[0350] Fourth step: Preparation of 3-(aminomethyl)-N-(4-bromo-2,6-difluorobenzyl)-6-fluoro-7-methoxyquinolin-4-amine 4-((4-Bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxamide (380 mg, 0.86 mmol, 1 eq.) was added to tetrahydrofuran (20 mL), and a tetrahydrofuran solution of 1 M borane (8.6 mL, 8.6 mmol, 10 eq.) was added. The reaction was carried out at 60°C for 15 hours. After the reaction was completed, 10 mL of methanol solution was added, the solvent was dried on a rotary evaporator, the sample was added, and the target compound (160 mg, yield 43.5%) was obtained by elution through a flash silica gel column (Silica gel, DCM:MeOH = 65:35). LCMS (ESI) [M + H] + = 426.1.
[0351] Fifth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one 3-(Aminomethyl)-N-(4-bromo-2,6-difluorobenzyl)-6-fluoro-7-methoxyquinolin-4-amine (160 mg, 0.38 mmol, 1 eq.) was added to tetrahydrofuran (10 mL) and N,N'-carbonyldiimidazole (123.1 mg, 0.76 mmol, 2 eq.) was added. The reaction mixture was incubated at room temperature for 15 hours, and the product was monitored by LCMS. The reaction mixture was concentrated and purified using a flash silica gel column (Silica gel, DCM:MeOH = 70:30) to obtain the desired compound (70 mg, 41.24% yield). LCMS (ESI) [M + H] + = 452.1.
[0352] Step 6: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-9-fluoro-8-methoxy-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one 1-(4-Bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one (45 mg, 0.1 mmol, 1 eq.) and (4-methoxyphenyl)methanethiol (18.5 mg, 0.12 mmol, 1.2 eq.) were added to dioxane (10 mL), and tris(dibenzylideneacetone)dipalladium (5 mg, 0.03 mmol, 0.3 eq.), 4,5-bisdiphenylphosphino-9,9-dimethylxanthene (39 mg, 0.07 mmol, 0.2 eq.), and N,N-diisopropylethylamine (25.8 mg, 0.2 mmol, 2 eq.) were added, and the mixture was reacted at 100°C for 1 hour under a nitrogen atmosphere. After the reaction was completed, silica gel was added to the reaction mixture to prepare a sample, which was then isolated and purified by flash silica gel column chromatography (Silica gel, DCM:MeOH = 95:5) to obtain the target compound (20 mg, yield 38.06%). LCMS (ESI) [M + H] + = 526.1.
[0353] Step 7: Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-2-oxo-3,4-dihydropyrimido[5,4-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-9-fluoro-8-methoxy-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one (18 mg, 0.03 mmol, 1 eq.) was added to 2 mL of tetrahydrofuran, and 1 drop of acetic acid, 1 drop of water, and 1,3-dichloro-5,5-dimethylhydantoin (20.2 mg, 0.12 mmol, 3 eq.) were added at 0 ° C., and the reaction was continued for 2 hours at 0 ° C. After the reaction was completed, 2 mL of aqueous ammonia was added dropwise at 0 ° C. The product was monitored by LCMS, the solvent was evaporated under reduced pressure, and the product was purified to obtain the target compound (1.6 mg, yield 11.12%). LCMS (ESI) [M+H] + = 453.0; 1H NMR (400 MHz, CD3OD) δ 8.73 (s, 1H), 8.14 (d, J = 12.6 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.6 Hz, 2H), 5.72 (s, 2H), 4.60 (s, 2H), 4.26 (s, 3H).
[0354] Example 8 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxopyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (compound 8): [ka]
[0355] First step: Preparation of 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carbaldehyde (4-((4-Bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (300 mg, 0.73 mmol, 1 eq.) was dissolved in dichloromethane (10 mL) and tetrahydrofuran (10 mL), and manganese dioxide (317 mg, 3.65 mmol, 5 eq.) was added. The reaction was carried out at 25 °C for 2 h. The reaction mixture was monitored for completion by LCMS. The reaction mixture was washed with water, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash silica gel column chromatography (Silica gel, MeOH:DCM = 5:95) to give the target compound (160 mg, yield 53.42%). LCMS (ESI) [M+H] + =408.0; 1H NMR (400 MHz, CDCl3) δ 10.10 (s, 1H), 9.77 (s, 1H), 8.68 (s, 1H), 8.44 (d, J = 9.2 Hz, 1H), 7.20 (d, J = 7.2 Hz, 2H), 6.84 (d, J = 8.8 Hz, 1H), 4.92 (d, J = 4.8 Hz, 2H), 4.10 (s, 3H).
[0356] Second step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one 4-((4-Bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carbaldehyde (150 mg, 0.37 mmol, 1 eq.) was dissolved in methanol (15 mL), and ethyl 2-(dimethoxyphosphoryl)acetate (247 mg, 1.1 mmol, 3 eq.) and potassium carbonate (254 mg, 1.84 mmol, 5 eq.) were added. The reaction was carried out at 85 °C for 8 hours, and completion of the reaction was monitored by LCMS. The reaction solution was concentrated and purified by flash silica gel column chromatography (Silica gel, MeOH:DCM = 2:98) to obtain the target compound (110 mg, 69.26% yield). LCMS (ESI) [M+H] + = 432.0; 1 H NMR (400 MHz, DMSO-d6) δ 9.15 (s, 1H), 8.70 (d, J = 9.2 Hz, 1H), 8.19 (d, J = 9.2 Hz, 1H), 7.42 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 9.2 Hz, 1H), 6.71 (d, J = 9.2 Hz, 1H), 5.69 (s, 2H), 4.04 (s, 3H).
[0357] Third step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one (145 mg, 0.34 mmol, 1 eq.) was dissolved in dioxane (10 mL), and 3-(4-methoxyphenyl)methanethiol (103 mg, 0.67 mmol, 2 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (40 mg, 0.07 mmol, 0.2 eq.), tris(1,5-diphenylpenta-1,4-dien-3-one)dipalladium (61 mg, 0.07 mmol, 0.2 eq.), and N,N-diisopropylethylamine (130 mg, 1.01 mmol, 3 eq.) were added and the mixture was reacted at 90 °C for 2 h. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and purified by flash silica gel column chromatography (Silica gel, MeOH:DCM = 5:95) to give the target compound (110 mg, yield 64.86%). LCMS (ESI) [M + H] + = 506.1.
[0358] Step 4: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxopyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one (110 mg, 0.22 mmol, 1.0 eq.)), acetic acid (91 mg, 1.52 mmol, 7.0 eq.), and water (55 mg, 3.05 mmol, 14.0 eq.) were dissolved in tetrahydrofuran (15 mL), and 1,3-dichloro-5,5-dimethylhydantoin (129 mg, 0.65 mmol, 3 eq.) was added at 0°C. The mixture was reacted at 0°C for 1 hour. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and purified by preparative HPLC to give the target compound (40.9 mg, yield 43.47%). LCMS (ESI) [M+H] + = 433.0; 1 H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.72 (d, J = 9.2 Hz, 1H), 8.21 (d, J = 9.6 Hz, 1H), 7.62 (s, 2H), 7.43 (d, J = 7.6 Hz, 2H), 7.12 (d, J = 9.2 Hz, 1H), 6.70 (d, J = 9.2 Hz, 1H), 5.78 (s, 2H), 4.05 (s, 3H).
[0359] Example 9 Preparation of 3,5-difluoro-4-((8-methoxy-3-oxo-4-(2,2,2-trifluoroethyl)-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (Compound 11) [ka]
[0360] First step: Preparation of N-(4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)-2-chloroacetamide N 4-(4-Bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine (120 mg, 0.3 mmol, 1.0 eq.), 2-chloroacetyl chloride (38 mg, 0.34 mmol, 1.1 eq.), and potassium carbonate (47 mg, 0.34 mmol, 1.1 eq.) were dissolved in 10 mL of tetrahydrofuran, and the reaction mixture was stirred at ambient temperature for 20 minutes. The product was monitored, concentrated, and the resulting crude product was purified by flash silica gel column chromatography (Silica gel, DCM:MeOH = 20:1) to give the desired compound (68 mg, 48% yield). LCMS (ESI) [M + H] + = 471.0.
[0361] Second step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one N-(4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)-2-chloroacetamide (48 mg, 0.15 mmol, 1.0 eq.) was dissolved in 10 mL of N,N-dimethylformamide and stirred at room temperature for 20 minutes. The reaction mixture was then concentrated, and the resulting crude product was purified by flash silica gel column chromatography (Silica gel, DCM:MeOH = 20:1) to obtain the target compound (50 mg, yield 77%). LCMS (ESI) [M + H] + = 435.0.
[0362] Third step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one (50 mg, 0.12 mmol, 1 eq.) and potassium carbonate (49 mg, 0.35 mmol, 3 eq.) were dissolved in N,N-dimethylformamide (10 mL), and then 2,2,2-trifluoroethyl trifluoromethanesulfonate (27 mg, 0.12 mmol, 1 eq.) was added and the mixture was reacted at 80°C for 2 hours. The reaction was monitored for completion by LCMS. Then, it was diluted with water and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (Silica gel, PE:EA = 2:1) to give the target compound (32 mg, yield 53.93%). LCMS (ESI) [M + H] + = 517.0.
[0363] Fourth step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one (32 mg, 0.06 mmol, 1 eq.) was dissolved in dioxane (10 mL), followed by the addition of (4-methoxyphenyl)methanethiol (19 mg, 0.12 mmol, 2 eq.), tris(dibenzylideneacetone)dipalladium (10 mg, 0.01 mmol, 0.17 eq.), 4,5-bisdiphenylphosphine-9,9-dimethyloxa (10.4 mg, 0.02 mmol, 0.3 eq.), and diisopropylethylamine (23 mg, 0.18 mmol, 3 eq.). The mixture was allowed to react under a nitrogen atmosphere at 100°C for 2 hours. The reaction was monitored for completion by LCMS. Then, the mixture was extracted with water and ethyl acetate (15 mL × 3), and the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (Silica gel, PE:EA = 2:1) to give the target compound (10 mg, yield 28.25%). LCMS (ESI) [M + H] + = 591.1.
[0364] Fifth step: Preparation of 3,5-difluoro-4-((8-methoxy-3-oxo-4-(2,2,2-trifluoroethyl)-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-4-(2,2,2-trifluoroethyl)-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one (10 mg, 0.017 mmol, 1 eq.) was dissolved in tetrahydrofuran (2 mL) and acetonitrile (1 mL). Acetic acid (7 mg, 0.05 mmol, 7 eq.), water (1.8 mg, 0.1 mmol, 14 eq.), and 1,3-dichloro-5,5-dimethylhydantoin (5.91 mg, 0.03 mmol, 1.8 eq.) were added at 0 °C, and the reaction was continued at 0 °C for 2 hours. Aqueous ammonia (178 mg, 5.1 mmol, 300 eq.) was then added, and the reaction was continued at 0 °C for 1 hour. After the reaction was completed, the mixture was extracted with water and ethyl acetate (15 mL x 3) and the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified to obtain the target compound. LCMS (ESI) [M+H] + = 518.0; 1H NMR (400 MHz, CD3OD) δ 8.80 (s, 1H), 8.57 (d, J = 9.0 Hz, 1H), 8.52 (s, 2H), 7.39 (d, J = 7.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 1H), 4.78 - 4.66 (m, 4H), 4.11 (s, 3H), 4.04 (s, 2H).
[0365] Example 10 Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonyl (Compound 48) [ka]
[0366] First step: Preparation of (4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)methanol Ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinoline-3-carboxylate (500 mg, 1.07 mmol, 1 eq.) was dissolved in ethanol (15 mL), and sodium borohydride (202 mg, 5.35 mmol, 5 eq.) was added, followed by reaction at 25°C for 16 hours. The reaction was monitored for completion by LCMS. The reaction mixture was poured into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column (Silica gel, DCM:MeOH = 97:3) to give the target compound (300 mg, yield 65.63%). LCMS (ESI) [M + H] + = 427.0.
[0367] Second step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (4-((4-Bromo-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)methanol (150 mg, 0.35 mmol, 1 eq.) was dissolved in dichloromethane (10 mL), and triphosgene (313 mg, 1.05 mmol, 3 eq.) and N,N-diisopropylethylamine (227 mg, 1.76 mmol, 5 eq.) were added. The reaction was carried out at 25 °C for 1 h. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness and purified by silica gel column (Silica gel, DCM:MeOH = 97:3) to give the target compound (100 mg, yield 62.66%). LCMS (ESI) [M + H] + = 453.0.
[0368] Third step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-9-fluoro-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one 1-(4-Bromo-2,6-difluorobenzyl)-9-fluoro-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (90 mg, 0.2 mmol, 1 eq.) was dissolved in dioxane (10 mL), and 3-(4-methoxyphenyl)methanethiol (61 mg, 0.4 mmol, 2 eq.), tris(dibenzylideneacetone)dipalladium (18 mg, 0.02 mmol, 0.1 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (23 mg, 0.04 mmol, 0.2 eq.), and N,N-diisopropylethylamine (77 mg, 0.13 mmol, 3 eq.) were added. The reaction was carried out at 90 °C for 2 h. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and purified by silica gel column chromatography (Silica gel, DCM:MeOH = 97:3) to give the target compound (60 mg, yield 57.38%). LCMS (ESI) [M + H]+ = 527.0.
[0369] Step 4: Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-9-fluoro-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (5 mg, 0.01 mmol, 1.0 eq.)), acetic acid (4.0 mg, 0.07 mmol, 7.0 eq.), and water (2.4 mg, 0.13 mmol, 14.0 eq.) were dissolved in tetrahydrofuran (15 mL). 1,3-Dichloro-5,5-dimethylhydantoin (5.6 mg, 0.03 mmol, 3 eq.) was added at 0 °C, and the mixture was reacted at 0 °C for 2 hours. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0 °C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and purified to give the desired compound (12.1 mg, 25.55% yield). LCMS (ESI) [M+H] + = 454.0; 1 H NMR (400 MHz, MeOD) δ 8.65 (s, 1H), 8.01 (d, J = 12.8 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 7.2 Hz, 2H), 5.61 (s, 2H), 5.31 (s, 2H), 4.08 (s, 3H).
[0370] Example 11 Preparation of 3,5-difluoro-4-((8-methoxy-2,3-dioxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (Compound 62): [ka]
[0371] Preparation of 3,5-difluoro-4-((8-methoxy-2,3-dioxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one (100 mg, 1.0 eq.)), 10 mL of tetrahydrofuran, acetic acid (10 mg, 0.84 eq.), and water (10 mg, 2.81 eq.) were added to a 50 mL round-bottom flask, and 1,3-dichloro-5,5-dimethylhydantoin (118 mg, 3.0 eq.) was added to the mixture under ice-water cooling. The reaction mixture was stirred for 1 hour, and then 3 mL of aqueous ammonia was added and the reaction mixture was stirred for 1 hour. After monitoring the completion of the reaction by LCMS, the reaction mixture was extracted with ethyl acetate, the layers were separated, the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude product, which was isolated and purified to give the target compound (19.3 mg, yield 21%). LCMS (ESI) [M+H] + = 450.1; 1 HNMR (400MHz, DMSO-d6) δ 12.44 (s, 1H), 8.76 (s, 1H), 8.67 (d, J = 9.6 Hz, 1H), 7.60 (s, 2H), 7.43 (d, J = 7.2 Hz, 2H), 7.11 (d, J = 9.2 Hz, 1H), 5.69 (s, 2H), 4.01 (s, 3H).
[0372] Example 12 Preparation of 7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (compound 39): [ka]
[0373] Step 1: Preparation of ethyl 4-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate 4-Chloro-7-methoxy-1,8-naphthyridine-3-carboxylic acid ethyl ester (600 mg, 1 eq.), 7-amino-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (838.4 mg, 1.5 eq.), and N,N-diisopropylethylamine (1.45 g, 5 eq.) were dissolved in ethanol (150 mL), heated to 90°C, and reacted for 24 hours. After monitoring the completion of the reaction by LCMS, the target compound was isolated and purified by flash silica gel column chromatography (800 mg, yield 74.3%). LCMS (ESI) [M+H] + = 479.0; 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.02 (s, 1H), 8.10 (d, J = 9.6 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 9.6 Hz, 1H), 6.90 (d, J = 9.6 Hz, 2H), 4.41 (s, 2H), 4.16 (q, J = 7.2 Hz, 2H), 4.00 (s, 3H), 3.54 (t, J = 5.6 Hz, 2H), 2.73 (t, J = 5.6 Hz, 2H), 1.42 (s, 9H), 1.24 (t, J = 7.2 Hz, 3H).
[0374] Second step: Preparation of tert-butyl 7-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate Ethyl 4-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (400 mg, 1 eq.) and sodium borohydride (307.8 mg, 10 eq.) were dissolved in ethanol (40 mL), warmed to 60° C., and the reaction was stirred for 4 h. After monitoring the completion of the reaction by LCMS, the solvent was distilled off under vacuum, 100 mL of water was added to dissolve the residue, and the residue was extracted with ethyl acetate (200 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and then purified by flash chromatography to obtain the target compound (230 mg, yield 62%). LCMS (ESI) [M+H] + = 437.3; 1 H NMR (400 MHz, DMSO-d6) δ 8.86 (s, 1H), 8.35 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H), 6.97 (d, J = 9.0 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 5.33 (t, J = 5.4 Hz, 1H), 4.46 (d, J = 5.4 Hz, 2H), 4.36 (s, 2H), 4.00 (s, 3H), 3.51 (t, J = 5.8 Hz, 2H), 2.67 (t, J = 5.6 Hz, 2H), 1.41 (s, 9H).
[0375] Third step: Preparation of tert-butyl 7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate tert-Butyl 7-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate (230 mg, 1 eq.) was added to tetrahydrofuran (20 mL), N,N-diisopropylethylamine (683.7 mg, 10 eq.) and triphosgene (312.7 mg, 2 eq.) were added, and the mixture was allowed to react at room temperature for 1 hour. The completion of the reaction was monitored by LCMS, silica gel was added to prepare a sample, and the sample was isolated and purified by flash chromatography to obtain the target compound (200 mg, yield: 81.61%). LCMS (ESI) [M+H] + = 463.0; 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.57 - 8.43 (m, 1H), 7.33 (s, 2H), 7.18 (d, J = 9.6 Hz, 1H), 6.78 (d, J = 9.2 Hz, 1H), 5.60 (s, 2H), 4.45 (s, 2H), 3.58 (s, 3H), 3.14 (s, 2H), 2.85 (s, 2H), 1.41 (s, 9H).
[0376] Fourth step: Preparation of 8-methoxy-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one tert-Butyl 7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (200 mg, 1 eq.) was added to dichloromethane (10 mL), trifluoroacetic acid (3 mL) was added, and the reaction was allowed to proceed at room temperature for 2 hours. The reaction was monitored by LCMS and was complete. The solvent was removed under vacuum to give the crude target compound (140 mg). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 363.1.
[0377] Fifth step: Preparation of tert-butyl ((7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)carbamate 8-Methoxy-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (130 mg, crude product) and triethylamine (54.6 mg) were added to dichloromethane (20 mL), and tert-butyl N-(chlorosulfonyl)carbamate (154.7 mg) was added dropwise at 0°C, followed by reaction at room temperature for 4 hours. After the completion of the reaction monitored by LCMS, 50 mL of water was added, and the mixture was extracted with dichloromethane (100 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give the crude target compound (150 mg), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 542.1.
[0378] Step 6: Preparation of 7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide tert-Butyl (7-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)carbamate (150 mg, crude product) was added to dichloromethane (10 mL), trifluoroacetic acid (2 mL) was added, and the reaction was carried out at room temperature for 4 hours. The reaction was monitored by LCMS and completed. The solvent was evaporated under vacuum, and the residue was dissolved in 3 mL of N,N-dimethylformamide and purified by preparative HPLC to give the target compound (27 mg, 22% yield). LCMS (ESI) [M+H] + = 442.1; 1H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 7.38 (s, 1H), 7.30 (s, 2H), 7.18 (d, J = 9.2, 1H), 6.95 (s, 2H), 6.79 (d, J = 9.2, 1H), 5.60 (s, 2H), 4.17(s, 2H), 3.95 (s, 3H), 3.28 (t, J = 5.6, 2H), 2.98 (t, J = 5.6, 2H).
[0379] Example 13 Preparation of 3,5-difluoro-4-((2-hydroxy-8-methoxy-3-oxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (Compound 65) [ka]
[0380] Step 1: Preparation of 5-chloro-2-methoxy-6-nitro-1,8-naphthyridine 7-Methoxy-3-nitro-1,8-naphthyridin-4-ol (3 g, 1 eq.) was dissolved in dichloromethane (30 mL), N,N-dimethylformamide (1 mL) was added, thionyl chloride (3 mL, 1.9 eq.) was slowly added dropwise in an ice bath, the mixture was heated to 40°C, and the reaction was carried out for 2 hours. After monitoring the completion of the reaction by LCMS, it was quenched with ice water and extracted with dichloromethane (100 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain the target compound (2.8 g, yield 88%). LCMS (ESI) [M + H] + = 240.0.
[0381] Second step: Preparation of N-(4-bromo-2,6-difluorobenzyl)-7-methoxy-3-nitro-1,8-naphthyridin-4-amine 5-Chloro-2-methoxy-6-nitro-1,8-naphthyridine (2 g, 1 eq.) and 1-(4-bromo-2,6-difluorophenyl)methylamine (5.07 g, 1.1 eq.) were dissolved in acetonitrile (100 mL), potassium carbonate (8.63 g, 3 eq.) was added, and the mixture was reacted at 40°C for 2 hours. After monitoring the completion of the reaction by LCMS, the reaction mixture was concentrated, diluted with water, and extracted with ethyl acetate (20 mL × 3). The organic phase was collected, dried over anhydrous ammonium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain the target compound (3 g, yield 85%). LCMS (ESI) [M + H] + = 427.0.
[0382] 3rd step:N 4 Preparation of -(4-bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine N-(4-bromo-2,6-difluorobenzyl)-7-methoxy-3-nitro-1,8-naphthyridin-4-amine (3 g, 1 eq.) was dissolved in ethanol (50 mL), and iron powder (4 g, 10 eq.) and saturated ammonium chloride solution (2 mL) were added, followed by reaction at 80°C for 2 hours. After monitoring the completion of the reaction by LCMS, part of the solvent was removed by concentration, then diluted with water and extracted with ethyl acetate (50 mL×3). The organic phase was collected, dried over anhydrous ammonium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to give N 4 -(4-Bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine (1.5 g, 54% yield) was obtained. LCMS (ESI) [M + H] + = 397.0.
[0383] Fourth step: Preparation of N-(4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)-2-chloroacetamide N 4-(4-Bromo-2,6-difluorobenzyl)-7-methoxy-1,8-naphthyridine-3,4-diamine (500 mg, 1.0 eq.), 2-chloroacetyl chloride (154 mg, 1.1 eq.), and potassium carbonate (197 mg, 1.1 eq.) were dissolved in 30 mL of tetrahydrofuran and reacted at room temperature for 20 minutes. Completion of the reaction was monitored by LCMS, and the resulting crude product was concentrated in the reaction mixture and purified by flash silica gel column chromatography to give the desired compound (330 mg, 56% yield). LCMS (ESI) [M+H] + = 471.0; 1 H NMR (400 MHz, dmso-d6) δ 10.49 (s, 1H), 8.88 (d, J = 9.2 Hz, 1H), 8.42 (s, 1H), 7.51 (d, J = 7.4 Hz, 2H), 7.19 (d, J = 9.2 Hz, 1H), 4.94 (d, J = 4.4 Hz, 2H), 4.38 (s, 2H), 4.05 (s, 3H), 3.17 (s, 1H).
[0384] Fifth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one N-(4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)-2-chloroacetamide (320 mg, 1.0 eq.) and sodium hydride (18 mg, 1.1 eq.) were dissolved in N,N-dimethylformamide (20 mL), and the mixture was allowed to react at room temperature for 20 minutes. The completion of the reaction was monitored by LCMS, and the resulting crude reaction solution was concentrated and purified by flash silica gel column chromatography to obtain the target compound (120 mg, yield 42%). LCMS (ESI) [M+H] + = 435.0; 1H NMR (400 MHz, dmso-d6) δ 10.56 (s, 1H), 8.48 (d, J = 9.0 Hz, 1H), 8.37 (s, 1H), 7.41 (d, J = 7.2 Hz, 2H), 7.12 (d, J = 9.0 Hz, 1H), 4.49 (s, 2H), 3.99 (s, 3H), 3.77 (s, 2H).
[0385] Step 6: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one (120 mg, 1 eq.) was dissolved in dioxane (10 mL), and then (4-methoxyphenyl)methanethiol (73 mg, 2 eq.), tris(dibenzylideneacetone)dipalladium (32 mg), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (72 mg), and diisopropylethylamine (58 mg, 3 eq.) were added sequentially, and the mixture was reacted at 100°C for 2 hours under a nitrogen atmosphere. The completion of the reaction was monitored by LCMS, and then extracted with water and ethyl acetate (15 mL × 3), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain the target compound (76 mg, yield 64%). LCMS (ESI) [M + H] + = 509.1.
[0386] Seventh step: Preparation of 3,5-difluoro-4-((2-hydroxy-8-methoxy-3-oxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide) 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydropyrazino[2,3-c][1,8]naphthyridin-3(2H)-one (40 mg, 1 eq.) was dissolved in tetrahydrofuran (2 mL) and acetonitrile (1 mL), and the solution was reacted with acetic acid (41 mg, 7 eq.), water (11.5 mg, 14 eq.), and N-chlorosuccinimide (25 mg, 1.8 eq.) at 0°C for 2 hours. Subsequently, aqueous ammonia (1 g, 300 eq.) was added, and the reaction was continued at 0°C for 1 hour. After monitoring the completion of the reaction by LCMS, the reaction mixture was diluted with water and extracted with ethyl acetate (15 mL) × 3. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified to give the target compound (5.1 mg, yield: 17%). LCMS (ESI) [M+H] + = 452.0; 1 H NMR (400 MHz, MeOD) δ 8.63 (d, J = 9.2 Hz, 1H), 8.44 (s, 1H), 7.41 (d, J = 7.0 Hz, 2H), 7.14 (d, J = 9.0 Hz, 1H), 5.21 (s, 1H), 5.03 (s, 2H), 4.12 (s, 3H).
[0387] Example 14 Preparation of 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidine-1-sulfonamide (Compound 46) [ka]
[0388] Step 1: Preparation of ethyl 4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (300 mg, 1 eq.), tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (241 mg, 1 eq.), and N,N-diisopropylethylamine (726 mg, 5 eq.) were dissolved in ethanol (100 mL), heated to 90°C, and reacted for 24 hours. After monitoring the completion of the reaction by LCMS, the product was isolated and purified by flash silica gel column chromatography to obtain the target compound (300 mg, yield 24%). LCMS (ESI) [M + H] + = 445.2.
[0389] Second step: Preparation of tert-butyl 4-(((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)piperidine-1-carboxylate Ethyl 4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (300 mg, 1 eq.) and sodium borohydride (248 mg, 10 eq.) were dissolved in ethanol (40 mL), heated to 60°C, and reacted for 16 hours. After completion of the reaction monitored by L CMS, the solvent was evaporated under vacuum, 50 mL of water was added, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by flash chromatography to obtain the target compound (50 mg, 18% yield). LCMS (ESI) [M + H] + = 403.3.
[0390] Third step: Preparation of tert-butyl 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidine-1-carboxylate tert-Butyl 4-(((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)piperidine-1-carboxylate (50 mg, 1 eq.) was added to tetrahydrofuran (5 mL), N,N-diisopropylethylamine (160 mg, 10 eq.) and triphosgene (73 mg, 2 eq.) were added, and the mixture was allowed to react at room temperature for 1 hour. After monitoring the completion of the reaction by LCMS, 10 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL×3). The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude target compound (50 mg). LCMS (ESI) [M+H] + = 429.2. It was used directly in the next reaction without further purification.
[0391] Step 4: Preparation of 8-methoxy-1-(piperidin-4-ylmethyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one tert-Butyl 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidine-1-carboxylate (50 mg, crude product) was added to dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added and the reaction was carried out at room temperature for 2 hours. After monitoring the completion of the reaction by LCMS, the solvent was evaporated under vacuum to give the crude target compound (30 mg). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 329.2.
[0392] Fifth step: Preparation of tert-butyl ((4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidin-1-yl)sulfonyl)carbamate 8-Methoxy-1-(piperidin-4-ylmethyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (30 mg, crude product) and triethylamine (46 mg) were added to dichloromethane (5 mL), and tert-butyl N-(chlorosulfonyl)carbamate (39 mg) was added dropwise at 0°C, followed by reaction at room temperature for 5 hours. After monitoring the completion of the reaction by LCMS, 10 mL of water was added, and the mixture was extracted with dichloromethane (20 mL×2). The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude target compound (30 mg), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 508.2.
[0393] Step 6: Preparation of 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidine-1-sulfonamide tert-Butyl ((4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)piperidin-1-yl)sulfonyl)carbamate (28 mg, crude product) was added to dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added, followed by reaction at room temperature for 4 hours. After monitoring the completion of the reaction by LCMS, the solvent was evaporated under vacuum to give the crude product, which was purified by liquid-phase preparative HPLC to give the target compound (5.2 mg, 18% yield). LCMS (ESI) [M+H] + = 408.1; 1 H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.53 (d, J = 9.2, 1H), 7.11 (d, J = 9.2, 1H), 6.62 (s, 2H), 5.41 (s, 2H), 4.12 (d, J = 6.8, 2H), 4.02 (s, 3H), 2.39-2.33 (m, 2H), 1.73-1.61 (m, 3H), 1.13-1.06 (m, 2H).
[0394] Example 15 Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2,3-dihydropyrazino[2,3-c][1,8]naphthyridine-4(1H)-carboxylate (compound 50): [ka]
[0395] First step: Preparation of 2-((4-bromo-2,6-difluorobenzyl)amino)ethan-1-ol 4-Bromo-2,6-difluorobenzaldehyde (10 g, 1 eq.) and 2-aminoethan-1-ol (8.29 g, 3 eq.) were dissolved in dichloromethane (200 mL), acetic acid (5.43 g, 2 eq.) was added, and the mixture was allowed to react at room temperature for 30 minutes. After that, sodium bis(acetoxy)boroacetate (19.18 g, 2 eq.) was added, and the mixture was allowed to react at room temperature overnight. The reaction was monitored for completion by LCMS. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (DCM / MeOH = 10:1) to give the target compound (8.5 g, 70% yield). LCMS (ESI) [M+H] + = 266.0; 1 H NMR (400 MHz, CDCl3) δ 7.13 - 7.06 (m, 2H), 3.87 (s, 2H), 3.68 - 3.62 (m, 2H), 2.77 - 2.69 (m, 2H).
[0396] Second step: Preparation of 2-((4-bromo-2,6-difluorobenzyl)(7-methoxy-3-nitro-1,8-naphthyridin-4-yl)amino)ethan-1-ol 5-Chloro-2-methoxy-6-nitro-1,8-naphthyridine (5.00 g, 1 eq.) and 2-((4-bromo-2,6-difluorobenzyl)amino)ethan-1-ol (8.32 g, 1.5 eq.) were dissolved in dimethylformamide (100 mL), and ethyldi(propan-2-yl)amine (10.78 g, 4 eq.) was added. The reaction was allowed to proceed at room temperature overnight, and the reaction completion was monitored by LCMS. Water was added to the reaction mixture to precipitate a large amount of solid. The precipitate was filtered, and the filter cake was dried to obtain the desired compound (4.5 g, 45% yield). LCMS (ESI) [M+H] + = 468.9; 1 H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.10 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 6.8 Hz, 2H), 6.99 (d, J = 9.1 Hz, 1H), 4.45 (s, 2H), 4.17 (s, 3H), 3.96 - 3.81 (m, 2H), 3.59 - 3.46 (m, 2H), 2.66 (s, 1H)
[0397] Third step: Preparation of 2-((3-amino-7-methoxy-1,8-naphthyridin-4-yl)(4-bromo-2,6-difluorobenzyl)amino)ethan-1-ol 2-((4-Bromo-2,6-difluorobenzyl)(7-methoxy-3-nitro-1,8-naphthyridin-4-yl)amino)ethan-1-ol (4.5 g, 1 eq.) was dissolved in methanol (20 mL), tetrahydrofuran (20 mL), and water (10 mL), and zinc (3.13 g, 5 eq.) and ammonium chloride (5.13 g, 10 eq.) were added, and the mixture was allowed to react at room temperature overnight. The reaction was monitored for completion by LCMS. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL), washed with water (100 mL) and saturated brine (80 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the target compound (3.0 g, crude product), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 440.9.
[0398] Fourth step: Preparation of 2-((3-amino-7-methoxy-1,8-naphthyridin-4-yl)(4-bromo-2,6-difluorobenzyl)amino)ethyl methylsulfonate 2-((3-amino-7-methoxy-1,8-naphthyridin-4-yl)(4-bromo-2,6-difluorobenzyl)amino)ethan-1-ol (1.2 g, crude product) was dissolved in dichloromethane (30 mL), triethylamine (829.3 mg) was added, and methanesulfonyl chloride (469.4 mg) was added in an ice bath, and the mixture was allowed to react in an ice bath for 30 minutes. The reaction was monitored for completion by LCMS. Water (30 mL) was added and extracted with dichloromethane (30 mL x 2). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the target compound (1.2 g, crude). LCMS (ESI) [M + H] + = 519.0 It was used directly in the next reaction without further purification.
[0399] Fifth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,2,3,4-tetrahydropyrazino[2,3-c][1,8]naphthyridine 2-((3-amino-7-methoxy-1,8-naphthyridin-4-yl)(4-bromo-2,6-difluorobenzyl)amino)ethyl methylsulfonate (1.5 g, crude product) was dissolved in acetonitrile (50 mL), and cesium carbonate (2.83 g) was added, followed by reaction at 50° C. for 16 hours. The completion of the reaction was monitored by LCMS. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (DCM / EA = 1:1) to obtain the target compound (500 mg, yield 41%). LCMS (ESI) [M+H] + = 423.1; 1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 8.9 Hz, 1H), 8.39 (s, 1H), 7.17 (d, J = 7.0 Hz, 2H), 6.94 (d, J = 9.0 Hz, 1H), 4.32 (s, 2H), 4.11 (s, 3H), 3.37 - 3.30 (m, 2H), 3.09 - 3.02 (m, 2H).
[0400] Step 6: Preparation of 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-1,2,3,4-tetrahydropyrazino[2,3-c][1,8]naphthyridine 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,2,3,4-tetrahydropyrazino[2,3-c][1,8]naphthyridine (300 mg, 1 eq.) and benzenemethanethiol (2.13 g, 1.5 eq.) were dissolved in dioxane (15 mL). Subsequently, (1E,4E)-1,5-diphenylpenta-1,4-dien-3-onedipalladium (31.8 mg, 0.1 eq.), (5-(diphenylphosphino)-9,9-dimethyl-9H-xant-4-yl)diphenylphosphine (82.4 mg, 0.2 eq.), and triethylamine (216.2 mg, 3 eq.) were added. The atmosphere was purged with argon three times, and the reaction mixture was reacted at 90°C for 16 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain the target compound (300 mg, yield 91%). LCMS (ESI) [M+H] + = 465.2; 1H NMR (400 MHz, CDCl3) δ 8.48 (d, J = 8.9 Hz, 1H), 8.43 (s, 1H), 7.38 - 7.30 (m, 5H), 6.92 (d, J = 9.0 Hz, 1H), 6.85 (d, J = 8.2 Hz, 2H), 4.36 (s, 2H), 4.17 (s, 2H), 4.11 (s, 3H), 3.32 - 3.27 (m, 2H), 3.11 - 3.06 (m, 2H).
[0401] Seventh step: Preparation of tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2,3-dihydropyrazino[2,3-c][1,8]naphthyridine-4(1H)-carboxylate The compound 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-1,2,3,4-tetrahydropyrazino[2,3-c][1,8]naphthyridine (100 mg, 1 eq.) was dissolved in di-tert-butyl dicarbonate (5 mL, 106.38 eq.), 4-dimethylaminopyridine (100 mg, 3.8 eq.) was added, and the mixture was reacted at 40°C for 2 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain the target compound (100 mg, yield 82%). LCMS (ESI) [M + H] + = 565.3.
[0402] Eighth step: Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2,3-dihydropyrazino[2,3-c][1,8]naphthyridine-4(1H)-carboxylate The compound tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2,3-dihydropyrazino[2,3-c][1,8]naphthyridine-4(1H)-carboxylate (230 mg, 1 eq.) was dissolved in tetrahydrofuran (5 mL), water (102.8 mg, 14 eq.) and acetic acid (171.2 mg, 7 eq.) were added, and 1,3-dichloro-5,5-dimethylhydantoin (240.8 mg, 3 eq.) was added under ice-cooling, and the reaction was carried out for 10 minutes under ice-cooling. The reaction solution was slowly added dropwise to aqueous ammonia (5 mL) in an ice bath, and the reaction was carried out for 30 minutes in an ice bath. Completion of the reaction was monitored by LCMS. The reaction solution was extracted with ethyl acetate (20 mL), the organic phase was concentrated under reduced pressure, and the crude product was purified by preparative HPLC to obtain the target compound (13.0 mg, 6% yield). LCMS (ESI) [M+H] + = 522.5; 1 H NMR (400 MHz, MeOD-d4) δ 8.85 (s, 1H), 8.54 (d, J = 9.1 Hz, 1H), 7.48 (d, J = 7.0 Hz, 2H), 7.00 (d, J = 9.1 Hz, 1H), 4.98 (s, 2H), 4.09 (s, 3H), 3.71 - 3.64 (m, 2H), 3.46 - 3.38 (m, 2H), 1.48 (s, 9H).
[0403] Example 16 Preparation of 3,5-difluoro-4-((8-methoxy-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (Compound 66) [ka]
[0404] The compound tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2,3-dihydropyrazino[2,3-c][1,8]naphthyridine-4(1H)-carboxylate (10 mg, 1 eq.) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (0.2 mL) was added, followed by reaction at room temperature for 2 hours. The reaction was monitored for completion by LCMS. The reaction solution was concentrated under reduced pressure, and the crude product was purified to give the target compound, 3,5-difluoro-4-((8-methoxy-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (4.4 mg, 52% yield). LCMS (ESI) [M+H] + = 422.1; 1 H NMR (400 MHz, MeOD-d4) δ 8.54 (d, J = 9.1 Hz, 1H), 8.11 (s, 1H), 7.54 (t, J = 5.3 Hz, 2H), 6.99 (d, J = 9.1 Hz, 1H), 4.83 (s, 2H), 4.07 (s, 3H), 3.30 - 3.27 (m, 2H), 3.24 - 3.20 (m, 2H).
[0405] Example 17 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-3,4-dihydropyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (compound 54): [ka]
[0406] First step: Preparation of (4-chloro-7-methoxy-1,8-naphthyridin-3-yl)methanol 4-Chloro-7-methoxy-1,8-naphthyridine-3-carboxylic acid ethyl ester (10 g, 1 eq.) was dissolved in dichloromethane (200 mL), the atmosphere was purged with nitrogen, the temperature was lowered to -68°C, a solution of diisobutylaluminum hydride in cyclohexane (86 mL, 1 M) was slowly added dropwise to the reaction solution, and stirring was continued at -68°C for 2 hours. The reaction was monitored for completion by LCMS. The reaction was quenched with saturated ammonium chloride solution, and the aqueous phase was extracted with ethyl acetate (100 mL×5). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography to give the target compound (5.5 g, 83% yield). LCMS (ESI) [M + H] + = 225.0.
[0407] Step 2: Preparation of 4-chloro-7-methoxy-1,8-naphthyridine-3-carbaldehyde (4-Chloro-7-methoxy-1,8-naphthyridin-3-yl)methanol (5.5 g, 1 eq.) was dissolved in dichloromethane (20 mL), activated manganese dioxide (10.64 g, 5 eq.) was added, and the reaction mixture was stirred at 40° C. overnight. The reaction was monitored for completion by LCMS. The mixture was filtered through Celite, washed with dichloromethane, and the filtrate was concentrated to give the crude product, which was purified by column chromatography to give the desired compound (4.5 g, 99% yield). LCMS (ESI) [M+H] + = 223.0; 1 H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1H), 9.20 (s, 1H), 8.67 (d, J = 9.0 Hz, 1H), 7.37 (d, J = 9.0 Hz, 1H), 4.10 (s, 3H).
[0408] Third step: Preparation of (E)-ethyl 3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylate Sodium hydride (808.5 mg, 3 eq.) was dissolved in tetrahydrofuran (20 mL), and a solution of ethyl 2-(diethoxyphosphoryl)acetate (1.81 g, 1.2 eq.) in tetrahydrofuran (3 mL) was slowly added under ice bath. After stirring for 30 minutes, 4-chloro-7-methoxy-1,8-naphthyridine-3-carbaldehyde (1.5 g, 1 eq.) was dissolved in tetrahydrofuran (30 mL), and the mixture was allowed to react at room temperature for 30 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was quenched by adding water (20 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic layer was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the desired compound (1.5 g, 76% yield). LCMS (ESI) [M+H] + = 293.0; 1 H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.47 (d, J = 9.0 Hz, 1H), 8.15 (d, J = 16.2 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 6.68 (d, J = 16.2 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.19 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H).
[0409] Fourth step: Preparation of (E)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylic acid The compound ethyl (E)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylate (1.5 g, 1 eq.) was dissolved in tetrahydrofuran (30 mL), and lithium hydroxide (613.6 mg, 5 eq.) was added to water (10 mL), and the mixture was allowed to react at room temperature overnight. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure to remove tetrahydrofuran, and the aqueous phase was adjusted to pH 4 with 1N hydrochloric acid to precipitate a large amount of solid. The mixture was filtered, and the filter cake was dried to obtain the target compound (1.3 g, yield 96%). LCMS (ESI) [M+H]+ = 265.3; 1 H NMR (400 MHz, DMSO-d6) δ 12.78 (s, 1H), 9.39 (s, 1H), 8.56 (d, J = 9.0 Hz, 1H), 7.94 (d, J = 16.1 Hz, 1H), 7.30 (d, J = 9.0 Hz, 1H), 6.94 (d, J = 16.1 Hz, 1H), 4.07 (s, 3H).
[0410] Fifth step: Preparation of (E)-N-(4-(benzylthio)-2,6-difluorobenzyl)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylamide Compound (E)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylic acid (1.3 g, 1 eq.) was dissolved in dimethylformamide (30 mL), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.24 g, 1.2 eq.) and ethyldi(propan-2-yl)amine (2.54 g, 4 eq.) were added, and the mixture was allowed to react at room temperature for 30 minutes. (4-(benzylthio)-2,6-difluorophenyl)methylamine (1.3 g, 1 eq.) was added to the reaction solution, and the mixture was allowed to react at room temperature for 1 hour. The reaction was monitored for completion by LCMS. Water (50 mL) was added to the reaction mixture to precipitate a large amount of solid, which was filtered and the filter cake was dried to give the desired compound (1.5 g, 59% yield). LCMS (ESI) [M + H] + = 512.2.
[0411] Step 6: Preparation of N-(4-(benzylthio)-2,6-difluorobenzyl)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)propanamide The compound (E)-N-(4-(benzylthio)-2,6-difluorobenzyl)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)acrylamide (1.5 g, 1 eq.) was dissolved in tetrahydrofuran (60 mL) and water (20 mL), and 4-toluene-1-sulfonylhydrazide (5.45 g, 10 eq.) and sodium acetate trihydrate (3.99 g, 10 eq.) were added, and the reaction mixture was reacted at 80° C. for 4 hours. The reaction was monitored for completion by LCMS. The reaction mixture was cooled to room temperature, and aqueous sodium bicarbonate (60 mL) was added to the mixture. The mixture was extracted with ethyl acetate (80 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to obtain the desired compound (800 mg, yield 53%). LCMS (ESI) [M + H] + = 514.2.
[0412] Seventh step: Preparation of 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-3,4-dihydropyrido[2,3-H][1,6]naphthyridin-2(1H)-one The compound N-(4-(benzylthio)-2,6-difluorobenzyl)-3-(4-chloro-7-methoxy-1,8-naphthyridin-3-yl)propanamide (750 mg, 1 eq.) was dissolved in dimethylformamide (10 mL), and cesium carbonate (1.43 g, 3 eq.) was added thereto, followed by reaction at 100° C. for 4 hours. The reaction was monitored for completion by LCMS. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the desired compound (300 mg, 43% yield). LCMS (ESI) [M+H] + = 478.2; 1H NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 8.19 (d, J = 9.1 Hz, 1H), 7.33 - 7.27 (m, 4H), 7.02 - 6.91 (m, 2H), 6.61 (t, J = 6.0 Hz, 2H), 5.36 (s, 2H), 4.15 (s, 3H), 4.05 (s, 2H), 2.94 - 2.91 (m, 2H), 2.71 - 2.68 (m, 2H).
[0413] Eighth Step: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-3,4-dihydropyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide Compound 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-3,4-dihydropyrido[2,3-H][1,6]naphthyridin-2(1H)-one (250 mg, 1 eq.) was dissolved in tetrahydrofuran (5 mL), water (132.1 mg, 14 eq.) and acetic acid (220.1 mg, 7 eq.) were added, and 1,3-dichloro-5,5-dimethylhydantoin (309.4 mg, 3 eq.) was added under ice-cooling, and the reaction was allowed to proceed for 10 minutes under ice-cooling. The reaction solution was slowly added dropwise to aqueous ammonia (5 mL) in an ice bath, and the reaction was allowed to proceed for 30 minutes in an ice bath. Completion of the reaction was monitored by LCMS. The reaction solution was extracted with ethyl acetate (20 mL), the organic phase was concentrated under reduced pressure, and the crude product was purified to obtain the target compound (93 mg, 41% yield). LCMS (ESI) [M+H] + = 435.1; 1 H NMR (400 MHz, MeOD-d4) δ 8.68 (s, 1H), 8.48 (d, J = 9.2 Hz, 1H), 7.40 - 7.33 (m, 2H), 7.09 (d, J = 9.2 Hz, 1H), 5.50 (s, 2H), 4.10 (s, 3H), 2.99 - 2.92 (m, 2H), 2.72 - 2.64 (m, 2H).
[0414] Example 18 Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (compound 52): [ka]
[0415] Step 1: Preparation of 7-methoxy-3-nitroquinolin-4-ol 7-Methoxyquinolin-4-ol (1 g, 1 eq.) was dissolved in propionic acid (10 mL), 70% nitric acid (1 mL) was added, and the reaction mixture was stirred at 140° C. for 12 hours. The reaction was monitored by LCMS for completion of the reaction and the appearance of the product. The reaction mixture was slowly poured into ice water to precipitate a solid, which was then filtered. The solid was washed three times with methanol and dried on a rotary evaporator to give the desired compound (800 mg, 63% yield). LCMS (ESI) [M+H] + = 221.3; 1 H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 9.14 (s, 1H), 8.29 - 8.02 (m, 1H), 7.26 - 7.01 (m, 2H), 3.89 (s, 3H).
[0416] Step 2: Preparation of 4-chloro-7-methoxy-3-nitroquinoline 7-Methoxy-3-nitroquinolin-4-ol (800 mg, 1 eq.) was dissolved in N,N-dimethylformamide (10 mL), and thionyl chloride (0.66 mL, 2.51 eq.) was added to the reaction solution, followed by stirring at 25°C for 1 hour. The reaction mixture was monitored for completion by LCMS. The reaction mixture was poured into ice water, made basic with sodium carbonate solution, extracted with ethyl acetate (20 mL), washed with saturated brine (20 mL × 3), and the organic phase was dried and concentrated to give the desired compound (600 mg, yield 69%). LCMS (ESI) [M+H] += 239.2; 1 H NMR (400 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.34 (d, J = 9.1 Hz, 1H), 7.60 (dd, J = 7.2, 5.7 Hz, 2H), 4.02 (s, 3H).
[0417] Third step: Preparation of N-(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxy-3-nitroquinolin-4-amine 4-Chloro-7-methoxy-3-nitroquinoline (2.6 g, 1 eq.) was dissolved in N,N-dimethylformamide (30 mL), (4-(benzylthio)-2,6-difluorophenyl)methylamine (4.34 g, 1.5 eq.) and N,N-diisopropylethylamine (4.22 g, 3 eq.) were added successively, and the reaction was stirred at 25° C. for 12 hours. The reaction was monitored for success by LCMS. The reaction was filtered, the filter cake was rinsed with acetonitrile, and the solid was dried to give the desired compound (2 g, 39% yield). LCMS (ESI) [M+H] + = 468.2.
[0418] 4th step:N 4 Preparation of -(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxyquinoline-3,4-diamine N-(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxy-3-nitroquinolin-4-amine (2 g, 1 eq.) was dissolved in tetrahydrofuran (10 mL), methanol (10 mL), and water (5 mL), and ammonium chloride (2.29 g, 10 eq.) and zinc powder (1.4 g, 5 eq.) were added, followed by stirring at 25°C for 1 hour. The success of the reaction was monitored by LCMS, filtered, the filtrate was centrifuged, washed with water, extracted with ethyl acetate, and the organic phase was dried and concentrated to give the target compound (1.5 g, crude), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 438.2.
[0419] Fifth step: Preparation of (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-7-methoxyquinolin-3-yl)glycine N 4 -(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxyquinoline-3,4-diamine (1 g, crude, obtained in the previous reaction) and ethyl glyoxylate (466.7 mg) were dissolved in methanol (10 mL) and stirred for 1 hour. Sodium cyanoborohydride (424.0 mg) was then added and the reaction was stirred at 25°C for 1 hour. The success of the reaction was monitored by LCMS. The reaction was quenched with water and extracted with dichloromethane (20 mL×3), and the organic phase was dried and concentrated to give the target compound (1 g, crude), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 496.3.
[0420] Step 6: Preparation of 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-3,4-dihydropyrazino[2,3-c]quinolin-2(1H)-one (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-7-methoxyquinolin-3-yl)glycine (1 g, crude, obtained in the previous reaction) was dissolved in tetrahydrofuran (10 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.45 g) was added and stirred at room temperature for 1 hour. After stirring, N,N-diisopropylethylamine (740.6 mg) was added and the reaction was stirred at 25°C for 1 hour. The LCMS detection reaction was successful, but the reaction solution was washed with water (10 mL), extracted with ethyl acetate (20 mL), the organic phase was dried and concentrated, and the crude product was isolated and purified by column chromatography to obtain the target compound (600 mg). LCMS (ESI) [M + H] + = 478.2.
[0421] Step 7: Preparation of tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-3,4-dihydropyrazino[2,3-c]quinolin-2(1H)-one (300 mg, 1 eq.), di-tert-butyl dicarbonate (5 mL), and 4-dimethylaminopyridine (230.25 mg, 3 eq.) were stirred at 40° C. for 1 hour. The reaction was monitored for success by LCMS. The reaction mixture was concentrated, and the crude product was purified by flash chromatography to give the target compound (270 mg, 74% yield). LCMS (ESI) [M + H] + = 578.1.
[0422] Eighth step: Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate Tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (270 mg, 1 eq.) was dissolved in tetrahydrofuran (5 mL), and glacial acetic acid (196.5 mg, 7 eq.) and water (117.9 mg, 14 eq.) were added. 1,3-Dichloro-5,5-dimethylhydantoin (276.3 mg, 3 eq.) was added in an ice bath, and the mixture was stirred at 0°C for 6 minutes. The success of the reaction was monitored by LCMS, the reaction was added to aqueous ammonia (6 mL) and stirred for 6 minutes, the product was monitored by LCMS, the reaction was adjusted to neutral pH with 1 M hydrochloric acid, extracted with ethyl acetate (5 mL x 2), the aqueous phase was concentrated, the solid was precipitated, the solid was filtered, and the filtrate was purified by preparative HPLC to give the desired compound (22.4 mg, 9% yield). LCMS (ESI) [M+H] + = 534.9; 1 H NMR (400 MHz, MeOD-d4) δ 8.92 (s, 1H), 8.13 (d, J = 9.3 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.34 (d, J = 9.3 Hz, 1H), 7.27 (d, J = 7.2 Hz, 2H), 5.59 (s, 2H), 4.36 (s, 2H), 3.96 (s, 3H), 1.54 (s, 9H).
[0423] Example 19 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide (Compound 51): [ka]
[0424] The starting material, tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (8 mg, 1 eq.), was dissolved in dichloromethane (1 mL), trifluoroacetic acid (1 mL) was added, and the reaction mixture was stirred at room temperature for 1 hour. The product was detected by LCMS, the reaction was concentrated, and the crude product was purified by preparative HPLC to give the desired compound (1.4 mg, 21% yield). LCMS (ESI) [M+H] + =434.9; 1 H NMR (400 MHz, MeOD-d4) δ 8.54 (s, 1H), 8.12 (d, J = 9.5 Hz, 1H), 7.39-7.32 (m, 4H), 5.55 (s, 2H), 3.98 (s, 3H), 3.85 (s, 2H).
[0425] Example 20 Preparation of 4-((8-ethoxy-2-oxopyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)-3,5-difluorobenzenesulfonamide (compound 63): [ka]
[0426] First step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-ethoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one 4-((4-Bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carbaldehyde (120 mg, 1 eq.) was dissolved in ethanol (15 mL), and ethyl 2-(dimethoxyphosphoryl)acetate (198 mg, 3.4 eq.) and potassium carbonate (203 mg, 5 eq.) were added. The reaction was carried out at 85°C for 36 hours, and the completion of the reaction was monitored by LCMS. The reaction solution was concentrated to dryness and purified by flash silica gel column chromatography to obtain the target compound (100 mg, 76% yield). LCMS (ESI) [M + H] + = 446.0.
[0427] Second step: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-ethoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one 1-(4-Bromo-2,6-difluorobenzyl)-8-ethoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one (90 mg, 1 eq.) was dissolved in dioxane (5 mL), and 4-(4-methoxyphenyl)methanethiol (62 mg, 2 eq.), 4,5-bisdiphenylphosphino-9,9-dimethylxanthene (23 mg, 0.2 eq.), tris(dibenzylideneacetone)dipalladium (37 mg, 0.2 eq.), and N,N-diisopropylethylamine (78 mg, 3 eq.) were added, followed by reaction at 90°C for 2 hours under a nitrogen atmosphere. The reaction was monitored for completion by LCMS, and the reaction mixture was concentrated to dryness and purified by flash silica gel column chromatography to obtain the target compound (70 mg, yield 66%). LCMS (ESI) [M + H] + = 520.1.
[0428] Third Step: Preparation of 4-((8-ethoxy-2-oxopyrido[2,3-H][1,6]naphthyridin-1(2H)-yl)methyl)-3,5-difluorobenzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-ethoxypyrido[2,3-H][1,6]naphthyridin-2(1H)-one (65 mg, 1 eq.), acetic acid (53 mg, 7 eq.), and water (32 mg, 14 eq.) were dissolved in tetrahydrofuran (5 mL), and 1,3-dichloro-5,5-dimethylhydantoin (74 mg, 3 eq.) was added at 0°C. The mixture was reacted at 0°C for 1 hour. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction was concentrated to dryness and purified by preparative HPLC to give the desired compound (2.6 mg, 4.7% yield). LCMS (ESI) [M+H] + = 447.1; 1 H NMR (400 MHz, DMSO-d6) δ 9.15 (s, 1H), 8.71 (d, J = 9.6 Hz, 1H), 8.20 (d, J = 9.2 Hz, 1H), 7.62 (s, 2H), 7.43 (d, J = 7.2 Hz, 2H), 7.09 (d, J = 9.6 Hz, 1H), 6.69 (d, J = 9.6 Hz, 1H), 5.77 (s, 2H), 4.53 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.2 Hz, 3H).
[0429] Example 21 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide (compound 49): [ka]
[0430] Step 1: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-2(1H)-one 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxypyrazino[2,3-c][1,8]naphthyridin-2(1H)-one (50 mg, 1 eq.) was dissolved in ethanol (5 mL), followed by the addition of sodium borohydride (11 mg, 3 eq.) and the reaction was stirred at 25° C. for 2 h. The reaction was monitored for completion by LCMS. The reaction mixture was diluted with water (10 mL) and extracted three times with ethyl acetate (50 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product (50 mg). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 509.1.
[0431] Second step: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-1(2H)-yl)methyl)benzenesulfonamide A 25 mL round-bottom flask was charged with 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-3,4-dihydropyrazino[2,3-c][1,8]naphthyridin-2(1H)-one (20 mg, crude product, obtained in the previous reaction), tetrahydrofuran (10 mL), acetic acid (10 mg), and water (10 mL). The solution was cooled with ice and 1,3-dichloro-5,5-dimethylhydantoin (23 mg) was added, and the reaction was stirred for 60 minutes. 1 mL of aqueous ammonia was added, and stirring was continued for 60 minutes. Sodium borohydride (15 mg, 10 eq.) was added, and after completion of the reaction, the mixture was partitioned between water and ethyl acetate. The ethyl acetate layer was dried and concentrated to give the crude product, which was then purified by liquid-phase isolation to give the target compound (2.1 mg). LCMS (ESI) [M+H] + = 436.1; 1 HNMR (400MHz, DMSO-d6) δ 8.55 (s, 1H), 8.44 (d, J = 9.2 Hz, 1H), 7.32 (d, J = 6.8 Hz, 2H), 7.02 (d, J = 9.2 Hz, 1H), 6.44 (s, 1H), 5.32 (s, 2H), 3.96 (s, 3H), 3.70 (s, 2H).
[0432] Example 22 Preparation of 4-((8,9-dimethoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)-3,5-difluorobenzenesulfonamide (compound 31): [ka]
[0433] Step 1: Preparation of diethyl 2-(((3,4-dimethoxyphenyl)amino)methylene)malonate 3,4-Dimethoxyaniline (7 g, 1 eq.) and 1,3-diethyl 2-(ethoxymethylene)malonate (10 g, 1.01 eq.) were added to ethanol (200 mL) and stirred at room temperature for 4 hours. After the reaction was completed, the solvent was distilled off under reduced pressure to give the crude target compound (18 g), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + =324.1.
[0434] Step 2: Preparation of ethyl 4-chloro-6,7-dimethoxyquinoline-3-carboxylate Diethyl 2-(((3,4-dimethoxyphenyl)amino)methylene)malonate (18 g, crude product, obtained in the reaction of the previous step) and phosphorus oxychloride (8 mL) were placed in a 100 mL flask, heated to 100°C, and reacted with stirring for 5 hours. The reaction was monitored for completion by LCMS, cooled to room temperature, and slowly added dropwise to a flask containing 200 mL of water. After the addition, the mixture was cooled, and then neutralized by slowly adding aqueous sodium bicarbonate solution. The mixture was extracted with ethyl acetate (200 mL×2). The combined organic phases were washed with brine and then concentrated under vacuum to give the crude target compound (16 g), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 296.1.
[0435] Step 3: Preparation of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-6,7-dimethoxyquinoline-3-carboxylate Ethyl 4-chloro-6,7-dimethoxyquinoline-3-carboxylate (1 g, crude product, obtained in the reaction of the previous step) was dissolved in acetonitrile (20 mL), and potassium carbonate (1 g) and (4-bromo-2,6-difluorophenyl)methylamine (0.79 g) were added, followed by refluxing under a nitrogen atmosphere at 100°C for 20 hours. The reaction was monitored for completion by LCMS, and the reaction mixture was dried on a rotary evaporator, diluted with ethyl acetate, washed with water, and the organic layer was dried over anhydrous sodium sulfate and dried on a rotary evaporator. The crude product was purified by flash chromatography to give the target compound (0.68 g). LCMS (ESI) [M + H] + = 481.0.
[0436] Fourth step: Preparation of (4-((4-bromo-2,6-difluorobenzyl)amino)-6,7-dimethoxyquinolin-3-yl)methanol Ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-6,7-dimethoxyquinoline-3-carboxylate (150 mg, 1 eq.) was dissolved in ethanol (15 mL), and sodium borohydride (60 mg, 5 eq.) was added, followed by reaction at 25°C for 16 hours. The reaction was monitored for completion by LCMS. The reaction mixture was poured into water, extracted with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, concentrated to dryness, and purified by silica gel chromatography to give the desired compound (100 mg, yield 72%). LCMS (ESI) [M + H] + = 439.0.
[0437] Fifth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8,9-dimethoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (4-((4-Bromo-2,6-difluorobenzyl)amino)-6,7-dimethoxyquinolin-3-yl)methanol (100 mg, 1 eq.) was dissolved in dichloromethane (10 mL), and triphosgene (219 mg, 3.2 eq.) and N,N-diisopropylethylamine (159 mg, 5.4 eq.) were added. The reaction was carried out at 25°C for 1 hour. The reaction was monitored for completion by LCMS, and the reaction mixture was concentrated to dryness and purified by silica gel chromatography to give the desired compound (85 mg, 80% yield). LCMS (ESI) [M + H] + = 465.0.
[0438] Step 6: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8,9-dimethoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one 1-(4-Bromo-2,6-difluorobenzyl)-8,9-dimethoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (85 mg, 1 eq.) was dissolved in dioxane (10 mL), followed by the addition of (4-methoxyphenyl)methyl mercaptan (55 mg, 2 eq.), tris(dibenzylideneacetone)dipalladium (18 mg, 0.1 eq.), 4,5-bisdiphenylphosphine-9,9-dimethyloxaanthracene (23 mg, 0.2 eq.), and N,N-diisopropylethylamine (71 mg, 3 eq.). The reaction was continued at 90°C for 2 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness and purified by silica gel column chromatography to give the target compound (50 mg, yield 51%). LCMS (ESI) [M + H] + = 539.2.
[0439] Seventh step: Preparation of 4-((8,9-dimethoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)-3,5-difluorobenzenesulfonamide 1-(2,6-Difluoro-4-((4-methoxybenzyl)thio)benzyl)-8,9-dimethoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (50 mg, 1.0 eq.), acetic acid (28.0 mg, 5 eq.), and water (24 mL) were dissolved in tetrahydrofuran (15 mL), and 1,3-dichloro-5,5-dimethylhydantoin (19 mg, 1 eq.) was added at 0°C. The mixture was reacted at 0°C for 2 hours. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS, and the reaction mixture was concentrated to dryness and purified by preparative HPLC to give the desired compound (2.7 mg, 6% yield). LCMS (ESI) [M+H] + = 466.0; 1 H NMR (400 MHz, CD3OD) δ 8.69 (s, 1H), 7.52 (s, 1H), 7.50 - 7.43 (m, 2H), 7.25 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 5.71 (s, 2H), 5.34 (s, 2H), 4.07 (s, 3H), 4.02 (s, 3H).
[0440] Example 23 Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide (compound 30): [ka]
[0441] Step 1: Preparation of diethyl 2-((3-methoxyphenyl)amino)methylene)malonate 3-Methoxyaniline (10.0 g, 1 eq.) was dissolved in ethanol (100 mL), and diethyl 2-(ethoxymethylene)malonate (21 g, 1.2 eq.) was added, followed by reaction at 90° C. for 16 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness under reduced pressure to give the crude target compound (20 g), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 294.1.
[0442] Step 2: Preparation of ethyl 4-chloro-7-methoxyquinoline-3-carboxylate Diethyl 2-((3-methoxyphenyl)amino)methylene)malonate (5 g, crude product, obtained from the previous reaction) was dissolved in phosphorus oxychloride (15 mL), and the reaction was carried out at 110° C. for 4 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness under reduced pressure to give a mixture of ethyl 4-chloro-7-methoxyquinoline-3-carboxylate and ethyl 4-chloro-5-methoxyquinoline-3-carboxylate (3.8 g), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 266.0.
[0443] Step 3: Preparation of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxyquinoline-3-carboxylate A mixture of ethyl 4-chloro-7-methoxyquinoline-3-carboxylate and ethyl 4-chloro-5-methoxyquinoline-3-carboxylate (2 g, mixture, obtained in the previous reaction) was dissolved in N,N-dimethylformamide (10 mL), and 1-(4-bromo-2,6-difluorophenyl)methylamine (1.84 g) and N,N-diisopropylethylamine (2.92 g, 3 eq.) were added. The reaction was carried out at 50°C for 16 hours. The reaction was monitored for completion by LCMS. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified on a silica gel column to give a mixture of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxyquinoline-3-carboxylate and ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-5-methoxyquinoline-3-carboxylate (1.6 g). LCMS (ESI) [M + H] + = 451.0.
[0444] Fourth step: Preparation of (4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxyquinolin-3-yl)methanol A mixture of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxyquinoline-3-carboxylate and ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-5-methoxyquinoline-3-carboxylate (1.6 g, mixture, obtained in the reaction of the previous step) was dissolved in ethanol (50 mL), sodium borohydride (671 mg, 5.0 eq.) was added, and the mixture was reacted at 50° C. for 16 hours. The reaction was monitored for completion by LCMS. After cooling to room temperature, the reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography to give a mixture of (4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxyquinolin-3-yl)methanol and (4-((4-bromo-2,6-difluorobenzyl)amino)-5-methoxyquinolin-3-yl)methanol (400 mg). LCMS (ESI) [M + H] + = 409.1.
[0445] Fifth step: Preparation of 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one ((4-((4-Bromo-2,6-difluorobenzyl)amino)-7-methoxyquinolin-3-yl)methanol and (4-((4-bromo-2,6-difluorobenzyl)amino)-5-methoxyquinolin-3-yl)methanol (400 mg, mixture, obtained from the reaction in the previous step) were dissolved in dichloromethane (10 mL), triphosgene (870 mg, 3 eq.) and N,N-diisopropylethylamine (632 mg, 5 eq.) were added, and the reaction was carried out at 25° C. for 2 hours. The completion of the reaction was monitored by LCMS. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified using a silica gel column to give 1-(4-bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (70 mg) and 1-(4-bromo-2,6-difluorobenzyl)-10-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (60 mg). LCMS (ESI) [M + H] + = 435.1.
[0446] Step 6: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (65 mg, 1 eq.) was dissolved in dioxane (5 mL), and 3-(4-methoxyphenyl)methanethiol (46 mg, 2 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (17 mg, 0.2 eq.), tris(dibenzylideneacetone)dipalladium (27 mg, 0.2 eq.), and N,N-diisopropylethylamine (58 mg, 3 eq.) were added. The reaction was carried out at 90°C for 2 hours. The completion of the reaction was monitored by LCMS. The reaction mixture was concentrated under reduced pressure and then purified by silica gel column chromatography to obtain the target compound (60 mg, yield 79%). LCMS (ESI) [M + H] + = 509.1.
[0447] Step 7: Preparation of 3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide A mixture of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (30 mg, 1.0 eq.), acetic acid (25 mg, 7.0 eq.), and water (15 mL) was dissolved in tetrahydrofuran (5 mL), and 1,3-dichloro-5,5-dimethylhydantoin (35 mg, 3 eq.) was added at 0°C. The mixture was reacted at 0°C for 1 hour. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure and then purified by preparative HPLC to give the desired compound (5.8 mg, 22% yield). LCMS (ESI) [M+H] + = 436.0; 1 H NMR (400 MHz, DMSO) δ 8.72 (s, 1H), 8.22 (d, J = 9.6 Hz, 1H), 7.62 (s, 2H), 7.49 - 7.43 (m, 3H), 7.29 (dd, J = 9.2, 2.4 Hz, 1H), 5.50 (s, 2H), 5.27 (s, 2H), 3.94 (s, 3H).
[0448] Example 24 Preparation of 3,5-difluoro-4-((10-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide (Compound 68): [ka]
[0449] Step 1: Preparation of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-10-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one 1-(4-Bromo-2,6-difluorobenzyl)-10-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (60 mg, 1 eq.) was dissolved in dioxane (5 mL), and 3-(4-methoxyphenyl)methanethiol (43 mg, 2 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (16 mg, 0.2 eq.), tris(dibenzylideneacetone)dipalladium (25 mg, 0.2 eq.), and N,N-diisopropylethylamine (53 mg, 3 eq.) were added. The reaction was carried out at 90°C for 2 hours. The completion of the reaction was monitored by LCMS. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography to give the target compound (50 mg). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 509.1.
[0450] Second step: Preparation of 3,5-difluoro-4-((10-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide A mixture of 1-(2,6-difluoro-4-((4-methoxybenzyl)thio)benzyl)-10-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (30 mg, 1.0 eq.), acetic acid (25 mg, 7.1 eq.), and water (15 mg, 14.1 eq.) was dissolved in tetrahydrofuran (5 mL), and 1,3-dichloro-5,5-dimethylhydantoin (35 mg, 3 eq.) was added at 0°C. The mixture was reacted at 0°C for 1 hour. Aqueous ammonia (0.2 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure and then purified by preparative HPLC to give the desired compound (2.0 mg, yield 8%). LCMS (ESI) [M+H] + = 436.0; 1H NMR (400 MHz, DMSO) δ 8.74 (s, 1H), 7.73 (t, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.60 (s, 2H), 7.41 (d, J = 6.4 Hz, 2H), 7.20 (d, J = 8.0 Hz, 1H), 5.21 (s, 2H), 5.08 (s, 2H), 4.05 (s, 3H).
[0451] Example 25 Preparation of 6-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)pyridine-3-sulfonamide (compound 70): [ka]
[0452] Step 1: Preparation of ethyl 4-(((5-bromopyridin-2-yl)methyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (200 mg, 1 eq.), (5-bromopyridin-2-yl)methylamine (210.4 mg, 1.5 eq.), and N,N-diisopropylethylamine (289.0 mg, 3 eq.) were dissolved in ethanol (50 mL), heated to 90°C, and reacted for 16 hours. Completion of the reaction was monitored by LCMS. The reaction mixture was concentrated under reduced pressure and purified by flash silica gel column chromatography to give the target compound (150 mg, 48% yield). LCMS (ESI) [M + H] + = 417.1.
[0453] Second step: Preparation of (4-(((5-bromopyridin-2-yl)methyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol Ethyl 4-(((5-bromopyridin-2-yl)methyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (150 mg, 1 eq.) was added to dichloromethane (20 mL), and a 1 mol / L solution of diisobutylaluminum hydride (7.2 mL, 20 eq.) in tetrahydrofuran was added at -78 °C. The reaction was allowed to proceed for 2 hours, and the reaction completion was monitored by LCMS. The mixture was quenched with water and extracted with dichloromethane (100 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by flash chromatography to obtain the target compound (100 mg, 74% yield). LCMS (ESI) [M + H] + = 377.1.
[0454] Third step: Preparation of 1-((5-bromopyridin-2-yl)methyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (4-(((5-Bromopyridin-2-yl)methyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (100 mg, 1 eq.) was added to tetrahydrofuran (20 mL), N,N-diisopropylethylamine (335.4 mg, 9.74 eq.) and triphosgene (154.3 mg, 1.95 eq.) were added, and the reaction was allowed to proceed at room temperature for 1 hour. Completion of the reaction was monitored by LCMS. The reaction was quenched by adding 20 mL of water and extracted three times with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain the target compound (60 mg, yield: 56%). LCMS (ESI) [M + H] + = 401.2.
[0455] Fourth step: Preparation of 8-methoxy-1-((5-((4-methoxybenzyl)thio)pyridin-2-yl)methyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one 1-((5-Bromopyridin-2-yl)methyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (60 mg, 1 eq.), (4-methoxyphenyl)methanethiol (46.2 mg, 2 eq.), tris(dibenzylideneacetone)dipalladium (6 mg, 0.04 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (17.4 mg, 0.2 eq.), and N,N-diisopropylethylamine (97.5 mg, 5 eq.) were added to 1,4-dioxane (10 mL), purged with nitrogen three times, and the reaction was heated at 90 °C for 3 h and monitored for completion by LCMS. After the reaction mixture was cooled to room temperature, water (20 mL) was added and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and then purified by column chromatography to obtain the target compound (50 mg, yield: 70%). LCMS (ESI) [M + H] + = 475.1.
[0456] Fifth step: Preparation of 6-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)pyridine-3-sulfonamide A 25 mL round-bottom flask was charged with 8-methoxy-1-((5-((4-methoxybenzyl)thio)pyridin-2-yl)methyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (50 mg, 1.0 eq.), tetrahydrofuran (10 mL), acetic acid (8.0 mg, 1.3 eq.), water (4.0 mg, 2.1 eq.), and 1,3-dichloro-5,5-dimethylhydantoin (43.1 mg, 2.1 eq.) at 0 °C. The reaction was allowed to proceed for 1 hour. The reaction was monitored for completion by LCMS. 1 mL of aqueous ammonia was added and the reaction was allowed to proceed for 1 hour at room temperature. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and purified by preparative HPLC to give the desired compound (3.8 mg, 9% yield). LCMS (ESI) [M+H] + = 402.1; 1H NMR (400 MHz, DMSO-d6) δ 8.88 (d, J = 2.2 Hz, 1H), 8.79 (s, 1H), 8.42 (d, J = 9.2 Hz, 1H), 8.15 (m, J = 8.2,1H), 7.66 (d, J = 8.4 Hz, 1H), 7.59 (s, 2H), 7.07 (d, J = 9.2 Hz, 1H), 5.55 (s, 2H), 5.51 (s, 2H), 4.00 (s, 3H).
[0457] Example 26 Preparation of 3-fluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide (Compound 71): [ka]
[0458] Step 1: Preparation of ethyl 4-((4-bromo-2-fluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (500 mg, 1 eq.), 1-(4-bromo-2-fluorophenyl)methylamine (381 mg, 1 eq.), and N,N-diisopropylethylamine (2.45 g, 10.1 eq.) were dissolved in acetonitrile (20 mL), heated to 70 °C, and reacted for 16 hours. Completion was monitored by LCMS. The reaction mixture was cooled to room temperature, water (20 mL) was added, and extracted with ethyl acetate (50 mL × 3). The combined organic phases were concentrated under reduced pressure and purified by column chromatography to obtain the target compound (500 mg, 61% yield). LCMS (ESI) [M + H] + =434.0.
[0459] Second step: Preparation of 2-(4-((4-bromo-2-fluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol Ethyl 4-((4-bromo-2-fluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (250 mg, 1.0 eq.) was dissolved in ethanol (20 mL), followed by the addition of sodium borohydride (211 mg, 9.7 eq.). The reaction was incubated at 60 °C for 16 hours and monitored for completion by LCMS. The reaction mixture was cooled to room temperature and quenched with water. The ethanol was removed under reduced pressure. Water (50 mL) was added to the residue, and the mixture was extracted with ethyl acetate (100 mL × 2). The combined organic phases were washed five times with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under vacuum. The target compound (100 mg, yield: 44%) was obtained by filtration using a flash silica gel column. LCMS (ESI) [M + H] + = 392.0.
[0460] Third step: Preparation of 1-(4-bromo-2-fluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (4-((4-Bromo-2-fluorobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (100 mg, 1 eq.) was added to tetrahydrofuran (10 mL), N,N-diisopropylethylamine (329 mg, 10 eq.) and triphosgene (378 mg, 5 eq.) were added, and the reaction was allowed to proceed at room temperature for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was quenched by adding 10 mL of water and extracted three times with ethyl acetate (20 mL). The organic phases were combined and concentrated under reduced pressure. The mixture was then purified by column chromatography to obtain the target compound (35 mg, 32% yield). LCMS (ESI) [M + H] + = 418.0.
[0461] Fourth step: Preparation of 1-(2-fluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one 1-(4-Bromo-2-fluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (33 mg, 1 eq.) was dissolved in dioxane (10 mL), and 3-(4-methoxyphenyl)methanethiol (24 mg, 2 eq.), tris(dibenzylideneacetone)dipalladium (10 mg, 0.1 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (9 mg, 0.2 eq.), and N,N-diisopropylethylamine (30 mg, 3 eq.) were added. The reaction was carried out at 90 °C for 2 h. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness under reduced pressure and purified by thin layer chromatography to give the desired compound (22 mg, 56% yield). LCMS (ESI) [M + H] + = 492.1.
[0462] Fifth step: Preparation of 3-fluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide 1-(2-Fluoro-4-((4-methoxybenzyl)thio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (20 mg, 1.0 eq.), acetic acid (16 mg, 6.6 eq.), and water (10 mg, 13.6 eq.) were dissolved in tetrahydrofuran (5 mL), and 1,3-dichloro-5,5-dimethylhydantoin (16 mg, 2 eq.) was added at 0°C. The mixture was reacted at 0°C for 2 hours. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 0°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated to dryness under reduced pressure and purified by preparative HPLC to give the desired compound (2.5 mg, 15% yield). LCMS (ESI) [M+H] + = 419.0; 1H NMR (400 MHz, DMSO) δ 8.79 (s, 1H), 8.41 (d, J = 9.2 Hz, 1H), 7.65 - 7.56 (m, 3H), 7.48 (s, 2H), 7.08 (d, J = 9.2 Hz, 1H), 5.43 (s, 4H), 4.01 (s, 3H).
[0463] Example 27 Preparation of 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide (Compound 67): [ka]
[0464] Step 1: Preparation of ethyl 4-((4-bromobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (500 mg, 1.0 eq.) was dissolved in acetonitrile (30 mL), and then potassium carbonate (1.3 g, 5.0 eq.) and (4-bromophenyl)methylamine (523.2 mg, 1.5 eq.) were added, and the reaction was carried out at 70° C. for 5 hours under nitrogen protection. The reaction was monitored for completion by LCMS. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by flash chromatography to give the desired compound (0.5 g, 64% yield). LCMS (ESI) [M + H] + = 416.1.
[0465] Second step: Preparation of (4-((4-bromobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol Ethyl 4-((4-bromobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (300 mg, 1.0 eq.) was dissolved in ethanol (10 mL), and sodium borohydride (245.4 mg, 9.0 eq.) was added. The reaction system was purged with nitrogen gas, and then the mixture was stirred at 70°C for 10 hours. The reaction was monitored for completion by LCMS. After cooling to room temperature, the reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined organic phases were washed with saturated sodium bicarbonate and concentrated to give the crude product, which was purified by flash chromatography to give the target compound (200 mg, 74% yield). LCMS (ESI) [M + H] + = 376.0.
[0466] Third step: Preparation of 1-(4-bromobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (4-((4-Bromobenzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (300 mg, 1.0 eq.) was dissolved in dichloromethane (10 mL), and then N,N-diisopropylethylamine (243 mg, 2.35 eq.) and triphosgene (237 mg, 1.0 eq.) were added successively at 0°C and stirred at 0°C for 2 hours. The reaction was confirmed to be complete by LCMS, and the reaction mixture was quenched with saturated saline (20 mL) and extracted with dichloromethane (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography to obtain the target compound (200 mg, yield 62%). LCMS (ESI) [M + H] + = 402.0.
[0467] Fourth step: Preparation of 8-methoxy-1-(4-((4-methoxybenzyl)thio)benzyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one 1-(4-Bromobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (200 mg, 1.0 eq.) was dissolved in dioxane (10 mL), and 3-(4-methoxyphenyl)methanethiol (154 mg, 2.0 eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (57 mg, 0.2 eq.), tris(dibenzylideneacetone)dipalladium (44 mg, 0.1 eq.), and N,N-diisopropylethylamine (193 mg, 3 eq.) were added. The reaction was carried out at 90 °C for 2 h. The reaction was monitored for completion by LCMS. After cooling to room temperature, the reaction mixture was concentrated and purified by flash silica gel column chromatography to isolate the desired compound (100 mg, 42% yield). LCMS (ESI) [M + H] + = 474.1.
[0468] Fifth step: Preparation of 4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)benzenesulfonamide 8-Methoxy-1-(4-((4-methoxybenzyl)thio)benzyl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (90 mg, 1.0 eq.), acetic acid (80 mg, 7.0 eq.), and water (50 mg, 14.6 eq.) were dissolved in tetrahydrofuran (15 mL), and 1,3-dichloro-5,5-dimethylhydantoin (112 mg, 3.0 eq.) was added at 0°C. The mixture was reacted at 25°C for 1 hour. Aqueous ammonia (0.5 mL) was added, and the mixture was reacted at 25°C for 10 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated and purified by preparative HPLC to give the desired compound (13.9 mg, 18% yield). LCMS (ESI) [M+H] + = 401.1; 1HNMR (400MHz, MMSO-d6) δ 8.79 (s, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.33 (s, 2H), 7.02 (d, J = 8.0 Hz, 1H), 5.51 (s, 2H), 5.43 (s, 2H), 3.99 (s, 3H).
[0469] Example 28 Preparation of 2-(3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)phenyl)boronic acid (compound 41): [ka]
[0470] 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (100 mg, 1.0 eq.) prepared in the fourth step of Example 6 was dissolved in 1,4-dioxane (10 mL), and pinacol diborate (76 mg, 1.3 eq.), palladium (1,1'-bis(diphenylphosphino)ferrocene) dichloride (34 mg, 0.2 eq.), and sodium acetate (38 mg, 2.0 eq.) were added. The reaction was carried out at 90°C for 2 hours under nitrogen protection. The reaction was monitored for completion by LCMS, and the reaction mixture was concentrated to dryness and purified by preparative HPLC to give the desired compound (15.8 mg, 17% yield). LCMS (ESI) [M+H]+ =402.1; 1 H NMR (400 MHz, MeOD) δ 8.71 (s, 1H), 8.62 (d, J = 9.2 Hz, 1H), 7.15 - 7.04 (m, 3H), 5.57 (s, 2H), 5.31 (s, 2H), 4.13 (s, 3H).
[0471] Example 29 Preparation of (3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)phenyl)phosphonic acid (compound 43): [ka]
[0472] Step 1: Preparation of diethyl (3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)phenyl)phosphonate 1-(4-Bromo-2,6-difluorobenzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (25 mg, 1.0 eq.) prepared in the fourth step of Example 6 was added to ethanol (5 mL), and diethylphosphonate (12 mg, 1.5 eq.), N-methyldicyclohexylamine (18 mg, 1.5 eq.), triphenylphosphine (24 mg, 1.6 eq.) and palladium acetate (6 mg, 0.5 eq.) were added, and the reaction was carried out under nitrogen at 80°C for 16 hours, and the completion of the reaction was monitored by LCMS. The reaction mixture was cooled to room temperature, and water (5 mL) was added. The mixture was extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and isolated and purified by preparative preparation to obtain the target compound (15 mg, yield 53%). LCMS (ESI) [M + H] + =494.1.
[0473] Second step: Preparation of (3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)phenyl)phosphonic acid Diethyl (3,5-difluoro-4-((8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)methyl)phenyl)phosphonate (15 mg, 1.0 eq.) was added to anhydrous dichloromethane (5 mL), bromotrimethylsilane (0.46 mg, 0.1 eq.) was added, and the reaction was carried out at room temperature for 16 hours under nitrogen protection. Completion of the reaction was monitored by LCMS. 3 mL of methanol was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. Completion of the reaction was monitored by LCMS. The mixture was purified by preparative HPLC to obtain the target compound (1.5 mg, 11% yield). LCMS (ESI) [M+H] + = 438.1; 1 H NMR (400 MHz, MeOD) δ 8.72 (s, 1H), 8.63 (d, J = 9.2 Hz, 1H), 7.28-7.25 (m, 2H), 7.15 (d, J = 9.2Hz, 1H), 5.57 (s, 2H), 5.30 (s, 2H), 4.12 (s, 3H).
[0474] Example 30 Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-9-fluoro-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (Compound 69) [ka]
[0475] First step: Preparation of 5-(((4-fluoro-3-methoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 2,2-Dimethyl-1,3-dioxane-4,6-dione (5.11 g, 1 eq.) was dissolved in triethoxymethane (15.75 g, 3 eq.), stirred at 90°C for 1 hour, cooled to 70°C, and 4-fluoro-3-methoxyaniline (5 g, 1 eq.) was added and reacted at 70°C for 0.5 hours. The reaction was monitored for completion by LCMS, cooled to room temperature, filtered, and the filter cake was washed with petroleum ether and dried to give the desired compound (10 g, 95% yield). 1 H NMR (400 MHz, DMSO-d6) δ 11.24 (d, J = 14.5 Hz, 1H), 8.59 (d, J = 14.5 Hz, 1H), 7.50 (dd, J = 7.6, 2.6 Hz, 1H), 7.27 (dd, J = 11.1, 8.8 Hz, 1H), 7.19 - 7.03 (m, 1H), 3.90 (s, 3H), 1.68 (s, 6H).
[0476] Second step: Preparation of 6-fluoro-7-methoxyquinolin-4-ol 5-(((4-Fluoro-3-methoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (10 g, 1 eq.) was dissolved in diphenyl ether (40 mL) and stirred at 200° C. for 6 hours. The reaction was monitored for completion by LCMS. The reaction was cooled to room temperature, filtered, and the filter cake was washed with petroleum ether to give the desired compound (6.3 g, 96% yield). LCMS (ESI) [M+H] + = 194.1; 1 H NMR (400 MHz, DMSO-d6) δ 11.65 (s, 1H), 7.92 - 7.81 (m, 1H), 7.71 (d, J = 11.8 Hz, 1H), 7.13 (d, J = 7.4 Hz, 1H), 5.97 (d, J = 7.4 Hz, 1H), 3.94 (s, 3H).
[0477] Third step: Preparation of 6-fluoro-7-methoxy-3-nitroquinolin-4-ol 6-Fluoro-7-methoxyquinolin-4-ol (3 g, 1 eq.) was dissolved in propionic acid (50 mL), and 70% nitric acid (5 mL) was added, followed by reaction at 140°C for 12 hours. The reaction was monitored for completion by LCMS. After cooling to room temperature, water was added and the mixture was filtered. The cake was washed with water and ethyl acetate to obtain the target compound (2.4 g, yield 65%). LCMS (ESI) [M+H] + =239.3; 1 H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1H), 9.17 (s, 1H), 7.90 (d, J = 11.5 Hz, 1H), 7.32 (d, J = 7.3 Hz, 1H), 3.98 (s, 3H).
[0478] Step 4: Preparation of 4-chloro-6-fluoro-7-methoxy-3-nitroquinoline 6-Fluoro-7-methoxy-3-nitroquinolin-4-ol (2.4 g, 1 eq.) was dissolved in dichloromethane (70 mL) and N,N-dimethylformamide (20 mL), sulfonyl dichloride (3 g, 2.2 eq.) was added, and the mixture was stirred at 40° C. for 3 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure, and water was added to the crude product to precipitate a solid. The solid was filtered, and the filter cake was washed with water and ethyl acetate to give the desired compound (2.5 g, 96% yield). LCMS (ESI) [M + H] + = 257.3.
[0479] Fifth step: Preparation of N-(4-(benzylthio)-2,6-difluorobenzyl)-6-fluoro-7-methoxy-3-nitroquinolin-4-amine 4-Chloro-6-fluoro-7-methoxy-3-nitroquinoline (2.8 g, 1 eq.) and (4-(benzylthio)-2,6-difluorophenyl)methylamine (2.89 g, 1 eq.) were dissolved in tetrahydrofuran (40 mL), and N,N-diisopropylethylamine (4.23 g, 3 eq.) was added, followed by stirring at room temperature for 1.5 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure, filtered, and the filter cake was rinsed with methanol to give the desired compound (3.2 g, yield: 60%). LCMS (ESI) [M + H] + = 486.1.
[0480] 6th step: N 4 Preparation of -(4-(benzylthio)-2,6-difluorobenzyl)-6-fluoro-7-methoxyquinoline-3,4-diamine N-(4-(benzylthio)-2,6-difluorobenzyl)-6-fluoro-7-methoxy-3-nitroquinolin-4-amine (3.1 g, 1 eq.) was dissolved in a mixture of methanol (50 mL) and tetrahydrofuran (50 mL), and a solution of zinc powder (2.09 g, 5 eq.) and ammonium chloride (3.4 mg, 10 eq.) in water (25 mL) was added. The mixture was allowed to react at room temperature for 1 hour. N 4 After that, the mixture was filtered to remove the zinc powder, water (20 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined and evaporated to dryness under reduced pressure to give the crude target compound (2.2 g), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 456.0.
[0481] Step 7: Preparation of ethyl (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)aminoacetate N 4 -(4-(benzylthio)-2,6-difluorobenzyl)-6-fluoro-7-methoxyquinoline-3,4-diamine (1.9 g, crude product) and a toluene solution of ethyl glyoxylate (50 wt%, 20 mL) were dissolved in methanol (10 mL), and the mixture was stirred at room temperature for 1.5 hours. Sodium cyanoborohydride (1.29 g) was added, and the mixture was continued stirring at room temperature for 0.5 hours. The reaction was monitored for completion by LCMS. The reaction mixture was spin-dried, water (30 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were spin-dried to give the target compound (4 g, crude product). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 542.2.
[0482] Step 8: Preparation of (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)aminoacetic acid (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)ethylaminoacetic acid (2 g, crude product) was dissolved in a mixed solution of tetrahydrofuran (50 mL) and methanol (15 mL), and a solution of lithium hydroxide (353.8 mg) in water (10 mL) was added, followed by stirring at room temperature for 2 hours. The reaction was monitored for completion by LCMS. The pH of the solution was adjusted to 2, and the reaction mixture was dried on a rotary evaporator. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried on a rotary evaporator to give the target compound (1.1 g, 58% yield). LCMS (ESI) [M + H] + =514.1.
[0483] Step 9: Preparation of 1-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-3,4-dihydropyrazino[2,3-c]quinolin-2(1H)-one (4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-6-fluoro-7-methoxyquinolin-3-yl)glycine (1.1 g, 1 eq.) was dissolved in N,N-dimethylformamide (10 mL), HATU (2443.4 mg, 3 eq.) and N,N-diisopropylethylamine (830.5 mg, 3 eq.) were added, and the mixture was stirred at room temperature for 2 hours. The reaction was completed after LCMS detection, and water (20 mL) was added and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine, filtered, and the filtrate was spin-dried to obtain the crude product. The crude product was purified by column separation to obtain the desired product (800 mg, yield 75%). LCMS (ESI) [M + H] += 496.1.
[0484] Tenth step: Preparation of tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate 1-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-3,4-dihydropyrazino[2,3-c]quinolin-2(1H)-one (300 mg, 1 eq.) was dissolved in di-tert-butyl dicarbonate (3 mL), and 4-dimethylaminopyridine (221.9 mg, 3 eq.) was added, followed by stirring at 40°C for 1 hour. The completion of the reaction was monitored by LCMS, water (10 mL) was added, extracted with ethyl acetate (20 mL × 3), the organic phases were combined and rotary evaporated to give the crude product, which was purified by column separation to give the target compound (100 mg, yield 28%). LCMS (ESI) [M + H] + =596.4.
[0485] Eleventh step: Preparation of tert-butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-9-fluoro-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate Tert-butyl 1-(4-(benzylthio)-2,6-difluorobenzyl)-9-fluoro-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (80 mg, 1 eq.) was dissolved in tetrahydrofuran (2 mL), and water (33.9 mg, 14 eq.) and acetic acid (56.5 mg, 7 eq.) were added under ice-cooling, and 1,3-dichloro-5,5-dimethylhydantoin (52.9 mg, 2 eq.) was added and stirred for 5 minutes under ice-cooling. The reaction was monitored for completion by LCMS. The reaction mixture was added to stirred aqueous ammonia (3 mL) and monitored for completion by LCMS. The mixture was extracted with ethyl acetate (5 mL x 3). The organic phases were combined and distilled under reduced pressure to obtain the crude product, which was purified by preparative HPLC to obtain the target compound (6 mg, 8% yield). LCMS (ESI) [M+H] + =553.1; 1 H NMR (400 MHz, MeOD-d4) δ 8.91 (s, 1H), 7.94 (d, J = 12.4 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.27 (d, J = 7.2 Hz, 2H), 5.59 (s, 2H), 4.36 (s, 2H), 4.03 (s, 3H), 1.54 (s, 9H).
[0486] Example 31 Preparation of 3,5-difluoro-4-((9-fluoro-8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide (Compound 55) [ka]
[0487] tert-Butyl 1-(2,6-difluoro-4-sulfamoylbenzyl)-9-fluoro-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinoline-4(1H)-carboxylate (50 mg, 1 eq.) prepared in Example 30 was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure and then purified by preparative HPLC to give the desired compound (1.23 mg, 3% yield). LCMS (ESI) [M + H] + =453.1.
[0488] Example 32 Preparation of 3,5-difluoro-4-((4-(2-hydroxyacetyl)-8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide (Compound 72) [ka]
[0489] First step: Preparation of 2-(1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinolin-4(1H)-yl)-2-oxoethyl acetate 1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-3,4-dihydropyrazino[2,3-c]quinolin-2(1H)-one (400 mg, 1 eq.) prepared in the sixth step of Example 18 was dissolved in dichloromethane (4 mL), and 2-chloro-2-oxoethyl acetate (171.6 mg, 1.5 eq.) and triethylamine (254.3 mg, 3 eq.) were added, followed by reaction at room temperature for 1 hour. The reaction was monitored for completion by LCMS. The mixture was diluted with water, the organic layer was extracted, the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by column chromatography to obtain the target compound (120 mg, 25% yield). LCMS (ESI) [M + H] + = 578.2.
[0490] Second Step: Preparation of 3,5-difluoro-4-((4-(2-hydroxyacetyl)-8-methoxy-2-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide 2-(1-(4-(benzylthio)-2,6-difluorobenzyl)-8-methoxy-2-oxo-2,3-dihydropyrazino[2,3-c]quinolin-4(1H)-yl)-2-oxoethyl acetate (50 mg, 1 eq.) was dissolved in ultra-dry tetrahydrofuran (2 mL), and glacial acetic acid (39.3 mg, 7.6 eq.), water (23.6 mg, 15.1 eq.), and 1,3-dichloro-5,5-dimethylhydantoin (55.3 mg, 3.2 eq.) were added in an ice bath, followed by stirring at 0°C for 5 minutes. Completion of the reaction was monitored by LCMS, and aqueous ammonia (5 mL) was added to the reaction mixture. After stirring for 30 minutes, sodium hydrogen carbonate (39.3 mg, 5.4 eq.) was added and stirring was continued for 1 hour. The product was monitored by LCMS, the reaction mixture was filtered, the filtrate was adjusted to neutral pH with 1 M hydrochloric acid, and concentrated. The residue was then purified by preparative HPLC to obtain the target compound (3.2 mg, yield 7.5%). LCMS (ESI) [M+H] + = 493.0; 1 H NMR (400 MHz, MeOD-d4) δ 9.10 (s, 1H), 8.25 (d, J = 10.3 Hz, 1H), 7.43 (s, 2H), 7.33 (d, J = 6.4 Hz, 2H), 5.63 (s, 2H), 4.46 (d, J = 20.1 Hz, 4H), 4.00 (s, 3H).
[0491] Example 33 Preparation of 3,5-difluoro-4-((7-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide (Compound 61) [ka]
[0492] Step 1: Preparation of diethyl 2-(((2-methoxyphenyl)amino)methylene)malonate 2-Methoxyaniline (20 g, 1 eq.) was dissolved in diethyl 2-(ethoxymethylene)malonate (35.12 g, 1 eq.) and stirred at 140° C. for 45 minutes. The reaction was monitored for completion by LCMS. After cooling to room temperature, petroleum ether was added and stirred to precipitate a white solid, which was filtered and the filter cake was washed with petroleum ether to give the target compound (39.6 g, yield: 83%). LCMS (ESI) [M+H] + =294.1; 1 H NMR (400 MHz, CDCl3) δ 11.12 (d, J = 13.4 Hz, 1H), 8.57 (d, J = 14.1 Hz, 1H), 7.24 (s, 1H), 6.99 (dd, J = 42.4, 26.6 Hz, 3H), 4.33 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
[0493] Step 2: Preparation of ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate Diethyl 2-(((2-methoxyphenyl)amino)methylene)malonate (15 g, 1 eq.) was added to diphenyl ether (75 mL) and reacted at 260°C for 45 minutes. Completion of the reaction was monitored by LCMS. After cooling to room temperature, petroleum ether was added, and a solid precipitated. The solid was filtered, and the filter cake was washed with petroleum ether and dried to obtain the target compound (8.5 g, yield 67%). LCMS (ESI) [M + H] + = 248.0.
[0494] Step 3: Preparation of ethyl 4-chloro-8-methoxyquinoline-3-carboxylate Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate (4 g, 1 eq.) was dissolved in dichloromethane (40 mL), N,N-dimethylformamide (4 mL) was added, and oxalyl chloride (3.08 g, 1.5 eq.) was slowly added dropwise thereto, followed by stirring at room temperature for 1 hour. The reaction was monitored for completion by LCMS. The reaction mixture was dried on a rotary evaporator, ethyl acetate was added, filtered, the filter cake was washed with ethyl acetate and dried to give the desired compound (4 g, 93% yield). LCMS (ESI) [M+H] + =266.1; 1 H NMR (400 MHz, CDCl3) δ 9.67 (s, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.94 (t, J = 8.3 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 4.55 (d, J = 7.1 Hz, 2H), 4.26 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H).
[0495] Step 4: Preparation of ethyl 4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-8-methoxyquinoline-3-carboxylate Ethyl 4-chloro-8-methoxyquinoline-3-carboxylate (2 g, 1 eq.) and (4-(benzylthio)-2,6-difluorophenyl)methylamine (2 g, 1 eq.) were dissolved in DMF (40 mL), and N,N-diisopropylethylamine (3.89 g, 4 eq.) was added, followed by reaction at 50°C for 16 hours. The reaction was monitored for completion by LCMS. The mixture was diluted with water (40 mL) and extracted with ethyl acetate (30 mL x 3). The organic layers were combined, concentrated, and purified by column separation to give the target compound (2.3 g, 62% yield). LCMS (ESI) [M + H] + =495.0.
[0496] Fifth step: Preparation of 4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-8-methoxyquinolin-3-yl)methanol Ethyl 4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-8-methoxyquinoline-3-carboxylate (2.1 g, 1 eq.) was dissolved in a mixed solution of tetrahydrofuran (30 mL) and methanol (8 mL), and lithium borohydride (462.4 mg, 5 eq.) was added, followed by reaction at room temperature for 2 hours. The reaction was monitored for completion by LCMS and quenched with saturated aqueous ammonium chloride, concentrated under reduced pressure, and the solid precipitated was filtered. The filter cake was washed with ethyl acetate and dried to give the desired compound (1.2 g, 62% yield). LCMS (ESI) [M + H] + = 452.9.
[0497] Step 6: Preparation of 1-(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one 4-((4-(benzylthio)-2,6-difluorobenzyl)amino)-8-methoxyquinolin-3-yl)methanol (400 mg, 1 eq.) was dissolved in ultra-dry tetrahydrofuran (40 mL), N,N-diisopropylethylamine (342.7 mg, 3 eq.) was added, and triphosgene (262.3 mg, 2 eq.) was added under ice cooling, followed by stirring at room temperature for 3 hours. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure, and then purified by reverse column chromatography to give the target compound (100 mg, yield 24%). LCMS (ESI) [M + H] + =479.1.
[0498] Step 7: Preparation of 3,5-difluoro-4-((7-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)methyl)benzenesulfonamide 1-(4-(benzylthio)-2,6-difluorobenzyl)-7-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c]quinolin-2-one (50 mg, 1 eq.) was dissolved in tetrahydrofuran (2 mL), and water (26.4 mg, 14 eq.) and acetic acid (43.9 mg, 7 eq.) were added under ice-cooling. 1,3-Dichloro-5,5-dimethylhydantoin (41.2 mg, 2 eq.) was added, and the mixture was stirred for 5 minutes under ice-cooling. Aqueous ammonia (1 mL) was added, stirring was continued, and the reaction was monitored for completion by LCMS. Tetrahydrofuran was evaporated under reduced pressure, and the mixture was extracted with ethyl acetate (10 mL). The organic phase was concentrated and purified by preparative HPLC to give the target compound (2.0 mg, yield 4.4%). LCMS (ESI) [M+H] + =436.0; 1 H NMR (400 MHz, MeOD-d4) δ 8.67 (s, 1H), 8.50 (s, 2H), 7.79 (d, J = 8.5 Hz, 1H), 7.63 (t, J = 8.3 Hz, 1H), 7.44 (d, J = 7.4 Hz, 2H), 7.27 (d, J = 8.2 Hz, 1H), 5.59 (s, 2H), 5.32 (s, 2H), 4.07 (s, 3H).
[0499] Example 34 Preparation of 6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Compound 59) [ka]
[0500] Step 1: Preparation of ethyl 4-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (2 g, 1 eq.) was dissolved in N,N-dimethylformamide (20 mL), and N,N-diisopropylethylamine (2.91 g, 3 eq.) and tert-butyl 6-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.79 g, 1.5 eq.) were added, followed by stirring at 50° C. for 10 hours. The reaction was monitored for completion by LCMS. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain the target compound (2.3 g, yield 64%). LCMS (ESI) [M+H] + =479.1; 1 H NMR (400 MHz, CDCl3) δ 10.37 (s, 1H), 9.30 (s, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.93 - 6.81 (m, 2H), 6.58 (d, J = 9.1 Hz, 1H), 4.56 (s, 2H), 4.43 (q, J = 7.1 Hz, 2H), 4.13 (s, 3H), 3.63 (t, J = 5.0 Hz, 2H), 2.74 (s, 2H), 1.50 (s, 9H), 1.45 (t, J = 7.1Hz, 3H).
[0501] Second step: Preparation of tert-butyl 6-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate Ethyl 4-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (2 g, 1 eq.) was dissolved in tetrahydrofuran (20 mL), and lithium borohydride (0.27 g, 3 eq.) and methanol (2 mL) were added in an ice bath, and the reaction mixture was stirred at 25° C. for 2 hours. The completion of the reaction was monitored by LCMS. Saturated ammonium chloride solution (10 mL) was slowly added dropwise under ice bath, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the target compound (1.5 g, crude product). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + =437.3.
[0502] Third step: Preparation of tert-butyl 6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate tert-Butyl 6-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.9 g, crude product) was dissolved in tetrahydrofuran (20 mL), N,N-diisopropylethylamine (1.69 g) and triphosgene (1.29 g) were added, and the reaction mixture was stirred at 25° C. for 4 hours. The reaction was monitored for completion by LCMS. Water (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3), washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude product, which was purified by column chromatography to give the target compound (300 mg). LCMS (ESI) [M+H] + =463.1; 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 7.24 (dd, J = 18.5, 9.1 Hz, 3H), 7.16 (d, J = 9.3 Hz, 1H), 6.63 (d, J = 9.3 Hz, 1H), 5.47 (s, 2H), 4.64 (s, 2H), 4.11 (s, 3H), 3.67 (s, 2H), 2.83 (t, J = 5.7 Hz, 2H), 1.51 (s, 9H).
[0503] Fourth step: Preparation of 8-methoxy-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one Tert-butyl 6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (200 mg) was dissolved in trifluoroacetic acid (2 mL), and the reaction mixture was stirred at 40°C for 4 hours. The reaction was monitored for completion by LCMS. Trifluoroacetic acid was removed by concentration to give the target compound (170 mg, crude), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + =363.3.
[0504] Fifth step: Preparation of tert-butyl ((6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)carbamate tert-Butyl chlorosulfonylcarbamate (128.9 mg) was dissolved in dichloromethane (2 mL), and tert-butanol (67.5 mg) was added in an ice bath. The reaction mixture was stirred for 0.5 hours. 8-Methoxy-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (300 mg, crude) was dissolved in dichloromethane (8 mL), and triethylamine (100.5 mg) was added in an ice bath. The former was then slowly added dropwise to the reaction mixture, and the mixture was stirred for 1.5 hours in an ice bath. The reaction was monitored for completion by LCMS. The solvent was concentrated, water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (5 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to give the target compound (203 mg, crude product). This was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 542.2.
[0505] Step 6: Preparation of 6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide tert-Butyl ((6-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)carbamate (203 mg, crude) was dissolved in trifluoroacetic acid (3 mL), and the reaction mixture was stirred at 40° C. for 4 hours. The reaction was monitored for completion by LCMS. Trifluoroacetic acid was removed by concentration to give the crude product, which was purified by preparative HPLC to give the target compound (1.06 mg). LCMS (ESI) [M+H] + =442.1; 1H NMR (400 MHz, MeOD-d4) δ 8.88 (s, 1H), 7.43 (d, J = 6.4 Hz, 2H), 7.38 (d, J = 8.9 Hz, 1H), 7.19 (d, J = 9.5 Hz, 1H), 6.88 (d, J = 9.5 Hz, 1H), 5.66 (s, 2H), 4.44 (s, 2H), 4.12 (s, 3H), 3.47 (t, J = 5.8 Hz, 2H), 3.02 (t, J = 5.8 Hz, 2H).
[0506] Example 35 Preparation of (N-(4-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)sulfamoyl)amine (Compound 64): [ka]
[0507] Step 1: Preparation of tert-butyl (4-oxocycloheptyl)carbamate n-Butyllithium (2.5 M in hexane) (4.2 mL) was dissolved in tetrahydrofuran (100 mL), and the reaction system was purged with nitrogen. Trimethylsilyldiazomethane TMSCHN2 (2 M in hexane) (6.96 mL) was then added at −78° C. and stirred for 30 minutes. tert-Butyl(4-oxocyclohexyl)carbamate (10.0 g, 1 eq.) was then added at −78° C., and the reaction system was purged with nitrogen and stirred at −78° C. for 1 hour. The reaction was monitored for completion by LCMS, saturated with aqueous ammonium chloride, extracted with ethyl acetate, and the organic phase was concentrated and purified by flash chromatography to give the desired compound (9.0 g, 84.4% yield). LCMS (ESI) [M + Na] + = 250.1.
[0508] Step 2: Preparation of tert-butyl (4-aminocycloheptyl)carbamate tert-Butyl (4-oxocycloheptyl)carbamate (2.0 g, 1 eq.) and ammonium formate (3.33 g, 6 eq.) were dissolved in methanol (30 mL), Pd / C (936 mg, 1 eq.) was added, the reaction system was purged with hydrogen, and the mixture was stirred under a hydrogen atmosphere at 20°C for 5 hours. The reaction was monitored for completion by LCMS. The reaction mixture was filtered, and the filtrate was dried on a rotary evaporator. It was then dissolved in hydrochloric acid (5 M, 5 mL). Ethyl acetate was added and the layers were separated. The aqueous phase was alkalized and extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium sulfate, filtered, and the filtrate was dried on a rotary evaporator under reduced pressure to give the desired compound (1.0 g, 50% yield). LCMS (ESI) [M + H] + = 229.2.
[0509] Step 3: Preparation of ethyl 4-((4-((tert-butoxycarbonyl)amino)cycloheptyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (50 mg, 1 eq.) was dissolved in acetonitrile (10 mL), and then potassium carbonate (77 mg, 3.0 eq.) and tert-butyl (4-aminocycloheptyl)carbamate (128 mg, 3 eq.) were added, and the reaction was carried out under nitrogen protection at 40°C for 16 hours. The completion of the reaction was monitored by LCMS, and the reaction mixture was evaporated to dryness under reduced pressure, dissolved in ethyl acetate, and washed with water. The organic layer was then dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and then purified by flash chromatography to obtain the target compound (50 mg, yield 58%). LCMS (ESI) [M + H] + = 459.3.
[0510] Step 4: Preparation of tert-butyl (4-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)cycloheptyl)carbamate Ethyl 4-((4-((tert-butoxycarbonyl)amino)cycloheptyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (30.0 mg, 1 eq.) was suspended in ethanol (2 mL) and methanol (0.5 mL), and then sodium borohydride (15.1 mg, 6.1 eq.) was added. The reaction was carried out under nitrogen protection at 80°C for 10 hours, and completion of the reaction was monitored by LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (5 mL) and extracted three times with ethyl acetate (5 mL). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by flash chromatography to obtain the target compound (10 mg, 37% yield). LCMS (ESI) [M + H] + = 417.3.
[0511] Fifth step: Preparation of tert-butyl (4-(8-methoxy-2-oxo-2H-[1,3]oxazinyl[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)carbamate tert-Butyl (4-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)cycloheptyl)carbamate (10 mg, 1 eq.) was dissolved in dichloromethane (1 mL), then triethylamine (7.3 mg, 3 eq.) and triphosgene (7.1 mg, 1 eq.) were added successively at 0°C, and the reaction was stirred at 0°C for 2 hours. The reaction was monitored for completion by LCMS. The reaction mixture was quenched with saturated brine (10 mL) and extracted three times with ethyl acetate (5 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by flash chromatography to obtain the target compound (10 mg, yield 94%). LCMS (ESI) [M + H] + = 443.2.
[0512] Step 6: Preparation of 1-(4-aminocycloheptyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one tert-Butyl (4-(8-methoxy-2-oxo-2H-[1,3]oxazinyl[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)carbamate (10 mg) was dissolved in dichloromethane (1 mL), followed by the addition of a solution of trifluoroacetic acid (0.5 mL) in dichloromethane (0.5 mL) at 0° C., and the reaction was stirred at 20° C. for 1 h. The reaction was monitored for completion by LCMS. The reaction mixture was evaporated under reduced pressure to give the target compound (10 mg, crude product), which was used directly in the next reaction without further purification. LCMS (ESI) [M + H] + = 343.2.
[0513] Seventh step: Preparation of tert-butyl N-(4-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)sulfamoyl)carbamate To a 50 mL single-neck round-bottom flask, tert-butyl chlorosulfonylcarbamate (2 mL), dichloromethane (2 mL), and then tert-butanol (2 mL) were slowly added at 0° C., and the reaction mixture was stirred for 1 hour at 0° C. The reaction mixture was added to a solution of 1-(4-aminocycloheptyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (10 mg, crude product, obtained in the previous reaction) in dichloromethane (2 mL) at 0° C., and the mixture was stirred for 1 hour at 0° C. The reaction was monitored for completion by LCMS. The reaction mixture was evaporated to dryness under reduced pressure to give the target compound (10 mg, crude), which was used directly in the next reaction without further purification.
[0514] Eighth Step: Preparation of (N-(4-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)sulfamoyl)amine tert-Butyl N-(4-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)cycloheptyl)carbamate (9 mg, crude) was dissolved in dichloromethane (1 mL), then a solution of trifluoroacetic acid (0.5 mL) in dichloromethane (0.5 mL) was added at 20° C. and the reaction was stirred at 20° C. for 1 hour. The reaction was monitored for completion by LCMS. The reaction mixture was concentrated under reduced pressure and then purified to give the target compound (1.2 mg). LCMS (ESI) [M+H] + = 422.2; 1 HNMR (400MHz, MeOD-d4) δ8.18 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 4.0 Hz, 1H), 5.21 (s, 2H), 5.10 (s, 2H), 4.03 (s, 3H), 3.35 (s, 1H), 3.03 (s, 1H), 2.93 (m, 1H), 2.56 (s, 1H), 2.5 (s, 1H), 2.4 (m, 1H), 2.10 (m, 2H), 1.94 (m, 2H), 1.51 (m, 1H), 1.30 (m, 1H), 1.25 (m, 3H).
[0515] Example 36 Preparation of 5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1 (4H)-yl)hexahydrocyclopenta[c]pyrrole-2 (1H)-sulfonamide (Compound 36) [ka]
[0516] Step 1: Preparation of tert-butyl 5-(benzylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate tert-Butyl 5-oxohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate (1.0 g) was dissolved in dichloromethane (100 mL). Benzylamine (475 mg) and acetic acid (266 mg) were added at 0 °C. The mixture was stirred at 0 °C for 30 minutes, then sodium borohydride acetate (1.88 g) was added in portions, the mixture was warmed to room temperature, and the reaction was continued for 16 hours. Completion of the reaction was monitored by LCMS. 20 mL of water was added, and the mixture was extracted with methylene chloride (50 mL × 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the target compound (1.2 g, crude). LCMS (ESI) [M + H] + = 317.3.
[0517] Step 2: Preparation of tert-butyl 5-aminohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate tert-Butyl 5-(benzylamino)hexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate (1.2 g, crude) was dissolved in methanol (30 mL), palladium hydroxide (10%, 400 mg) was added, the atmosphere was purged with hydrogen three times, and the reaction was stirred under hydrogen at 40° C. for 16 hours. The reaction was monitored for completion by LCMS, filtered, and the filtrate was concentrated under reduced pressure to give the desired compound (700 mg, crude). LCMS (ESI) [M + H] + = 227.2.
[0518] Third step: Preparation of ethyl 4-((2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (707 mg), tert-butyl 5-aminohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate (600 mg, crude), and N,N-diisopropylethylamine (3.43 g) were dissolved in ethanol (20 mL), heated to 90 °C, and reacted for 16 h. The reaction was monitored for completion by LCMS. The ethanol was removed under reduced pressure, 50 mL of water was added, and the mixture was extracted three times with ethyl acetate (50 mL). The combined organic phases were dried, filtered, concentrated, and purified by column chromatography (DCM:MeOH = 20:1) to give the target compound (1.0 g, 82% yield). LCMS (ESI) [M + H] + = 457.2.
[0519] Step 4: Preparation of tert-butyl 5-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate Ethyl 4-((2-(tert-butoxycarbonyl)octahydrocyclopenta[C]pyrrol-5-yl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (100 mg, 1.0 eq.) was dissolved in dichloromethane (20 mL) and cooled to -78 °C. Diisobutylaluminum hydride (2 M, 0.55 mL) was slowly added and the reaction was carried out at -78 °C for 2 hours. The reaction mixture was quenched by adding water and extracted three times with dichloromethane (20 mL). The organic phases were combined, dried, filtered, concentrated, and purified by column chromatography (DCM:MeOH = 10:1) to give the target compound (40 mg, 44% yield). LCMS (ESI) [M + H] + = 415.2.
[0520] Fifth step: Preparation of tert-butyl 5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate tert-Butyl 5-((3-(hydroxymethyl)-7-methoxy-1,8-naphthyridin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (40 mg, 1.0 eq.) in tetrahydrofuran (5 mL) was added, followed by N,N-diisopropylethylamine (124 mg, 10.0 eq.) and triphosgene (86 mg, 3.0 eq.). The reaction was allowed to proceed at room temperature for 1 hour and monitored for completion by LCMS. The reaction mixture was added to water (10 mL) and extracted three times with ethyl acetate (20 mL). The combined organic phases were dried, filtered, concentrated, and purified by column chromatography (DCM:MeOH = 10:1) to give the desired compound (30 mg, 70% yield). LCMS (ESI) [M + H] + = 441.2.
[0521] Sixth step: Preparation of 8-methoxy-1-(octahydrocyclopenta[c]pyrrol-5-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one tert-Butyl 5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (30 mg) was added to dichloromethane (10 mL), trifluoroacetic acid (1 mL) was added, and the reaction was carried out at room temperature for 2 hours. Completion of the reaction was monitored by LCMS, and the mixture was dried on a rotary evaporator under vacuum to obtain the target compound (20 mg, crude product). LCMS (ESI) [M + H] + = 341.2.
[0522] Seventh step: Preparation of tert-butyl ((5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)sulfonyl)carbamate 8-Methoxy-1-(octahydrocyclopenta[c]pyrrol-5-yl)-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (20 mg, crude product) and triethylamine (30 mg) were added to dichloromethane (10 mL), and tert-butyl N-(chlorosulfonyl)carbamate (25 mg) was added dropwise at 0°C. The reaction mixture was reacted at room temperature for 2 hours. The reaction mixture was added to water (10 mL), extracted three times with ethyl acetate (20 mL), and the organic phases were combined, dried, filtered, and concentrated to obtain the target compound (20 mg, crude product). LCMS (ESI) [M + H] + = 520.1.
[0523] Eighth Step: Preparation of 5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-sulfonamide tert-Butyl ((5-(8-methoxy-2-oxo-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-1(4H)-yl)hexahydrocyclopenta[c]pyrrole-2(1H)-yl)sulfonyl)carbamate (20 mg, crude product) was added to dichloromethane (5 mL), trifluoroacetic acid (0.5 mL) was added, and the reaction was carried out at room temperature for 4 hours. The completion of the reaction was monitored by LCMS. The reaction was completed, dried on a rotary evaporator under vacuum, and the crude product was obtained. The product was purified by liquid-phase preparative HPLC to obtain the target compound (2.8 mg). LCMS (ESI) [M+H] + = 420.1; 1H NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.33 (d, J = 9.2 Hz, 1H), 7.17 (d, J = 9.2 Hz, 1H), 6.78 (s, 2H), 5.33 (s, 2H), 4.34-4.25 (m, 1H), 4.03 (s, 3H), 3.10 - 3.06 (m, 2H), 2.99 - 2.97 (m, 2H), 2.62 - 2.54 (m, 2H), 2.40 - 2.36 (m, 2H), 2.27 - 2.19 (m, 2H).
[0524] Example 37 Preparation of 1-(2,6-difluoro-4-(S-methylsulfonimidoyl)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (Compound 216) [ka]
[0525] Step 1: Preparation of ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (20 g, 1.0 eq.), (4-bromo-2,6-difluorophenyl)methylamine (16.65 g, 1.0 eq.), and N,N-diisopropylethylamine (29.08 g, 3.0 eq.) were added to dimethylformamide (200 mL) and stirred at room temperature for 12 hours. Completion of the reaction was monitored by LCMS. The reaction mixture was added to 250 mL of petroleum ether, cooled to room temperature with stirring, and stirred for an additional 3 hours to allow the solid to precipitate. The solid was then filtered, and the filter cake was dried to obtain the desired compound (19 g, yield: 56%). LCMS (ESI) [M + H] + =453.9.
[0526] Second step: Preparation of ethyl 4-((2,6-difluoro-4-(methylthio)benzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate Ethyl 4-((4-bromo-2,6-difluorobenzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (450 mg, 1.0 eq.), sodium thiomethoxide (69.74 mg, 1.0 eq.), 4,5-bisdiphenylphosphino-9,9-dimethylxanthene (57.57 mg, 0.1 eq.), N,N-diisopropylethylamine (385.79 mg, 3.0 eq.), and bis(dibenzylideneacetone)palladium (91.12 mg, 0.1 eq.) were dissolved in dioxane (7 mL) and water (1 mL), and the mixture was stirred at 90° C. for 8 hours. LCMS showed the completion of the reaction, the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL *3), the organic phases were combined, dried, filtered, concentrated and eluted with normal phase column (PE:EA = 5:1) to give the target compound (250 mg, yield: 60%). LCMS (ESI) [M + H] + =419.9.
[0527] Third step: Preparation of (4-((2,6-difluoro-4-(methylthio)benzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol Ethyl 4-((2,6-difluoro-4-(methylthio)benzyl)amino)-7-methoxy-1,8-naphthyridine-3-carboxylate (190 mg, 1.0 eq.) was dissolved in tetrahydrofuran (5 mL), and lithium aluminum hydride (126.75 mg, 7.4 eq.) was added in an ice bath. The mixture was stirred for 2 hours in an ice bath. The product was monitored by LCMS. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried, filtered, concentrated, and eluted with a reverse phase system to give the desired compound (120 mg, yield: 70%). LCMS (ESI) [M + H] + =378.0.
[0528] Fourth step: Preparation of 1-(2,6-difluoro-4-(methylthio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one The compound (4-((2,6-difluoro-4-(methylthio)benzyl)amino)-7-methoxy-1,8-naphthyridin-3-yl)methanol (100 mg, 1.0 eq.) was dissolved in tetrahydrofuran (2 mL), triphosgene (235.8 mg, 3.0 eq.) and N,N-diisopropylethylamine (136.98 mg, 4.0 eq.) were added, and the reaction was carried out at 25°C for 1 hour. Completion of the reaction was monitored by LCMS. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give the target compound (105 mg, yield 98.24%). LCMS (ESI) (M + H) + = 404.1.
[0529] Fifth step: Preparation of 1-(2,6-difluoro-4-(S-methylsulfonimidoyl)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one The compound 1-(2,6-difluoro-4-(methylthio)benzyl)-8-methoxy-1,4-dihydro-2H-[1,3]oxazino[5,4-c][1,8]naphthyridin-2-one (100 mg, 1.0 eq.) was dissolved in ethanol (4 mL), and iodobenzenediacetic acid (239.54 mg, 3.0 eq.) and ammonium acetate (96.43 mg, 5.0 eq.) were added and reacted at room temperature for 2 hours. Completion of the reaction was monitored by LCMS, and the reaction mixture was concentrated. The crude product was purified by preparative HPLC to give the desired compound (24.05 mg, 22% yield).
[0530] The following compounds were prepared with reference to the preparation methods of Examples 1-37: [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12]
[0531] Biological Test Evaluation Test Example 1: In vitro inhibition test of ENPP1 enzyme ENPP1 is a transmembrane glycoprotein capable of hydrolyzing nucleotides, including derivatives with nucleotide-5'-monophosphate structures. ENPP1 can hydrolyze artificially synthesized p-nitrophenyl 5'-monophosphate (TMP-pNP) to produce nucleotide-5'-monophosphate and the color-producing product p-nitrophenol. The amount of p-nitrophenol produced can be directly measured from the absorbance at 405 nm, which is proportional to the enzyme activity.
[0532] Experimental procedure Compounds were prepared in 100x serial dilutions with DMSO, starting at 1 mM and diluted in 4x serial dilutions to give 10 concentrations. Using an Echo, 300 nL of the compound gradient was transferred to a 384-well plate (starting at 10 μM final concentration, 4x serial dilutions, 10 concentrations). Each well received 15 μL of 0.2 ng / μL hENPP1 enzyme (2x final concentration) prepared in experimental buffer (250 mM NaCl, 50 mM Tris, pH 9.5). Next, 15 μL of 400 μM TMP-pNP (2x final concentration) prepared in experimental buffer was added. After incubation at 37°C for 0.5 hours, the OD readings were measured using a microplate reader. 405nm The inhibition rate (%) was calculated using the following formula: IC 50 was calculated.
number
[0533] The selected compounds included compound 131 (ZX-131) disclosed in WO2021061803A1, and the data are shown in Table 1: [Table 4]
[0534] Test Example 2: In vitro ENPP1 enzyme inhibition test at the cellular level ENPP1 is primarily expressed on the cell membrane and can hydrolyze 2'3'-cGAMP to 5'-GMP and 5'-AMP. ENPP1 can also hydrolyze the artificially produced phosphate ester TMP-pNP to produce nucleotide-5'-monophosphate and the color-producing product p-nitrophenol. Therefore, in cultured MDA-MB-231 cells, TMP-pNP can be used as a substrate to reflect the enzymatic activity of ENPP1. The amount of p-nitrophenol formed in the medium is determined by absorbance at 405 nm, which is proportional to the activity of ENPP1.
[0535] Experimental procedure MDA-MB-231 cells were seeded at 6000 / well in a 384-well cell plate and incubated overnight (approximately 18 hours) at 37°C. Compounds were diluted 50x in serial steps using experimental buffer (250 mM NaCl, 50 mM Tris, pH 9.5) starting at 500 μM, followed by 4-fold serial dilutions to prepare 10 concentrations. The cell culture medium was removed, and 10 μL of gradient concentrations of compounds were added per well to the 384-well assay plate (starting at a final concentration of 10 μM, followed by 4-fold serial dilutions, resulting in 10 concentrations). Next, 10 μL of 1 mM TMP-pNP (2x final concentration) prepared in experimental buffer was added per well. After incubation at 37°C for 3 hours, the OD readings were measured using a microplate reader. 405nm The inhibition rate (%) was calculated using the following formula: IC 50 was calculated.
number
[0536] Test Example 3: Pharmacokinetic study of compound concentration measurement in mice by LC-MS / MS Test principle: Using LC-MS / MS, plasma drug concentrations were measured at different times, and the in vivo pharmacokinetic profile of the target compound was plotted.
[0537] Test method: Test compounds were dissolved in DMSO to prepare a stock solution at a final concentration of 20 mg / mL. The compounds were dissolved at 1 mg / mL in a solvent containing 5% DMSO (Sigma-Aldrich, SHBJ2847), 45% PEG400 (Sigma-Aldrich, BCCC0015), and 50% ddH2O. CD-1 male mice (JH Laboratory Animal Co., Ltd.) were used. Nine mice per compound group were administered 10 mg / kg PO. Blood was cross-sampled at 0.25, 0.5, 1, 2, 4, 8, and 24 hours, with three mice sampled per time point. 110 μL of whole blood (K2EDTA anticoagulated) was collected and immediately centrifuged at 2000 x g for 5 minutes at 4°C. Serum was collected and stored at -70°C. Drug concentrations in plasma were measured using a triple-quadrupole MS system (SCI EX). Standard curve and control preparation, as well as sample preparation, were performed. Standard curve and control preparation: Working solutions were prepared by diluting with MeOH:HO (1:1). 3 μL of the standard curve and control working solutions were added to 57 μL of blank plasma. Sample preparation: 200 μL of internal standard solution (propranolol, 40 ng / mL) was added to 30 μL of plasma sample, mixed for 1 minute, and centrifuged at 5800 rpm for 10 minutes. 100 μL of the supernatant was removed and transferred to a new plate for sample introduction analysis. Chromatographic conditions, such as mobile phase composition, eluent gradient, flow rate, and retention time, were optimized for each sample. The chromatography column was a Waters BEH C18 (2.1 × 50 mm, 1.7 μm) with a sample volume of 1 μL. Mass spectrometry was performed using an electrospray ion source (TuREo spray) in positive ion detection mode, with multiple reaction monitoring (MRM) mode selected for secondary mass spectrometry analysis. Based on the drug concentration-time data, pharmacokinetic parameters, including peak concentration (Cmax), time to peak concentration (Tmax), area under the drug-time curve (AUC), and elimination half-life (t1 / 2), were calculated using WinNonlin 8.2 software using a noncompartmental model. The AUC calculation method was the log-linear trapezoidal method (linear up log down). The test results show that the compounds of the present invention have good pharmacokinetics in vivo and also have drug-forming properties. [Table 6]
[0538] Test Example 4: Evaluation of the efficacy of compounds in a mouse pancreatic cancer model, Pan02 1. Experimental objective: To evaluate the in vivo efficacy of test substances in a mouse pancreatic cancer Pan02 cell subcutaneous allograft tumor model.
[0539] 2. Testing method: 2.1 Cell Culture: In vivo monolayer culture of mouse pancreatic cancer Pan02 cells was performed using DMEM medium supplemented with 10% fetal bovine serum, 0.01 mg / ml insulin, and 1% penicillin / streptomycin / amphotericin B in a 37°C, 5% CO2 incubator. When cell saturation reached 80-90% and the required volume was reached, cells were harvested, counted, and seeded. 2.2 Animals: C57BL / 6 mice, female, 6-8 weeks old, weighing 18-22g, provided by Sino-British Sippr / BK Lab Animal Co., Ltd. or other suppliers. 2.3 Tumor inoculation and animal grouping Administration: 0.1 mL (5 × 10 6 Pan02 cells were inoculated subcutaneously into the right dorsal region of each mouse, and tumors were grown to an average volume of approximately 100–200 mm. 3 When the tumor volume reached 3000 mm, the animals were divided into groups and the administration was initiated. Before administration, the animals were weighed and the tumor volume was measured. The animals were randomly divided into groups (8 animals per group) according to the tumor volume. The control group was administered with the solvent: 5% DMSO + 45% PEG400 + 50% H2O (1% CMC-Na), and the experimental group was administered with a dose of 20 mg / kg, administered orally and intragastrically, with the administration volume being 10 μl / g according to the mouse body weight, twice a day. The health condition of the animals was observed daily, and when the tumor volume reached 3000 mm, the animals were randomly divided into groups (8 animals per group). The control group was administered with the solvent: 5% DMSO + 45% PEG400 + 50% H2O (1% CMC-Na), and the experimental group was administered with the solvent: 20 mg / kg, administered orally and intragastrically, with the administration volume being 10 μl / g according to the mouse body weight, twice a day. The health condition of the animals was observed daily, and when the tumor volume reached 3000 mm, the animals were randomly divided into groups (8 animals per group). 3 Animals were euthanized if they exceeded 18 days, were severely ill, or in pain, lost more than 20% of their body weight, or showed persistent deterioration. 2.4 Tumor growth inhibition rate: The tumor diameter was measured twice a week with a caliper. The tumor volume was calculated using the formula: V = 0.5a × b 2 where a and b represent the long and short diameters of the tumor, respectively. The tumor-inhibitory effect of the compound, TGI (%), was calculated as follows: [(1 - (mean tumor volume after administration in the treatment group - mean tumor volume at the start of administration in the treatment group)) / (mean tumor volume before treatment in the vehicle control group - mean tumor volume after treatment in the vehicle control group)] × 100%. Data analysis was performed using a t-test to compare the two groups, and significant differences were recognized when p < 0.05.
[0540] 3 Experimental results: Using a mouse pancreatic cancer Pan02 model, the example compounds described in the present invention (e.g., the example compounds that showed excellent effects in the above test examples) were found to be able to significantly inhibit tumor growth, with a statistically significant difference from the control group (p<0.05), and to have no effect on mouse body weight, demonstrating high safety.
[0541] Test Example 5: Evaluation of the efficacy of compounds in a myocardial ischemia model 1. Experimental Objective: The purpose of this study was to evaluate the efficacy of compounds in a SD rat myocardial ischemia model.
[0542] 2. Test Method 2.1 Model construction One week after arrival at the facility, the animals were modeled using the left anterior descending artery (LAD) ligation method. After modeling, penicillin (80,000 units / rat im) was administered for 3 days as treatment to prevent infection. 2.2 Split-dose treatment One day after modeling, the modeled animals were randomly divided into groups of 4-6 animals per group based on baseline body weight and cardiac ultrasound imaging parameters, and treatment began. The control group received vehicle: 5% DMSO + 45% PEG400 + 50% H2O (1% CMC-Na), while the experimental groups received doses of 30 mg / kg and 75 mg / kg, respectively. The animals were orally administered intragastrically twice daily for 7 consecutive days. After administration, the animals' body weights were monitored daily, and cardiac ultrasound imaging parameters were measured 7 days later. The main parameters evaluated by ultrasound imaging were left ventricular shunt fraction (FS) and left ventricular ejection fraction (LVEF).
[0543] 3. Experimental Results The compounds of the present invention (e.g., the Example compounds that showed excellent effects in the above Test Examples) demonstrated activity in a rat myocardial infarction model. The compounds of the present invention significantl...
Claims
1. A compound of formula (I), a stereoisomer, tautomer, or mixture thereof, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound, [Formula 1] In the formula, X 1 , X 2 , X 3 , X 4 and Y are each independently CH or N; And X 1 , X 2 , X 3 , X 4 are both CH, then Y is not CH; R A isX 1 is a substituent of the ring in which R B is a substituent of the ring in which Y occurs, and each R A and R B are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -Z-OR 1 , -Z-SR 1 , -Z-NR 2 R 3 , -Z-NR 2 C(O)R 4 , -Z-NR 2 C(O)OR 1 , -ZC(O)R 4 , -ZC(O)OR 1 , -ZC(O)(CR 5 R 6 ) n C(O)R 4 , -ZC(O)(CR 5 R 6 ) n C(O)OR 1 , -ZC(O)NR 2 R 3 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3-20 membered heterocyclyl, 5-16 membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; n1 is 1, 2, 3 or 4; n2 is 1 or 2; Ring A is a 6-10 membered heterocyclyl or a 6-12 membered heteroaryl; Rc is a substituent of ring A, and each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -Z-OR 1 , -Z-SR 1 , -Z-NR 2 R 3 , -Z-NR 2 C(O)R 4 , -Z-NR 2 C(O)OR 1 , -ZC(O)R 4 , -ZC(O)OR 1 , -ZC(O)(CR 5 R 6 ) n C(O)R 4 , -ZC(O)(CR 5 R 6 ) n C(O)OR 1 , -ZC(O)NR 2 R 3 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, 3-20 membered heterocyclyl, C 6 - 12 aryl, 5-16 membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; n3 is 1, 2, 3, 4, 5 or 6; Z is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein the alkylene, alkyleneoxy, and alkylenethio are selected from deuterium, halogen, oxo, -CN, -OH, -NH 2 and optionally substituted with one or more substituents selected from Ring B is C 3 - 10 Cycloalkyl, 3-20 membered heterocyclyl, C 6 - 14 aryl or 5-16 membered heteroaryl; R D -W-OC(O)OR 1 , -WC(O)NR 2 R 3, -WC(O)NR 2 OR 1 , -W-OC(O)NR 2 R 3 , -W-NR 2 C(O)R 4 , -W-NR 2 C(O)OR 1 , -W-NR 2 C(O)NR 2 R 3 , -WS(O) 2 R 4 , -W-SO 2 NR 2 R 3 , -WS(O) =NR 2 , -WS(O)=NR 2 NR 2 R 3 , -W-NR 2 S(O) 2 R 4 , -W-OS(O) 2 R 4 , -W-NR 2 S(O) 2 NR 2 R 3 , -W-OS(O) 2 NR 2 R 3 , -WP(O)(OR 1 ) 2 , -WP(S)(OR 1 ) 2 , -WOP(S)(OR 1 ) 2 , -WB(OH) 2 Selected from: Each R E are independently hydrogen, deuterium, halogen, oxo, oxime, carboxy, -CN, -OH, -SH, -NO 2 , -NH 2 , -W-OR 1 , -W-SR 1 , -WC(O)R 4 , -WC(O)OR 1 , -W-OC(O)R 1 , -W-OC(O)OR 1 , -WC(O)NR 2 R 3 , -WC(O)NR 2 OR 1 , -W-OC(O)NR 2 R 3 , -W-NR 2 R 3 , -W-NR 2 C(O)R 4 , -W-NR 2 C(O)OR 1 , -W-NR 2 C(O)NR 2 R 3 , -WS(O) 2 R 4 , -W-SO 2 NR 2 R 3 , -W-NR 2 S(O) 2 R 4 , -W-OS(O) 2 R 4 , -W-NR 2 S(O) 2 NR 2 R 3 , -W-OS(O) 2 NR 2 R 3 , -WP(O)(OR 1 ) 2 , -WP(S)(OR 1 ) 2 , -WOP(S)(OR 1 ) 2 , -WB(OH) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 3-8 cycloalkenyl, 3-20 heterocyclyl, 5-16 membered heteroaryl; said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; n is 1, 2 or 3; n4 is 1, 2, 3, 4, 5 or 6; W is a bond, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 1-3 alkylenethio, wherein the alkylene, alkyleneoxy, and alkylenethio are selected from deuterium, halogen, oxo, -CN, -OH, -NH 2 and optionally substituted with one or more substituents selected from L is a bond, -O-, -S-, C 1-6 Alkylene, C 1-6 Alkyleneoxy, C 3-6 Cycloalkylene, C 1-6 Archillencio, C 2-6 Alkenylene, C 2-6 alkynylene, wherein the alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are selected from the group consisting of deuterium, halogen, C 1-3 Alkyl, C 1-6 Alkoxy, oxo, -CN, -OH, -NH 2 and optionally substituted with one or more substituents selected from R 1 When present, each independently represents hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3-20 membered heterocyclyl, where alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are selected from halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, Phenyl, C 1-3 Haloalkyl, C 1-4 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; R 2 and R 3 each independently, if present, is hydrogen, C 1-6 Alkyl, C 1-6Alkoxy, where alkyl and alkoxy are halogen, deuterium, cyano, hydroxy, amino, carboxy, C 1-3 Alkyl, C 1-4 Alkoxy, C 1-4 Alkyl, C 3-8 Cycloalkyl, Phenyl, C 1-3 Haloalkyl, C 1-3 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; R 4 When present, are independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 cycloalkyl, phenyl, 3-20 membered heterocyclyl, where alkyl, alkoxy, cycloalkyl, phenyl, heterocyclyl are selected from halogen, cyano, hydroxy, amino, C 1-3 Alkyl, C 1-4 Alkoxy, phenyl, C 1-3 Haloalkyl, C 1-3 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; R 5 and R 6 are independently hydrogen, C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl, 3-20 membered heterocyclyl, 5-16 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, and heteroaryl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NH 2 , C 1-3 Alkyl, C 1-3 may be substituted with one or more substituents selected from haloalkyl; Multiple R A , R B , R C or R E When both exist simultaneously, each R A , R B , R C or R E may be the same or different; Unless otherwise specified, the heteroatoms in the above heterocyclyl, heteroaryl are independently selected from O, N or S, and the number of heteroatoms is 1, 2, 3 or 4.
2. X 1 is N and X 2 , X 3 and X 4 are all CH or X 3 is N and X 1 , X 2 and X 4 are all CH or X 1 and X 3 are both N and X 2 and X 4 are both CH or X 1 , X 2 , X 3 and X 4 are CH; a stereoisomer, tautomer, or mixture thereof; a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of the compound; or a stable isotopic derivative, metabolite, or prodrug of the compound.
3. Y is CH; or Y is N A compound according to any one of claims 1-2, a stereoisomer, tautomer, or mixtures thereof of said compound, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
4. Each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -Z-NR 2 C(O)R 4, -Z-NR 2 C(O)OR 1 , 3-6 membered heterocyclyl, -ZC(O)R 4 , -ZC(O)OR 1 , -ZC(O)NR 2 R 3 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; Preferably, each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -Z-NR 2 C(O)R 4 , -Z-NR 2 C(O)OR 1 , 3-6 membered heterocyclyl, -ZC(O)R 4 , -ZC(O)OR 1 , -ZC(O)NR 2 R 3 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Alkoxy, C 1-6 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; More preferably, each R A are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -Z-NR 2 C(O)R 4 , -Z-NR 2 C(O)OR 1 , 3-6 membered heterocyclyl, -ZC(O)R 4 , -ZC(O)OR 1 , -ZC(O)NR 2 R 3 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-4 Alkyl, C 2 - 4 Alkenyl, C 2 - 4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, and cycloalkyl are each independently selected from the group consisting of deuterium, halogen, oxo, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy; More preferably, each R A are independently hydrogen, deuterium, F, Cl, Br, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -NR 2 C(O)R 4 , -NR 2 C(O)OR 1 , 3-6 membered heterocyclyl, -C(O)R 4 , -C(O)OR 1 , -C(O)NR 2 R 3 , -S(O) 2 R 4 , -S(O) 2 NR 2 R 3 , methyl, ethyl, propyl, isopropyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl, vinyl, ethynyl, propenyl, propynyl; More preferably, each R A are independently hydrogen, F, Cl, Br, oxime, -CN, -OH, -NH 2 , -NHC(O)C 1-3 Alkyl, -NHC(O)OC 1-3 Alkyl, 3-4 membered heterocyclyl, -C(O)C 1-3 Alkyl, -C(O)OC 1-3 Alkyl, -C(O)NHC 1-3 Alkyl, -S(O) 2 C 1-3 Alkyl, -S(O) 2 NH 2 , -S(O) 2 NHC 1-3 alkyl, methyl, ethyl, methoxy, ethoxy, methylthio, vinyl, propenyl, ethynyl, cyclopropyl, tert-butyl; Most preferably, R A is hydrogen, F, Cl, -CN, -NH 2 , oxime, methyl, methoxy, ethoxy, methylthio, -OCD 3 , -NHCOCH 3 , -NHCOOCH 3 , [chemical 2] -COCH 3 , -COOCH 3 , -COCH 2 OCH 3 , -CONHCH 3 , -SO 2 CH 3 , -SO 2 NH 2 , -CH=CH-CH 3 , ethynyl, cyclopropyl, tert-butyl; A compound according to any one of claims 1-3, a stereoisomer, tautomer, or mixtures thereof of said compound, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
5. n1 is 1, 2 or 3; preferably, n1 is 1 or 2. A compound according to any one of claims 1-4, a stereoisomer, tautomer, or mixture thereof, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
6. Each R B are independently hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , C 1-3 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6Cycloalkyl, where alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl are deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; More preferably, each R B are independently hydrogen, deuterium, F, Cl, Br, -CN, -OH, -SH, -NO 2 , -NH 2 , methyl, ethyl, propyl, isopropyl, vinyl, propenyl, ethynyl, propynyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl; More preferably, each R B are independently hydrogen, F, Cl, Br, -OH, -NH 2 , methyl, ethyl, methoxy, ethoxy, vinyl, ethynyl; Most preferably, R B is hydrogen, -NH 2 , methyl, methoxy, ethynyl; 6. A compound according to any one of claims 1-5, a stereoisomer, tautomer, or mixture thereof of said compound, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
7. The compound of any one of claims 1-6, wherein n2 is 1, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
8. Ring A is a 6-9 membered heterocyclyl or a 6-12 membered heteroaryl; preferably, Ring A is a 6-8 membered heterocyclyl or a 6-8 membered heteroaryl; Preferably, Ring A is a 6-membered heterocyclyl or a 6-membered heteroaryl; Preferably, Ring A is piperidinyl, hexahydropyrimidinyl, piperazinyl, 1,3-oxazinyl, morpholinyl, thiomorpholinyl, 1,3-thiazinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyrazinyl, 1,4,5,6-tetrahydropyrimidinyl, homopiperidinyl, homopiperazinyl, homomorpholinyl, pyridinyl, pyridazinyl, pyrimidinyl, 1,4-diazepane, 1,5-diazocane, 1,4-oxazepane, 1,3-oxazepane, 1,4-oxazacyclooctane, 2,3,6,7-tetrahydro-1,4-diazepine; More preferably, ring A is [C3] and [C4] represents the attachment position of the L group; Even more preferably, ring A is [C5] ** represents the condensation site, [C6] represents the bonding position of the L group, 8. A compound according to any one of claims 1-7, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
9. Each R Care independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -ZC(O)OR 1 , -ZNR 2 C(O)R 4 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-6 Alkyl, C 2 - 6 Alkenyl, C 2 - 6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3 - 6 Cycloalkyl, 3-8 membered heterocyclyl, 5-8 membered heteroaryl, C 6 - 12 and aryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; Preferably, each R C are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , -ZC(O)OR 1 , -ZNR 2 C(O)R 4 , -ZS(O) 2 R 4 , -ZS(O) 2 NR 2 R 3 , C 1-3 Alkyl, C 2 - 4 Alkenyl, C 2 - 4 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, 5-8 membered heteroaryl, C 6 - 12 and aryl; said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 optionally substituted with one or more substituents selected from haloalkoxy; More preferably, each R C are independently hydrogen, halogen, oxo, oxime, -CN, -OH, -SH, -NH 2 , -C(O)OC 1-6 Alkyl, carboxy, -NHC(O)C 1-6 Alkyl, -S(O) 2 C 1-6 Alkyl, -S(O) 2 NH 2 , -CH 2 S(O) 2 C 1-6 Alkyl, C 1-3 Alkyl, C 2 - 4 Alkenyl, C 2 - 4 Alkynyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, 5-8 membered heteroaryl, C 6 - 12 and aryl, wherein said alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, heteroaryl or aryl is halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-3Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy; More preferably, each R C are independently hydrogen, F, Cl, Br, oxo, oxime, -CN, -OH, -SH, -NH 2 , -C(O)OC 1-4 Alkyl, carboxy, -NHC(O)C 1-4 Alkyl, -S(O) 2 C 1-4 Alkyl, -S(O) 2 NH 2 , -CH 2 S(O) 2 C 1-4 alkyl, tetrahydrofuranyl, pyrrolyl, phenyl, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, vinyl, propenyl, ethynyl, propynyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl; [C7] 9. A compound according to any one of claims 1-8, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
10. The compound of any one of claims 1-9, wherein n3 is 1, 2, or 3, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative, or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
11. Preferably, when one or two Rc are oxo, the ring A substituted with said one or two Rc is [C8] where ** represents the condensation site. [C9] represents the attachment position of the L group; More preferably, ring A substituted with Rc is: [C10] is 11. A compound according to any one of claims 1-10, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
12.
11. has the following structure: [C12] Selected from 12. A compound according to any one of claims 1-11, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
13. Ring B is C 5 - 10 Cycloalkyl, 3-20 membered heterocyclyl, C 6 - 14 aryl or 5-16 membered heteroaryl; Preferably, ring B is C 5 - 7 Cycloalkyl, 5-7 membered monocyclic heterocyclyl, 5-14 membered spiroheterocyclyl, 5-14 membered fused heterocyclyl, C 6 - 10 aryl, 5-6 membered monocyclic heteroaryl or 5-14 membered fused heteroaryl; Preferably, ring B is C 6 Cycloalkyl, C 7Cycloalkyl, 6-membered monocyclic heterocyclyl, 7-membered monocyclic heterocyclyl, 4-membered / 4-membered spiroheterocyclyl, 4-membered / 5-membered spiroheterocyclyl, 5-membered / 4-membered spiroheterocyclyl, 5-membered / 5-membered spiroheterocyclyl, 4-membered / 6-membered spiroheterocyclyl, 6-membered / 4-membered spiroheterocyclyl, 5-membered / 6-membered spiroheterocyclyl, 6-membered / 5-membered spiroheterocyclyl, 6-membered / 6-membered spiroheterocyclyl, 4-membered / 4-membered fused heterocyclyl, 4-membered / 5-membered fused heterocyclyl, 5-membered / 4-membered fused heterocyclyl, 5-membered / 5-membered fused heterocyclyl, 5-membered / 6-membered fused heterocyclyl aryl, 6-membered / 5-membered fused heterocyclyl, 4-membered / 6-membered fused heterocyclyl, 6-membered / 4-membered fused heterocyclyl, 6-membered / 6-membered fused heterocyclyl, phenyl, naphthyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 5-membered / 5-membered fused heteroaryl, 5-membered / 6-membered fused heteroaryl, 6-membered / 5-membered fused heteroaryl, 6-membered / 6-membered bicyclic fused heteroaryl; heteroatoms in said heterocyclyl, heteroaryl, fused heterocyclyl, fused heteroaryl are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3; More preferably, ring B is [C13] is 13. A compound according to any one of claims 1-12, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
14. R D is -WC(O)NR 2 R 3 , -WC(O)NR 2 OR 1 , -W-OC(O)NR 2 R 3 , -W-NR 2 C(O)R 4 , -W-NR 2 C(O)OR 1 , -W-NR 2 C(O)NR 2 R 3 , -WS(O) 2R 4 , -W-SO 2 NR 2 R 3 , -W-NR 2 S(O) 2 R 4 , -W-OS(O) 2 R 4 , -W-NR 2 S(O) 2 NR 2 R 3 , -W-OS(O) 2 NR 2 R 3 , -WP(O)(OR 1 ) 2 , -WP(S)(OR 1 ) 2 , -WOP(S)(OR 1 ) 2 , -WB(OH) 2 is selected from Preferably, R D -C 0-3 Alkylene -C(O)NHOH, -C 0-3 Alkylene-OC(O)NH 2 , -C 0-3 Alkylene-SO 2 NH 2 , -C 0-3 Alkylene-NHS(O) 2 H, -C 0-3 Alkylene-OS(O) 2 H, -C 0-3 Alkylene-NHS(O) 2 NH 2 , -C 0-3 Alkylene-OS(O) 2 NH 2 , -C 0-3 Alkylene-P(O)(OH) 2 , -C 0-3 Alkylene-P(S)(OH) 2 , -C 0-3 Alkylene-OP(S)(OH) 2 , -C 0-3 Alkylene-B(OH) 2 , -C 0-3 Alkylene-S(O) 2 OH, -C 0-3AlkyleneC(O)NH 2 , -C 0-3 Alkylene S(O) 2 C 1-3 Alkyl, -C 0-3 Alkylene-OS(O) 2 -C 1-3 Alkyl, -C 0-3 Alkylene-S(O) 2 -C 1-3 Alkylene -C(O)OH, -C 0-3 Alkylene-S(O) 2 C 1-3 Alkylene-NH 2 , -C 0-3 Alkylene-S(O) 2 NHCH 2 C(O)OH, -C 0-3 Alkylene NHS(O) 2 CH 3 , -C 0-3 Alkylene S(O) 2 N.D. 2 , -C 0-3 Alkylene S(O) 2 NHNH 2 , -C 0-3 Alkylene S(O) 2 NHSC 1-3 Alkyl, -C 0-3 Alkylene-NHS(O) 2 C 1-3 Alkyl, -C 0-3 Alkylene-NH-C(O)C 1-3 Alkyl, -C 0-3 Alkylene-NH-CONH 2 , -C 0-3 Alkylene-NH-COOC 1-3 Alkyl or -C 0-3 Alkylene-S(O) 2 NHOH, Preferably, R D are -methylene-C(O)NHOH and -methylene-OC(O)NH 2 , -methylene-SO 2 NH 2 , -methylene-NHS(O) 2 H, -methylene-OS(O) 2 H, -methylene-NHS(O) 2NH 2 , -methylene-OS(O) 2 NH 2 , -methylene-P(O)(OH) 2 , -methylene-P(S)(OH) 2 , -Methylene-OP(S)(OH) 2 , -methylene-B(OH) 2 , -C(O)NHOH, -OC(O)NH 2 , -SO 2 NH 2 , -NHS(O) 2 H, -OS(O) 2 H, -NHS(O) 2 NH 2 , -OS(O) 2 NH 2 , -P(O)(OH) 2 , -P(S)(OH) 2 , -OP(S)(OH) 2 , -B(OH) 2 ;-S(O) 2 OH, -C(O)NH 2 , -S(O) 2 C 1-3 Alkyl, -OS(O) 2 C 1-3 Alkyl, -S(O) 2 C 1-3 Alkylene C(O)OH, -S(O) 2 C 1-3 Alkylene-NH 2 , -S(O) 2 NHCH 2 C(O)OH, -NHS(O) 2 CH 3 , -S(O) 2 N.D. 2 , -S(O) 2 NHNH 2 , -methylene-NHS(O) 2 C 1-3 Alkyl, -methylene-NH-C(O)C 1-3 Alkyl, -methylene-NH-CONH 2 , -NH-COOC 1-3 Alkyl or -S(O) 2 NHOH, Most preferably, R D-C(O)NHOH, -SO 2 NH 2 , -methylene-NHS(O) 2 NH 2 , -NHS(O) 2 NH 2 , -B(OH) 2 , -P(O)(OH) 2 , -OP(S)(OH) 2 , -OS(O) 2 NH 2 , -S(O) 2 OH, -C(O)NH 2 , -S(O) 2 CH 3 , -OS(O) 2 CH 3 , -S(O) 2 CH 2 CH 2 C(O)OH, -S(O) 2 CH 2 NH 2 , -S(O) 2 NHCH 2 C(O)OH, -NHS(O) 2 CH 3 , -S(O) 2 N.D. 2 , -S(O) 2 NHNH 2 , -methylene-NHS(O) 2 CH 3 , -methylene-NH-C(O)CH 3 , -methylene-NH-CONH 2 , -NH-COOCH 3 Or -S(O) 2 NHOH, 14. A compound according to any one of claims 1-13, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
15. Each R E are independently hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -SH, -NO 2 , -NH 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-8 and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, oxime, -CN, -OH, -NO 2 , -NH 2 , C 1-6 Alkyl, Phenyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Optionally substituted with one or more substituents selected from haloalkoxy, halophenyl; Preferably, each R E are independently hydrogen, halogen, -OH, -SH, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 and cycloalkyl, wherein the alkyl, alkoxy, and cycloalkyl are hydrogen, deuterium, halogen, oxo, -CN, -OH, -NO 2 , -NH 2 , C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 1-3 optionally substituted with one or more substituents selected from haloalkoxy; More preferably, each R E are independently hydrogen, F, Cl, Br, -OH, -SH, -methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoroethyl, difluoroethyl, monofluoroethyl, hydroxypropyl, hydroxyethyl, hydroxymethyl, methoxypropyl, methoxyethyl, methoxymethyl; [C14] 15. A compound according to any one of claims 1-14, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
16. n4 is 1, 2, 3 or 4; preferably, n4 is 1, 2 or 3. A compound according to any one of claims 1-15, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
17. L is a bond, -O-, -S-, C 1-3 Alkylene, C 1-3 Alkyleneoxy, C 3-6 Cycloalkylene, C 1-3 Archillencio, C 2-6 Alkenylene, C 2-6 Alkynylene, wherein the alkylene, alkyleneoxy, cycloalkylene, alkylenethio, alkenylene, and alkynylene are each independently selected from the group consisting of deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkoxy, oxo, -CN, -OH, -NH 2 and optionally substituted with one or more substituents selected from Preferably, L is a bond, -O-, -S-, methylene, ethylene, propylene, cyclopropylene, cyclobutylene, C 1-3 Alkyleneoxy, C 1-3 The methylene, ethylene, propylene, cyclopropylene, cyclobutylene, alkyleneoxy, alkylenethio, vinylene, and ethynylene are each independently selected from the group consisting of deuterium, halogen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, oxo, -CN, -OH, and -NH. 2 and optionally substituted with one or more substituents selected from More preferably, L is a bond, -O-, -S-, cyclopropylene, methylenemethoxy, methylenemethyl, methylene-OH, or methylene-NH. 2 , ethylene, propylene; Most preferably, L is a bond, -O-, or -CH 2 -, [C15] That is, 17. A compound according to any one of claims 1-16, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof.
18. The following compound, or a prodrug, tautomer, stereoisomer, metabolite, isotopic derivative or mixture thereof, or a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate thereof: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19] [Table 1-20]
19. 20. A pharmaceutical composition comprising a compound according to any one of claims 1-18, a stereoisomer, tautomer, or mixture thereof of said compound, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound.
20. Use of a compound according to any one of claims 1-18, a stereoisomer, a tautomer, or a mixture thereof, a pharma- ceutically acceptable salt, co-crystal, polymorph, or solvate of said compound, or a stable isotopic derivative, metabolite, or prodrug of said compound, or a pharmaceutical composition according to claim 19, in the manufacture of a medicament for the treatment or prevention of a disease mediated by ENPP1; Preferably, the disease mediated by ENPP1 is a cancer or tumor-related disease, or a cardiovascular disease, more preferably, the disease mediated by ENPP1 is pancreatic cancer, heart failure, or myocardial infarction.
Citation Information
Patent Citations
Tricyclic dual PI3K and mTOR inhibitors
CN102399220A
Tricyclic compounds as regulators of TNF-α synthesis and PDE4 inhibitors
JP2011510929A
Compounds and compositions as TLR activity modulators
JP2011513413A
Compounds and compositions as TLR activity modulators
JP2013503884A
Tricyclic PI3K and / or mTOR inhibitors
JP2014533661A
